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Preamble
Substantial parts of this thesis have already been published in two publications –
Keck et al. [61] and Seiwert et al. [110]. As a consequence, the work described in
the first two chapters of this thesis and the work published in the two mentioned
papers show significant overlap.
The results presented for the classification/taxonomy and the genomic analysis
of HNSCC are part of a joint project involving mainly Dr. Zhixiang Zuo (com-
puter scientist) and myself with me performing the lab work described here in the
respective methods sections and Dr. Zuo performing the statistics and bioinfor-
matics data analysis, which is described in detail in Keck et al. [61] and Seiwert
et al. [110]. Data interpretation was performed jointly.
Additional contributions of others are stated in the respective methods descriptions
in the methods sections. Main contributions of others were:
• Data analysis and bioinformatics analysis as described in Keck et al. [61]
and Seiwert et al. [110] was performed by Dr. Zhixiang Zuo (Seiwert Lab).
• Pooling and solution phase capture for validation of sequencing results were
performed by Dr. Arun Khattri (Seiwert Lab). Dr. Khattri also helped to
index and clean up a part of the samples for solution phase capture and
assisted with the interpretation of data and any possible molecular biology
question.
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Chapter 1
Introduction
1.1 Head and Neck Cancer
1.1.1 Disease Burden
The global cancer burden is increasing and the number of new cases is expected
to reach 20 million per year within the next decade – it is estimated that in
2012 there were 14.1 million new cancer cases and 8.2 million cancer deaths [29].
Malignancies of the head and neck are the sixth most frequent cancer in the world
with an incidence of more than 600,000 new cases each year and a 5-year survival
rate of 40–50% [29,70,109]. It is estimated that 59,340 new cases of head and neck
cancer will arise solely in the USA in 2015 – which accounts for about 3.6% of all
new cancer cases in 2015 – and that 12,290 patients will die from head and neck
cancer in the US in the same year [115]. Most head and neck cancers (90–95%) are
of squamous cell histology [38,112]. Survival rates for head and neck squamous cell
carcinomas (HNSCC) remained practically unchanged over the last decades, since
patients oftentimes develop recurrences, metastasis or second primary tumors [70].
About 50% of all HNSCC patients can be cured, the remaining 50% recur and have
a poor prognosis with a median overall survival of less than one year [38]. Prognosis
for HNSCC is good, if patients present with early-stage disease (5-year survival rate
≈ 80%), but the majority of patients – about two thirds – present with advanced
disease and lymph node metastases [38,70]. 5-year survival rates are approximately
50% for locally advanced disease and 25% for metastatic disease [38].
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1.1.2 Aetiology of HNSCC
HNSCC is comprised of at least two distinct disease entities, human papillomavirus
(HPV)-positive and HPV-negative tumors, that differ regarding their clinical,
pathologic, and molecular characteristics [36].
1.1.2.1 Aetiology of HPV-negative HNSCC
The classic risk factors for HPV-negative HNSCC are well established, i.e. tobacco
chewing or smoking and heavy alcohol consumption with synergy between both to-
bacco use and alcohol consumption leading to a 30-fold increased risk of developing
HNSCC [3]. Potentially malignant lesions such as leukoplakia are associated with
tobacco use and oftentimes regress or disappear after stopping exposure, which
highlights the importance of tobacco in the development of leukoplakia [88]. How-
ever the occurrence of idiopathic leukoplakias with an increased risk of developing
cancer compared to smoking associated leukoplakias has been reported as well [88].
Erythroplakia is another potentially malignant lesion that is associated with alco-
hol and tobacco use and a high likelihood to undergo transformation [135]. Further
risk factors for the development of HNSCC are Fanconi anemia, a congenital DNA
repair disorder, as well as a general genetic susceptibility [70,108].
1.1.2.2 Aetiology of HPV-positive HNSCC
Human papillomaviruses can infect epithelial cells, which, in the case of a persis-
tent infection with high-risk types (e.g. 16, 18, 31, 33, 34, 35, 39, 45, 51, 52, 56, 58,
59, 66, 68, and 70), can lead to cellular transformation and various types of cancer
such as cancer of the uterine, cervix, vulva, penis, anus (including perianal can-
cer), conjunctiva, upper aerodigestive tract (oropharynx) and possibly squamous
cell carcinomas of the skin [99, 119, 153]. A causal relationship has been estab-
lished between the occurrence of oropharyngeal HNSCC and infection with certain
high-risk HPVs, mainly HPV16, but also HPV18, HPV31, and HPV33 [36]. HPV-
positive HNSCCs show markedly improved survival compared to HPV-negative
HNSCCs and exhibit distinct histologic and genetic features such as poor tu-
mor grade, absent keratinization, basaloid morphology, and wild-type TP53 [36].
While the number of HPV-negative HNSCC is declining in the US due to a de-
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cline in smoking, the incidence of HPV-associated cancers is on the rise [16, 115],
which is probably attributable to a change in sexual behavior – HPV infections
are transmitted through sexual contact and associated with the number of sexual
partners [3, 16, 36]. It is estimated that by 2020 at least 70% of all oropharyngeal
squamous cell carcinomas (OPSCCs) will be HPV-positive and thus exceed the
incidence of cervical cancers, and that by 2030 approximately 47% of all head and
neck cancers will be OPSCCs [16].
1.1.3 Pathogenesis of HNSCC
HNSCC occurs in the upper aerodigestive tract and comprises tumors of the lip,
the nasal cavity, the paranasal sinuses, the oral cavity, the larynx, the hypophar-
ynx, and the oropharynx [38, 70, 103]. Potentially malignant disorders (PMDs)
termed oral leukoplakia are white plaques arising in the oral mucosa – mostly
in the buccal mucosa – that can undergo malignant transformation and give rise
to oral squamous cell carcinomas [70, 88]. The malignant transformation rate is
highly dependent on the type of leukoplakia (higher for the non-homogeneous type
compared to the homogeneous type), but is reported with approximately 1% for
all types of leukoplakia [135]. However, HNSCC may as well develop in other sites
of the upper aerodigestive tract independent of the previous existence of leuko-
plakia [70, 135]. Another type of PMD is termed erythroplakia – red lesions that
cannot be attributed to any other disease and that carry a high risk of malignant
transformation [135].
The term field cancerization describes the occurrence of multiple precursor dys-
plastic changes in the squamous cell epithelium as well as the dysplastic tumor-
surrounding tissue that harbors genetic alterations while appearing clinically nor-
mal, which are both responsible for the high incidence of multiple primary tumors
and local recurrences in HNSCC [70]. Figure 1.1 visualizes the concept of field can-
cerization and therewith related local relapse as published by Leemans et al. [70].
HNSCC development is a genetic multi-step process for which a patch – field –
tumor – metastasis progression model has been suggested [70]. A genetically al-
tered progenitor cell forms a patch that contains genetically altered daughter cells
– this patch evades growth control and develops into a field (a field is monoclonal,
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Figure 1.1: Field cancerization and local relapse as published by Leemans et
al. [70].
The schematic visualizes the concept of field cancerization and its role in relapse. HN-
SCC tumors develop in a field (light blue) surrounding the tumor (dark blue). Local
relapse after surgical resection of the tumor may either be due to incomplete excision
of the tumor itself (true recurrence) or the related field (second field tumor). Clinically,
second field tumors can represent a local recurrence, but also a second primary tumor
depending on the distance to the index tumor and the time interval between occurence
of primary tumor and relapse. Multiple independent fields can be present giving rise to
second primary tumors (true second primary tumor). [70]
does not exhibit invasive growth, and is either visible, e.g. as leukoplakia, or clin-
ically invisible) – a subclone in this field can develop into invasive cancer and
subsequently into metastatic disease [70]. In the course of this multi-step process
the sequential acquisition of genetic changes provides the genetic basis for the ob-
served phenotypic changes and progression of disease [38, 70]. Downregulation of
the p53 pathway occurs in at least 80% of HNSCCs and belongs to the earliest as
well as most frequent alterations in the course of HNSCC development leading to
clonal expansion of a putative precursor cell into a patch [103]. Inactivation of the
retinoblastoma (Rb) pathway is an important early event in HNSCC as well [70].
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1.1.3.1 Pathogenesis of HPV-negative HNSCC
Inactivation of the p53 pathway through mutation of the TP53 gene is seen in
HPV-negative HNSCC [103]. Another mechanism of p53 pathway inactivation is
overexpression or amplification of MDM2 leading to proteasomal degradation of
p53 [103]. CDKN2A, which encodes p16 and p14ARF that are negative regulators
of the Rb pathway (p16–cyclin D1-CDK4-RB or p16-cyclin D1-CDK6-RB) and
MDM2 respectively, is inactivated by mutation, copy number loss (homozygous
deletion or chromosome loss), or epigenetic modification (methylation) in up to
75% of HNSCCs [70,103]. Amplification of the long arm of chromosome 11 (11q13)
leads to amplification of CCND1 (encodes for cyclin D1) in more than 80% of HPV-
negative HNSCCs, which represents another early event in HNSCC carcinogenesis
[70]. Thus TP53, CDKN2A, and CCND1 are established cancer genes in HPV-
negative HNSCC [70].
1.1.3.2 Pathogenesis of HPV-positive HNSCC
In HPV-positive HNSCC expression of viral oncoprotein E6 leads to ubiquitination
and thus proteasomal degradation of p53 [99, 103]. Furthermore, expressed E6
(from high-risk HPVs) can interfere with multiple cellular processes by targeting
different proteins, which leads to genomic instability [99]. Viral oncoprotein E7
has multiple targets and is responsible for the inactivation of the Rb pathway
by binding hypophosphorylated Rb [99, 103]. This results in the release of E2F
transcription factors and expression of E2F target genes, which makes E7 the most
important driver of cell cycle deregulation [99]. Expression of viral E5 protein
causes increased levels of epidermal growth factor receptor (EGFR) in the cell
membrane by interfering with the degradation of EGFR [99]. The genes encoding
p53 and Rb are established cancer genes in HPV-positive HNSCC [70].
1.1.3.3 Pathogenesis – Further Changes
Multiple other molecular changes might play a role in HNSCC, such as increased
transforming growth factor-α (TGF-α) and EGFR mRNA levels [40], constitu-
tive activation of transcription factor nuclear factor-κB (NF-κB) through com-
promised transforming growth factor β (TGFβ) signaling [19], EGFR overexpres-
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sion, which was observed in 80–90% of HNSCC [77], EGFR amplification, Ras
mutations, activation of the PI3K signaling pathway with amplification or activat-
ing mutations in PIK3CA and inactivating mutations or loss of heterozygosity in
PTEN [70,103], or mutations and gene amplifications of hepatocyte growth factor
receptor (MET) [70].
1.1.4 Classification of HNSCC
Multiple studies seek to classify HNSCC based on the observed molecular changes
and considering the underlying biology of the disease. The study by Slebos et al.
identifies differential expression of 91 genes in HPV-positive and HPV-negative
HNSCC by analyzing 36 tumors, eight of which are HPV-positive. Among the
differentially expressed genes are cell cycle regulators, such as CDKN2A, and tran-
scription factors as well as genes located on the long arm of chromosome 3, which
are all overexpressed in the HPV-positive tumors [119]. Further studies investi-
gate HNSCC on a molecular level and propose classifications beyond the division
into HPV-positive and HPV-negative tumors. Chung et al. propose a classification
of HNSCC into four different subtypes – groups 1–4 – based on gene expression
patterns of 60 HNSCC samples with unknown HPV status including tumor stages
I–IV. Characteristics of these subtypes are first, increased EGFR signaling, second,
a mesenchymal cell signature with lack of expression of epithelial genes, third, a
normal epithelium-like subtype, and fourth, a subtype overexpressing antioxidant
enzymes. All four subtypes show statistically significant differences regarding their
clinical outcome [17]. A recent publication by Walter et al. reports four molecu-
lar subtypes – basal, mesenchymal, atypical, and classical – based on expression
profiling of 138 HNSCC samples (stage I–IV) including 14 HPV-positive tumors.
The discovered subtypes correspond to the four subtypes identified by Chung et
al. making this the only classification of HNSCC that has been reproduced in
a separate study [138]. The classification suggested by Pavo´n et al. consists of
three subtypes that are associated with survival and can be differentiated by gene
expression – subtype 1 with epithelial mesenchymal transition (EMT), cell ad-
hesion, NF-kappaB pathway, and integrin signaling, subtype 2 with development
and branching morphogenesis, and subtype 3 with epidermis morphogenesis and
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keratinocyte differentiation. 63 locally advanced HNSCC samples (HPV status
unknown) are analyzed to generate these three subtypes as well as a prognostic
signature [94]. 53 oral tongue squamous cell carcinomas and 22 matching nor-
mal tissues are investigated by Ye et al. to find expression patterns and potential
biomarkers regarding this particular subset of HNSCC. A 35-gene expression sig-
nature is derived that potentially identifies oral tongue SCC [146]. Rickman et al.
perform unsupervised hierarchical clustering based on gene expression on a set of
98 HPV-negative HNSCCs with stage I–IV to discover signatures that predict the
development of distant metastases. The resulting four groups are associated with
tumor differentiation and exhibit upregulation of different sets of genes, however
are not correlated with the propensity to develop metastasis [101].
1.1.5 Genomic Landscape of HNSCC
HPV-positive and HPV-negative HNSCC are distinct disease entities that show
differences regarding their molecular profile. Genomic aberrations such as gene
copy number alterations or mutations are present in various genes – e.g. TP53,
CDKN2A, CCND1, EGFR, MET, PIK3CA, PTEN, and SMAD4, which are all
established cancer genes in HNSCC with TP53, CDKN2A, and CCND1 being es-
tablished cancer genes in HPV-negative HNSCC [70]. Recently, several studies
have investigated the genomic landscape of HNSCC by next generation sequenc-
ing. Agrawal et al. studied 32 primary HNSCC tumors (28 HPV-negative, 4 HPV-
positive) using whole exome sequencing and copy number analyses and describe sig-
nificant mutations in TP53, CDKN2A, PIK3CA, HRAS, FBXW7, and NOTCH1
as well as a different genetic landscape in HPV-positive compared to HPV-negative
HNSCC [2]. Furthermore, they and others report more mutations in HPV-negative
than in HPV-positive tumors [2,124]. Stransky et al. describe the genetic profile of
74 primary and recurrent HNSCC tumors (63 HPV-negative, 11 HPV-positive) and
among other mutated genes find mutations in TP53, CDKN2A, PTEN, PIK3CA,
HRAS, NOTCH1, IRF6, and TP63 as well as copy number alterations in CCND1,
CDKN2A, MYC, EGFR, ERBB2, and CCNE1 [124]. Further publications repeat-
edly find mutations and copy number alterations in the same genes and additionally
detect mutations in FGFR3, CEBPA, FES, FAT1, CASP8 [32,95] and the TERT
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promoter [62]. All the reported cohorts focus primarily on HPV-negative HNSCC
and thus little is known about the genomic landscape of HPV-positive HNSCC.
The latest report – the large TCGA HNSCC cohort – includes 87% HPV-negative
tumors (36 HPV-positive, 243 HPV-negative) and confirms known alterations, re-
ports novel mutations in NFE2L2, NSD1, novel copy number changes in TRAF3,
E2F1, and novel co-amplifications involving 11q13 (CCND1, FADD, CTTN) and
11q22 (BIRC2, YAP1) [128].
1.1.6 Staging and Conventional Treatment
Staging of HNSCC is assessed using the TNM system (tumor, node, metastasis –
size and location of tumor, degree of regional lymph node involvement, absence or
presence of distant metastases) according to the guidelines of the American Joint
Committee on Cancer [23]. Owing to the multiple different anatomic subsites stag-
ing is complex and differs depending on the involved anatomic location [23, 112].
Three different clinical stages have been described – early, locoregionally advanced,
metastatic/recurrent [112]. Most patients present with advanced disease [96] and
locoregional recurrence is the primary cause of treatment failure and death [38].
Treatment choices are made based on staging and anatomic site and patients are
treated with a combination of surgery, radiation, and chemotherapy applying dif-
ferent approaches [96, 112]. However, treatment related systemic acute toxicities
or late side effects commonly occur due to the nonselective nature of conventional
therapies, which complicates adherence to treatment protocols and the manage-
ment of HNSCC care [67]. HPV-positive HNSCC shows a better outcome irre-
spective of treatment [103], but prognostic markers such as HPV status or tobacco
use are clinically not yet established to inform staging and hence treatment of
HNSCC [23,70].
1.1.7 Targeted Treatment
In order to improve survival outcomes and reduce treatment related toxicities in
HNSCC, different targeted therapies that are more selective than conventional
chemo- or radiotherapy and target specific molecular pathways, have entered the
field [67]. The only approved targeted therapy is the monoclonal anti-EGFR
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antibody Cetuximab (approved in 2006 by the US Food and Drug Adminis-
tration) [38] that shows a low single-agent response rate (13% with 95% CI =
7%–21%) and is used indiscriminately in palliative and curative care – predictive
biomarkers that qualify patients for treatment with Cetuximab remain to be iden-
tified [109, 137]. Overexpression and amplification of EGFR are associated with
poor survival [109], but EGFR expression by immunohistochemistry (IHC) as well
as an increased EGFR gene copy number do not correlate with successful anti-
EGFR therapy [76, 137]. More agents targeting EGFR, such as other anti-EGFR
monoclonal antibodies or tyrosine kinase inhibitors, as well as further targeted
approaches to treat HNSCC are currently being evaluated in clinical trials [109].
However, their efficacy will as well largely depend on the identification of predictive
biomarkers for the respective subset of patients that will benefit from the specific
targeted treatment.
Two therapeutic vaccines specifically for patients with HPV-associated HNSCC
are currently being tested in phase I clinical trials [109]. Furthermore, monoclonal
antibodies targeting immune checkpoint molecules such as programmed cell death
protein 1 (PD-1), or PD-1 ligand (PD-L1) might represent an interesting approach
to treat head and neck cancer [109] especially since the PD-1/PD-L1 pathway may
be relevant in a subset of both HPV-positive as well as HPV-negative HNSCC [79].
Treatment targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is be-
ing discussed in that context as well but shows significant toxicities in patients with
advanced metastatic melanoma [79,109].
Tumor hypoxia is another promising target under investigation. Hypoxia is in-
volved in resistance to chemotherapy and radiation and induces genes that con-
tribute to a malignant phenotype and promote angiogenesis, tumor cell survival,
progression, invasion, and metastasis [1,51,113]. Various hypoxia targeting agents
are currently being investigated such as Camptothecin and Topotecan (topoiso-
merase inhibitors), 17-allyl-aminogel-danamycin (a heat shock protein (HSP)90
inhibitor), and 2-methoxyoestradiol (disruptor of microtubule polymerization),
which cause reduced levels of the transcription factor hypoxia inducible factor
(HIF)1α that mediates the effects of hypoxia [1, 10, 113]. Multiple inhibitors of
various signal transduction pathways decrease HIF1α levels as well and might be
used to target hypoxia in addition to a specific signaling pathway [113].
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Tumor angiogenesis is targeted using antibodies against the vascular endothelial
growth factor (VEGF). Multiple agents are currently being tested in clinical trials
to examine their potential to treat HNSCC in combination with standard ther-
apy [38,109]. Results of VEGF inhibition are promising and targeting VEGF and
EGFR at the same time seems to be a valid approach in some patients as well, since
EGFR activation may upregulate VEGF and thereby cause resistance to EGFR-
targeting therapy [38,109]. However, biomarkers to identify the subset of patients
that potentially benefit most from VEGF or combined EGFR/VEGF inhibition
have not been identified. Furthermore, upregulation of fibroblast growth factor 2
(FGF2) and fibroblast growth factor receptor 3 (FGFR3) was found to mediate
resistance to VEGF inhibition in HNSCC and dual inhibition of both FGFR and
VEGFR may overcome resistance [45].
1.2 Fibroblast Growth Factor Receptor (FGFR)
Pathway
1.2.1 Fibroblast Growth Factor Receptors (FGFRs)
The family of fibroblast growth factor receptors (FGFRs) belongs to the super-
family of receptor tyrosine kinases (RTKs) and comprises four different genes,
namely FGFR1–FGFR4 [60, 139]. The structure of FGFRs accords with the gen-
eral structure of RTKs with an extracellular ligand-binding domain, a single-pass
transmembrane domain, and an intracellular tyrosine kinase domain [60,139]. The
cytoplasmic domain of FGFR1–FGFR4 contains a split tyrosine kinase domain re-
sponsible for signal transduction, the extracellular domain consists of three Ig-like
domains (I–III) and a serin-rich acid box in the linker between Ig-like domains I
and II [7,139]. Ig-like domain I as well as the acid box are involved in autoinhibi-
tion of the receptor, Ig-like domains II and III are responsible for ligand binding
and specificity [7, 139]. Figure 1.2 illustrates the structure of FGF receptors as
published by Beenken and Mohammadi [7].
Various isoforms of FGF receptors exist. Isoforms of FGFR1–3 can be gen-
erated by alternative splicing in the third Ig-like domain [7, 20, 37, 139]. The C-
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Figure 1.2: Schematic of the FGFR structure as published by Beenken and
Mohammadi [7].
Shown are the different domains of the FGF receptor from N- to C-terminus. Domains
D1–D3 correspond to Ig-like domains I–III. The C-terminal part of Ig-like domain III
can be encoded by two alternate exons (exon 8 or exon 9), which leads to different
isoforms (IIIb or IIIc) that exhibit distinct ligand binding specificity.
terminal part of Ig-like domain III is either encoded by exon 8 or by exon 9 in
a mutually exclusive manner, which results in the IIIb and IIIc isoform respec-
tively [37] (see figure 1.2). FGFR4 differs from FGFR 1–3 regarding the total
number of exons as it misses the alternative exon in the C-terminal part of Ig-
like domain III, which results in the expression of only one form of FGFR4 [39].
Expression of the IIIb and IIIc isoforms of FGFR1–3 is tissue specific and deter-
mines ligand binding specificity of the receptor [7, 20, 37, 139]. The IIIb isoforms
of FGFR1–3 are predominant in epithelial cells and bind specific FGFR ligands
(fibroblast growth factors, FGFs) secreted by mesenchymal cells whereas the IIIc
isoforms of FGFR1–3 are primarily expressed in mesenchymal cells and bind spe-
cific FGFs secreted by epithelial cells (see table 1.1 for FGFR/FGF binding speci-
ficity) [7, 37, 139]. An exception is FGF1, which binds both isoforms of the FGF
receptor [7, 139].
Multiple other isoforms of the FGF receptor than the aforementioned IIIb and IIIc
isoforms of FGFR1–3 have as well been described. Various isoforms of FGFR3
show a premature translation termination [130]. FGFR2 and FGFR3 can exist
as isoforms that lack exons 8–10 and hence the transmembrane domain causing
these ∆8-10 isoforms to be soluble instead of membrane bound [39]. Different
possibilities are being discussed regarding the function and localization of the sol-
uble ∆8-10 isoforms, which have been found in the nucleus of epithelial cells but
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were also secreted into the medium by different cell lines [71]. Soluble isoforms
could potentially function as ligand-traps thus having a negative regulatory ef-
fect on FGFR activation or as ligand transporters to support FGF signaling [39].
In urothelial cells FGFR3 ∆8-10 was shown to be a negative regulator of FGF1
induced proliferation [130]. Figure 1.3 illustrates a selection of different FGFR3
isoforms as published by L’Hoˆte and Knowles [71].
Figure 1.3: FGFR3 isoforms modified after L’Hoˆte and Knowles [71].
Shown are different isoforms of FGFR3 and their respective domains in reference to the
corresponding exons from N- to C-terminus. SN = signal peptide, Ig = Ig-like domain,
TM = transmembrane domain, TK = tyrosine kinase domain. A FGFR3 IIIb (using
exon 8, but not 9) or FGFR3 IIIc (using exon 9, but not 8) B FGFR3 ∆8-10 (splicing
out exons 8, 9, and 10).
1.2.2 Fibroblast Growth Factors (FGFs)
Fibroblast growth factors (FGFs) act as ligands for FGF receptors. There are 18
receptor-binding FGFs, which can be divided into six subfamilies – five paracrine
subfamilies (FGF 1,2 – FGF 3,7,10,22 – FGF 4,5,6 – FGF 8,17,18 – FGF 9,16,20)
and one endocrine subfamily (FGF 19,21,23) [7]. Paracrine FGFs show high affinity
for heparan sulphate glycosaminoglycan chains of heparan sulphate proteoglycans,
which causes their paracrine nature [7,37]. Endocrine FGFs exhibit decreased affin-
ity for heparan sulphate proteoglycans, which enables them to move away from
the site of their secretion and makes them dependent on the presence of Klotho
proteins for successful receptor binding and signaling [7, 37, 134]. As described in
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1.2.1 the different FGF receptor isoforms exhibit distinct ligand-binding specifici-
ties that are listed in table 1.1. The IIIc isoforms of the FGF receptor show a
much broader range of ligands than the IIIb isoforms [149].
IIIb isoform IIIc isoform
FGFR1 FGF1, FGF2 FGF1, FGF2
FGF3, FGF7, FGF10, FGF22 FGF4, FGF5, FGF6
FGF8, FGF17, FGF18
FGF9, FGF16, FGF20
FGF19, FGF21, FGF23
FGFR2 FGF1 FGF1, FGF2
FGF3, FGF7, FGF10, FGF22 FGF4, FGF5, FGF6
FGF8, FGF17, FGF18
FGF9, FGF16, FGF20
FGF19, FGF21, FGF23
FGFR3 FGF1 FGF1, FGF2
FGF8, FGF17, FGF18 FGF4, FGF5, FGF6
FGF9, FGF16, FGF20 FGF8, FGF17, FGF18
FGF9, FGF16, FGF20
FGF19, FGF21, FGF23
FGFR4 FGF1, FGF2, FGF4, FGF5, FGF6, FGF8, FGF17, FGF18
FGF9, FGF16, FGF20, FGF19, FGF21, FGF23
Table 1.1: FGF/FGFR binding specificity as published by Zhang et al. [149].
Table shows FGFR isoform specific binding by its ligands – the different FGFs – grouped
by FGFR isoforms and FGF subfamilies.
Another group of FGFs, the former FGF11 subfamily (FGF 11,12,13,14), does
not show any receptor binding activity [149]. These FGFs are therefore not con-
sidered FGF family members any more but FGF homologous factors (FHFs) due
to their sequence identity and structural similarity with FGFs and their heparin
binding properties [7]. To be complete it has to be mentioned that there is no
human FGF15, but FGF15 is the mouse orthologue of human FGF19 [7].
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1.2.3 FGF/FGFR Signaling
Binding of FGF to its receptor FGFR initiates several signaling cascades each
triggering distinct cellular responses. As illustrated in figure 1.4 FGF binds the
FGFR at its primary ligand-binding site, which consists of Ig-like domain II, Ig-like
domain III, and the linker between Ig-like domains II and III; heparan sulfate pro-
teoglycan interacts with FGF and binds Ig-like domain II of the FGF receptor [37].
Upon binding of FGF and heparan sulfate proteoglycan to the extracellular do-
mains of FGFR, two of these ternary complexes dimerize, the two FGF receptors
get in direct contact at Ig-like domain II, and FGF interacts with the second
FGF receptor via a secondary ligand-binding site in Ig-like domain II [7, 37]. The
dimerization of FGFR abrogates autoinhibition of receptor kinases due to a confor-
mational shift in the structure of FGFR [20]. The kinases, which are consequently
in close proximity, are able to transphosphorylate each other at multiple phospho-
rylation sites [7, 37, 139]. Subsequently, the activated kinases phosphorylate and
activate downstream substrates of FGFR [37,139].
Figure 1.4: Complex formation during FGF/FGFR signaling modified after
Wesche et al. [139].
Image shows the general structure of FGFR on the left and FGF rezeptor dimerization
upon binding of FGF and heparan sulfate proteoglycan, which leads to signal transmis-
sion to the interior of the cell on the right.
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Direct downstream targets of the FGF receptor are mainly FGFR substrate
2α (FRS2α) – which in turn activates the MAPK (mitogen activated protein ki-
nase) pathway as well as the PI3K/Akt (phosphoinositide 3-kinase) pathway – and
phospholipaseCγ1 (PLCγ1), but also signal transducers and activators of tran-
scription (STATs) [20, 133, 139]. Figure 1.5 illustrates the three main pathways
activated by FGF/FGFR signaling as published by Goetz and Mohammadi [37].
Figure 1.5: Pathways activated by FGF/FGFR signaling modified after Goetz
and Mohammadi [37].
Image shows the three main pathways activated by FGF/FGFR signaling – MAPK
pathway, PI3K/Akt pathway, and PLCγ1 pathway.
1.2.3.1 MAPK Pathway – Cell Proliferation
Five different MAP kinases have been identified in mammals so far among which
the extracellular signal-regulated kinase 1/2 (ERK1/2), the c-Jun amino-terminal
kinases (JNKs), and the p38 isoforms are the most comprehensively studied MAP
kinases [104]. Differential activation of the different MAPKs is dependent on the
respective extracellular stimulus, i.e. upon binding of growth factors, such as FGF,
to their receptors a signaling cascade is initiated, which results in the activation of
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ERK1/2 [44, 104, 134]. Common to the different MAPK pathways is a sequential
phosphorylation of multiple kinases involving MAPKKK (MAPK kinase kinase),
MAPKK (MAPK kinase), and MAPK [104,105].
After ligand binding and FGF receptor activation, phosphorylation of the adapter
protein FRS2α by the activated FGFR tyrosine kinases leads to the sequential
recruitment and activation of the growth factor receptor-bound 2 (GRB2)/son
of sevenless (SOS) complex and the GTP-binding protein Ras via SOS (see figure
1.5) [37,66,104]. Ras in turn activates the MAPKKK Raf, which further transmits
the signal by binding and phosphorylating the dual specificity MAPKKs MEK1/2,
which subsequently phosphorylate the MAPKs ERK1/2 [37, 104, 105]. Activated
ERK1/2 can either phosphorylate further targets in the cytosol or translocate
into the nucleus to phosphorylate and thus activate multiple transcription factors,
which in the case of FGF signaling primarily leads to increased cell proliferation
[37,87,104,105].
1.2.3.2 PI3K/Akt Pathway – Cell Survival
Three classes of phosphoinositide 3-kinases (PI3Ks) – named I, II, and III – are
known to exist in mammals [89]. Class I PI3Ks are responsible for cellular re-
sponses to extracellular signals, however upon stimulation of the cell by growth
factors primarily the subclass of Ia PI3Ks gets activated [12,89]. Ia PI3Ks consist
of a regulatory (p85) and a catalytic (p110) subunit [12, 89], which maintain a
strong interaction thus enabling the regulatory p85 subunit to stabilize and in-
hibit the catalytic p110 subunit in unstimulated cells [34]. In activated cells how-
ever, the regulatory p85 subunit is recruited to the plasma membrane to interact
with growth factor receptors or adapter proteins, which subsequently decreases
its interaction with the catalytic p110 subunit, which in turn enables p110 to
generate phosphatidylinositol-3,4,5-trisphosphate (PIP3) from membrane bound
phosphatidylinositol-4,5-bisphosphate (PIP2) [12, 34]. PI3K activity can be fur-
ther enhanced by binding of p110 to activated Ras [12,34]. Downstream targets of
PI3K, such as Akt (also named protein kinase B – PKB) and PDK1 consequently
bind PIP3 and Akt becomes double phosphorylated by PDK1 and another un-
known kinase [12, 89]. Upon activation Akt phosphorylates a large number of
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downstream targets, which mostly leads to inhibition of the respective target [12].
Activation of the PI3K/Akt pathway via FGF signaling does – as for MAPK path-
way activation – involve the activation of FGFR and its associated adapter protein
FRS2α (see 1.2.3.1 for the MAPK pathway, additionally see figure 1.5). Following
the binding and phosphorylation of GRB2 however, the PI3K/Akt and MAPK
pathways diverge and GRB2-associated binding protein 1 (GAB1) is recruited
and activated, which finally results in Akt activation via PI3K as described in
the previous paragraph [37]. Akt activation following FGF signaling leads to the
inactivation of pro-apoptotic transcription factors as well as other pro-apoptotic
downstream targets of Akt, hence promoting cell survival [37].
1.2.3.3 PLCγ1 Pathway – Cell Motility
Upon its activation the phosphoinositide-specific phospholipase C (PLC) is able to
convert phosphatidylinositol-4,5-bisphosphate (PIP2) to inositol-1,4,5-trisphosphate
(IP3) and diacylglycerol (DAG) which raise cytosolic calcium (Ca2+) levels and
induce activation of protein kinase C (PKC) respectively [42, 100, 116]. To date,
13 PLC isozymes divided into six subfamilies – β, γ, δ, , ζ, η – are known to exist
in mammals [22, 42]. The subfamily of PLCγ, consisting of PLCγ1 and PLCγ2,
can be activated through membrane recruitment and phosphorylation by RTKs at
different phosphorylation sites via growth factor induced RTK signaling [42,114].
FGF is one of the growth factors that are able to activate the PLCγ1 signaling
pathway, i.e. FGF induced activation of PLCγ1 results in the generation of the
second messengers IP3 and DAG [37, 100]. The latter activates PKC, which in
turn phosphorylates and activates its downstream targets such as the myristoy-
lated alanine-rich C-kinase substrate (MARCKS) that plays a role in the reg-
ulation of cell motility [37, 93]. IP3 mediated release of Ca2+ from intracellular
stores [100], i.e. the endoplasmic reticulum (ER) [22], as well as Ca2+ influx through
the plasma membrane lead to the activation of calcium-dependent proteins such
as the phosphatase calcineurin [81]. Calcineurin activation subsequently results in
dephosphorylation and hence activation of the transcription factor nuclear factor
of activated T cells (NFAT) that promotes both cell growth [56] and cell motility
in tumor cells [37,81].
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1.2.3.4 STAT Pathway – Cell Survival
The Janus kinase/signal transducers and activators of transcription (JAK/STAT)
signaling pathway is activated upon stimulation of the cell with cytokines or growth
factors [35, 47]. Cytokine or growth factor binding to their respective receptor
leads to the transphosphorylation of the intracellular, receptor-associated tyrosine
kinases JAKs [47]. JAK activation in turn leads to recruitment of STATs to the
receptor where JAKs subsequently phosphorylate and thus activate STATs, which
dimerize and translocate to the nucleus where they function as transcription factors
for their respective target genes [27,47]. To date, four JAKs (JAK1, JAK2, JAK3,
TYK2) and seven STATs (STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B,
STAT6) are known to exist in mammals [35,47].
FGF signaling is able to activate STAT signaling and promote cell survival [133]
either through activation of the previously described JAK/STAT pathway [27,73]
or through a probably direct FGFR/STAT interaction and subsequent phospho-
rylation of STATs by the FGF receptor [27].
1.2.4 Role of FGFR3 in Development and Cancer
FGFR3 is expressed in various tissues including kidney, lung, brain, intestine,
pancreas, testis, and chondrocytes [71]. Being a negative regulator of bone growth
FGFR3 – and FGFR3 signaling – are of major importance for the proliferation
and differentiation of chondrocytes, and germline genetic changes in FGFR3, such
as activating mutations, lead to developmental skeletal disorders [71]. Transmem-
brane FGFR3 mutations are associated with achrondroplasia and kinase domain
FGFR3 mutations with hypochondroplasia, thanatophoric dysplasia type II and
severe achondroplasia with developmental delay and acanthosis nigricans syndrome
(SADDAN syndrome) [7]. Many of the germline activating mutations found in
skeletal disorders have as well been reported as somatic mutations in cancer [71].
FGFR3 S249C, which causes a serine to cysteine exchange in the extracellular do-
main of FGFR3 and thus ligand independent dimerization of the receptor, is associ-
ated with thanatophoric dysplasia type I [71] as well as with bladder urothelial cell
carcinoma, cervical carcinoma [14], and benign seborrheic keratoses [43]. Recently,
FGFR3 S249C mutations were as well reported to be found in lung squamous
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cell carcinoma [75, 80]. Further activating genetic alterations in the FGFR3 gene
such as different mutations, gene amplifications, or chromosomal translocations
have been detected in multiple cancer types [25]. Transforming acidic coiled-coil 3
(TACC3), which is involved in the stabilization of the mitotic spindle apparatus [9],
was recently identified as a fusion partner for FGFR3 to generate an oncogenic in
frame FGFR3-TACC3 fusion in glioblastoma multiforme (GBM) [117], urothelial
bladder carcinoma [127,142], lung squamous cell carcinoma [65,80] and lung ade-
nocarcinoma [13], as well as HNSCC [128, 144]. In addition to these activating
genetic changes, an alteration regarding isoform expression levels of FGFR3 might
potentially contribute to carcinogenesis. Expression of FGFR3 ∆8-10 is down-
regulated in urothelial carcinoma cell lines compared to normal human urothelial
cells and some urothelial carcinoma cell lines show an increase in FGFR3 IIIc
expression [130].
1.3 Objectives
The aim of this investigation is the classification of HNSCC based on the expression
profiles of HNSCC tumor samples, the genomic characterization of HPV-negative
versus HPV-positive HNSCC, and the functional validation of one of the discov-
ered genetic changes.
HNSCC is a heterogeneous disease, which is comprised of two distinct disease enti-
ties, HPV-positive and HPV-negative HNSCC, that differ regarding their progno-
sis [36]. Due to a shift in risk factors – reduced tobacco consumption and change
of sexual behavior – the number of patients diagnosed with HPV-positive HN-
SCC is increasing substantially and HPV-positive HNSCC generally shows a more
favorable outcome than HPV-negative HNSCC [16, 115]. Besides Cetuximab, a
monoclonal antibody against the epidermal growth factor receptor (EGFR), that
shows a low single-agent response rate (13% with 95% CI = 7%–21%) and is
used in palliative and curative care [109, 137], there is no other targeted treat-
ment available for HNSCC and in general, patients are treated uniformly with a
combination of surgery, radiation, and chemotherapy based on stage and location
of the tumor [96, 112]. As a consequence, targeted therapies taking into account
the biologically and clinically different subtypes of HNSCC are urgently needed.
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The combination of conventional therapy with specific targeted treatments could
potentially allow to improve survival without aggravating the negative side effects
of chemoradiotherapy [67].
Multiple attempts were undertaken to classify HNSCC beyond HPV status using
gene expression data to uncover subtypes based on biology to allow personalized
care and targeted treatment [17, 94, 101, 119, 138, 146]. Sample selection criteria
differ between studies and show certain shortcomings – HPV status is unknown,
number of HPV-positive samples is small, HPV-positive samples are not included,
tumors are not homogeneous regarding their stage, total sample number is small,
clinical annotation is missing [17, 94, 101, 119, 138, 146]. Furthermore, previously
published studies use multiple different platforms leading to inter platform varia-
tion and thus differences across studies and the discovered subtypes that are not
attributable to biology. Overlap between the results published by Chung et al.
and Walter et al. has been described [17,138], but generally few common findings
have been identified and overall there is no therapeutically relevant classification.
A similar situation exists with respect to the genomic analysis of HNSCC. Pre-
viously published results of next generation sequencing of HNSCC tumors are
mainly derived from cohorts that include a small number of HPV-positive samples
and thus fail to include meaningful information about the genetic differences of
HPV-positive versus HPV-negative HNSCC [2, 32, 62, 95, 124, 128]. Furthermore,
some studies analyze a small number of samples [2] or include not only primary
but also recurrent tumors [124], whose genetic landscape may be changed due to
prior treatment. As a consequence, little is known about differential molecular
changes in HPV-positive and HPV-negative HNSCC, which is especially relevant
with respect to targetable genomic aberrations.
One aim of this study was the identification of a therapeutically relevant molecu-
lar classification that informs therapy and biomarker development for HNSCC and
hence personalized treatment. Therefore, a newly created homogeneous (locore-
gionally advanced tumors), clinically annotated HNSCC patient cohort (n=134,
all treated uniformly with organ-preserving chemoradiotherapy) with 44% HPV-
positive cases (n=59) was analyzed together with several literature derived cohorts
resulting in a total of 938 samples.
The second objective was the identification of targetable genomic changes through
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genomic profiling of HNSCC to discover potential therapeutic implications for both
disease entities. Therefore, a cohort of 120 matched tumor/normal pairs (120 sam-
ples out of the 134 from the previous part) including 42.5% HPV-positive tumors
(n=51) was processed, subjected to next generation sequencing and copy number
assays, and analyzed in an integrative manner to discover differential molecular
changes (mutations, copy number aberrations) and potential therapeutic targets
in both HPV-positive and HPV-negative HNSCC.
The aim of the final part of the investigation was the functional validation of
potential targets/oncogenic drivers predicted as a result of the next generation se-
quencing (NGS) data analysis that was performed in the previous part. Targeted
therapies taking into account the biologically and clinically different subtypes of
HNSCC are urgently needed for the treatment of HNSCC. Based on the results of
the genomic analysis of the HNSCC cohort of 120 matched tumor/normal samples
described above, the recurrent FGFR3 S249C (c.746C>G) mutation, which was
one of the most frequently observed mutations among HPV-positive tumors in this
cohort [110], was chosen for functional validation.
The FGFR3 S249C mutation causes ligand independent dimerization and activa-
tion of the FGF receptor and aberrant FGFR3 signaling is associated with various
cancers [14, 25, 71, 75, 80]. Identifying and validating specific alterations in the
FGFR3 gene that confer FGFR3 dependence to tumor cells is of importance with
respect to personalized treatment as clinically relevant FGFR inhibitors are avail-
able and targeting of genetic changes in FGFR3 with specific inhibitors has yielded
promising results in multiple in vitro and in vivo studies – e.g. FGFR3b-Y375C
mutation in bladder cancer [8], FGFR3 fusion proteins in bladder cancer [142] and
GBM [117] – which provides the rationale for clinical studies and further investiga-
tion of the role of FGFR3 in other types of cancer. Hence the purpose of the third
part of the investigation was to elucidate the role of FGFR3 S249C in HNSCC.
Chapter 2
Materials and Methods
2.1 General Materials
See table 2.1 for a list of general materials used in most of the described methods.
Item – Description Company
Equipment
Pipets, adjustable, different vol. Eppendorf, Hauppauge, NY
Disposables
TipOne RPT ultra low retention
filter tips, sterile, different sizes
USA Scientific, Inc., Ocala, FL
Ultra Clear Microcentrifuge Tube
1.7mL
DOT Scientific Inc., Burton, MI
Stretchease Powder-Free Nitrile
Examination Gloves
Denville Scientific Inc., South
Plainfield, NJ
Additional Supplies
70% Ethanol for cleaning purposes
(from Ethyl Alcohol 200 proof)
Decon Laboratories Inc., King of
Prussia, PA
Wet Ice
Table 2.1: General materials.
See table 2.2, which lists cell culture specific materials that were generally used.
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Item – Description Company
Equipment
sterilGARD R© Class II Biological
Safety Cabinet
The Baker Company, Sanford, ME
CO2 Incubator Model MCO-18AIC SANYO Electric Co., Ltd., Japan
CryoPlus2 Liquid N2 tank Thermo Fisher Scientific Company,
Pittsburgh, PA
GS-6R Centrifuge No. 277386 Beckman Coulter R©Inc., Brea, CA
Bio Star Microscope Reichert-Jung Inc., Depew, NY
VERSA-BATH R© water bath Fisher Scientific, Hanover Park, IL
Pipet Boy No. D157316 Drummond Sci. Co., Broomall, PA
Chemicals – Reagents – Commercial Solutions and -Kits
Dulbecco’s Modification of Eagle’s
Medium (DMEM), with 4.5 g/L
glucose, L-glutamine, and sodium
pyruvate
Mediatech Inc., A Corning Sub-
sidiary, Manassas, VA
DMEM/Ham’s F-12 50/50 Mix,
without L-glutamine
Mediatech Inc., A Corning Sub-
sidiary, Manassas, VA
BenchMarkTM Fetal Bovine Serum Gemini Bio-Products, West Sacra-
mento, CA
Penicillin-Streptomycin Solu-
tion, 100X, 10000I.U. Penicillin,
10000µg/mL Streptomycin
Mediatech Inc., A Corning Sub-
sidiary, Manassas, VA
HyCloneTM L-Glutamine, 200mM
in 0.85% NaCl
Fisher Scientific, Hanover Park, IL
Phosphate-Buffered Saline, 1X,
without calcium and magnesium
Mediatech Inc., A Corning Sub-
sidiary, Manassas, VA
Disposables
Falcon R© 100mm TC-Treated Cell
Culture Dish, Sterile
Corning Inc., Corning, NY
Serological Pipettes, 25mL, 10mL,
5mL, 2mL
Denville Scientific, Inc., South
Plainfield, NJ
Table 2.2: General materials – cell culture.
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Materials that are specific to each method are listed separately in each section.
Unless otherwise specified the company was located in the USA.
2.2 Patients and Samples
2.2.1 Taxonomy
Patient samples used in this cohort had been collected and banked to the Uni-
versity of Chicago Head and Neck Cancer Tissue Bank (IRB approved protocol
UCCCC#8980) between 1997 and 2010, more than 95% of these samples had
been banked after 2003. All HNSCC specimens used in this study had been de-
rived from surgical biopsies or resections of locoregionally advanced HNSCC prior
to treatment with organ-preserving chemoradiotherapy with curative intent and
thus were treatment na¨ıve. Figure 2.1 summarizes the patient characteristics of
the examined cohort as published in Keck et al. [61].
The aim was to build a homogeneous and clinically annotated patient cohort
that satisfied the sample size criteria for ConsensusClustering (n ≥ 100) and that
included sufficient oropharyngeal tumors to assert a high representation of HPV-
positive cases. Samples were furthermore selected based on the availability of
Optimal Cutting Temperature compound (OCT)-frozen tumor tissue. Clinical
data were derived from the clinical database of the University of Chicago (data
were extracted from the clinical database by Rebecca DeBoer).
Normal DNA samples purified from peripheral blood of four patients of this cohort
were obtained from the Department of Pathology at the University of Chicago and
utilized as reference for the Nanostring copy number assay (see 2.3.13).
2.2.2 Genomic Analysis
The genomic analysis of HNSCC was performed on the same patient cohort as the
classification using DNA derived from the already extracted tumor tissue samples
(with the one exception that only 120 samples were used). Normal DNA from the
same patient cohort was derived from uninvolved lymph nodes and skin biopsies
(n=96 – frozen OCT blocks or FFPE slides) or blood (n=24). Macrodissection of
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Figure 2.1: Sample selection criteria overview and sample processing workflow
as published in Keck et al. [61].
Tumor tissue samples were extracted and RNA/DNA/protein were purified. RNA was
used for expression arrays, DNA was subjected to HPV PCR. Copy number assays
and analysis were performed on samples with sufficient DNA, survival analysis was
performed using samples with complete survival history.
normal tissue samples from frozen OCT blocks (n=59) was performed as described
for tumor specimens in 2.3.1. Extraction of normal tissue samples from formalin-
fixed, paraffin-embedded (FFPE) slides (n=37) was performed as described in
2.3.3. DNA derived from peripheral blood (n=24) was provided by the Department
of Pathology at the University of Chicago. This DNA was further subjected to
isopropanol precipitation to concentrate and clean up the samples as described in
2.3.5.
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2.3 Molecular Biology Methods
2.3.1 Tissue Macrodissection
Tumor tissue (frozen OCT blocks) and the corresponding hematoxylin and eosin
(H&E) stained tumor sections on slides were obtained through the Department
of Pathology at the University of Chicago. H&E stained slides were reviewed by
an acknowledged head and neck cancer pathologist to determine and circle areas
with the highest tumor content. According to the previously defined selection
criteria (see 2.1) only samples with ≥ 60% tumor content were selected for this
study resulting in a total of 171 HNSCC specimens that were subjected to tissue
macrodissection.
Materials
See table 2.3 for the required materials. Unless otherwise specified the company
was located in the USA.
Specimens
• HNC specimens: fresh-frozen OCT blocks, tumor content ≥ 60%
• H&E stained slides: one slide corresponding to one OCT block
Procedure
The working area was cleaned with 70% ethanol and subsequently sprayed and
wiped down with RNaseZap R© to remove any potential sources of contamination
with nucleic acids or nucleases. All working materials (e.g. pipettes or pipette tip
boxes) that had to be put into the clean working area were as well cleaned with
RNaseZap R©. A piece of aluminum foil was put on the benchtop to serve as a dish,
on which the sample could be handled. Subsequently, aluminum foil and gloved
hands were cleaned with RNaseZap R© along with the respective H&E stained slide
that was put into place along with the scalpel and the Covaris supplies needed to
pulverize and homogenize the sample.
A frozen OCT sample block was taken out of the dry ice box and put on the
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Item – Description Company
Equipment
cryoPREPTMImpactor Covaris, Inc., Woburn, MA
tissueTUBE TT1 Covaris, Inc., Woburn, MA
tissueTUBE TT1 Adapter
12x24mm
Covaris, Inc., Woburn, MA
Glass Tube & Cap 12x24mm Covaris, Inc., Woburn, MA
S220 Focused-ultrasonicator Covaris, Inc., Woburn, MA
S-Series Holder 12x24 Tube Covaris, Inc., Woburn, MA
Bel-ArtTMSciencewareTMLiquid
Nitrogen-Cooled Mortar
Fisher Scientific, Hanover Park, IL
Thermo ScientificTMThermo-Flask
Benchtop Liquid Nitrogen Con-
tainer
Fisher Scientific, Hanover Park, IL
Chemicals – Reagents – Commercial Solutions and -Kits
AllPrep DNA/RNA/Protein Mini
Kit
QIAGEN Inc., Valencia, CA
β-Mercaptoethanol MP Biomedicals, LLC, Solon, Ohio
RNA/DNA/Protein Purification
Kit
Norgen Biotek Corp., Thorold, On-
tario, Canada
Disposables
Feather Disposable Scalpel #21 Fisher Scientific, Hanover Park, IL
Sharps-A-GatorTMSharps Con-
tainer
Fisher Scientific, Hanover Park, IL
Aluminum Foil Fisher Scientific, Hanover Park, IL
Additional Supplies
RNaseZap R© Life Technologies, Grand Island,
NY
Liquid Nitrogen
Dry Ice
Table 2.3: Materials – tissue macrodissection.
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aluminum foil. Guided by the respective H&E stained slide a portion of the frozen
sample (no more than an approximately 2mm cube ≈̂ 6–10 mm3) was cut out from
the area with the highest tumor content using the scalpel and immediately trans-
ferred to the center of a Covaris tissueTUBE. The remainder of the OCT block
was stored on dry ice. The tissue tube containing the cut sample was immediately
dipped into liquid nitrogen and connected to the adapter and glass tube before pul-
verizing the tissue by means of the Covaris cryoPREP impactor (level 4) and trans-
ferring it to the connected glass tube. The tissue tube and adapter were unscrewed
and the appropriate amount of lysis buffer from a standard DNA/RNA/protein
extraction kit, mostly 600µL (containing previously added β-mercaptoethanol ac-
cording to the manufacturer’s protocol, 10µL β-ME per 1mL lysis buffer), was
added to the sample in the glass tube. The glass tube was capped and labeled,
and the pulverized tissue (in lysis buffer) was immediately lysed and homogenized
using the prechilled and degased Covaris focused-ultrasonicator (Adaptive Focused
Acoustics (AFA)), S-series, duty cycle 20%, intensity 10, cycles per burst 500, time
60s. If any cell debris was present after ultrasonication, samples were subjected to
acoustic treatment once more and subsequently frozen at −80 ◦C until purification
of DNA, RNA, and protein could be performed.
Appropriate cooling of the tissue specimens was ensured at all times during the
process. Frozen OCT blocks were kept on dry ice before and after cutting. Cut
samples were repeatedly dipped into liquid nitrogen before, during, and after the
pulverization process and, once homogenized, were kept on dry ice (if processed
on the same day) or stored in a −80 ◦C freezer until further processing (see 2.3.2).
Any item in direct contact with the sample or sample block (gloves, aluminum
foil, scalpel, Covaris supplies) was discarded and replaced after each sample to
minimize the potential risk of cross-contamination of samples.
2.3.2 DNA/RNA/Protein Purification
DNA, RNA and protein were purified from each sample using the respective kit
(according to the lysis buffer used in 2.3.1) and buffers of the kits were prepared
as indicated by the manufacturer’s protocol. The previously pulverized, homoge-
nized, and lysed tissue sample tubes were transferred from dry ice (or the −80 ◦C
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freezer) to wet ice and allowed to thaw completely. Once thawed, all lysates were
pipetted up and down to dissolve any precipitate before starting the procedure.
The working area was cleaned with 70% ethanol and RNaseZap R©, working materi-
als (e.g. pipettes, pipette tip boxes, bottles) were as well cleaned with RNaseZap R©.
All steps of the procedure, including all centrifugation steps, were performed at
room temperature.
Materials
See table 2.4 for the required materials. Unless otherwise specified the company
was located in the USA.
Item – Description Company
Equipment
Eppendorf Microcentrifuge 5415D Eppendorf, Hauppauge, NY
Chemicals – Reagents – Commercial Solutions and -Kits
AllPrep DNA/RNA/Protein Mini
Kit
QIAGEN Inc., Valencia, CA
β-Mercaptoethanol MP Biomedicals, LLC, Solon, Ohio
Ethyl alcohol, pure, 200 proof, for
molecular biology
Sigma-Aldrich Corp., St. Louis,
MO
RNA/DNA/Protein Purification
Kit
Norgen Biotek Corp., Thorold, On-
tario, Canada
Additional Supplies
RNaseZap R© Life Technologies, Grand Island,
NY
Table 2.4: Materials – DNA/RNA/protein purification.
2.3.2.1 AllPrep DNA/RNA/Protein Mini Kit (Qiagen) – Procedure
The lysate was transferred from the Covaris glass tube to a microcentrifuge tube
and centrifuged at 13,000rpm for 3 minutes before the supernatant was transferred
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to an AllPrep DNA spin column (placed in a collection tube), which was spun at
8,000g for 30 seconds. The spin column was placed into a new collection tube
and stored at room temperature until purification of DNA was performed. The
flow-through was used for RNA purification. 1.5 volumes of pure 100% ethanol
(= modification of standard protocol to co-purify micro RNAs) were added to the
flow-through and mixed by pipetting. 700µL of the sample were transferred to
an RNeasy spin column in a 2mL collection tube that was subsequently spun at
8,000g for 15 seconds. The flow-through was transferred to a 2mL tube (for protein
purification) and the remaining sample (total volume exceeded 700µL) was loaded
to the same RNeasy spin column and centrifuged at 8,000g for 15 seconds. The
flow-through was added to the flow-through obtained after the first centrifugation
step and frozen at −80 ◦C for protein purification. 700µL wash buffer RW1 were
added to the RNeasy spin column, which was centrifuged at 8,000g for 15 seconds.
The flow-through was discarded and 500µL buffer RPE were loaded on the spin
column followed by centrifugation at 8,000g for 15 seconds, the flow-through was
discarded. The column was washed once more by adding another 500µL buffer
RPE and centrifuging at 8,000g for 2 minutes. After discarding the flow-through,
the column was placed into a new collection tube and dried by centrifuging the
empty column at 13,000rpm for 1 minute to ensure complete removal of buffer RPE
from the column. The spin column was subsequently placed into a new 1.5mL
collection tube, 50µL RNase-free water were added to the spin column membrane,
and RNA was eluted from the column by centrifugation at 8,000g for 1 minute.
Aliquots were removed for determination of RNA quality (see 2.3.7) and quantity
(see 2.3.6) before freezing the RNA at −80 ◦C for downstream applications.
Genomic DNA was purified from the AllPrep DNA spin column that had been
stored in the beginning of the procedure. 500µL buffer AW1 were added and the
column was spun at 8,000g for 15 seconds. The flow-through was discarded and
500µL buffer AW2 were added to the column, which was then spun at 13,000rpm
for 2 minutes to wash the column membrane. To ensure complete removal of buffer
AW2 the collection tube was emptied and the column was spun again at 13,000rpm
for 1 minute. The spin column was transferred to a new 1.5mL collection tube
and 100µL preheated (70 ◦C) buffer EB were added to the spin column membrane,
which was incubated at room temperature for 2 minutes and subsequently spun
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at 8,000g for 1 minute to elute DNA. Aliquots were removed for determination
of DNA quality (see 2.3.7) and quantity (see 2.3.6) before freezing the DNA at
−20 ◦C.
2.3.2.2 RNA/DNA/Protein Purification Kit (Norgen) – Procedure
The lysate was transferred from the Covaris glass tube to a microcentrifuge tube
and centrifuged at 13,000rpm for 2 minutes before the supernatant was transferred
to another microcentrifuge tube. An equal volume of 70% ethanol was added to
each sample, samples were vortexed for approximately 10 seconds, and 600µL of
the sample were transferred to a spin column placed in a collection tube, which
was spun at 13,000rpm for 1 minute. The flow-through was transferred to a new
microcentrifuge tube and kept for protein purification (stored on ice). The residual
sample was loaded on the same column and spun again at 13,000rpm for 1 minute.
The flow-through was added to the same microcentrifuge tube that was contain-
ing the flow-through from the previous centrifugation step. Microcentrifuge tubes
were stored on ice until protein purification was performed or stored at −80 ◦C,
if protein purification could not be performed on the same day. The spin column
was placed into a new collection tube and 400µL of RNA Wash Solution were
added to the column, which was then centrifuged at 13,000rpm for 1 minute. The
flow-through was discarded and the column was loaded with another 400µL of
RNA Wash Solution and spun at 13,000rpm for 1 minute. After discarding the
flow-through, the column was reassembled with its collection tube and spun at
13,000rpm for 2 minutes to dry the column. The collection tube was discarded
and the column was placed into a fresh microcentrifuge tube for RNA elution.
50µL of RNA Elution Solution were added to the column, which was subsequently
spun at 13,000rpm for 1 minute. As described previously, aliquots were removed
for determination of RNA quality (see 2.3.7) and quantity (see 2.3.6) before freez-
ing the RNA at −80 ◦C for downstream applications.
Genomic DNA was purified from the same column as RNA. Therefore, after the
elution of RNA, the spin column was placed into a new collection tube and 500µL of
gDNA Wash Solution were added to the column, which was then spun at 13,000rpm
for 2 minutes. The flow-through was discarded and the column was spun for an-
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other 2 minutes at 13,000rpm to dry the column. The collection tube was discarded
and the column was placed into a fresh microcentrifuge tube for gDNA elution.
100µL of gDNA Elution Buffer were added to the column, which was first spun
at 200g for 2 minutes and subsequently at 13,000rpm for 1 minute to elute DNA.
Aliquots were removed for determination of DNA quality (see 2.3.7) and quantity
(see 2.3.6) before freezing the DNA at −20 ◦C.
The same column that had been used for RNA and DNA purification was now
reused for protein purification. First, the entire flow-through retained for protein
purification was adjusted to 600µL using molecular biology grade water. Then,
48µL of Protein pH Binding Buffer were added and mixed by pipetting up and
down to adjust the pH of the samples. Then, the entire pH adjusted sample
(650µL) was loaded on the column and spun at 5,200g for 2 minutes. If a part of
the sample had not passed through the column, the respective sample was spun
again at 5,200g until everything had passed through (up to 10 minutes). The
flow-through was discarded and 500µL of Protein Wash Buffer were added to the
column, which was centrifuged at 5,200g for 2 minutes. In the meantime, 9.3µL
of Neutralizer were added to a fresh microcentrifuge tube. The flow-through of
the centrifugation step was discarded and the column was placed into the micro-
centrifuge tube containing the Neutralizer. 100µL of Protein Elution Buffer were
added to the column and protein was eluted by centrifugation at 5,200g for 2
minutes. Protein samples were stored at −80 ◦C.
2.3.3 Extraction of DNA/RNA Containing Tissue from
FFPE Tissue Slides
Materials
See table 2.5 for the required materials. Unless otherwise specified the company
was located in the USA.
Specimens
• Normal tissue specimens: up to 8 formalin-fixed, paraffin-embedded
(FFPE) slides, thickness 10µm, tumor content 0%
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Item – Description Company
Equipment
Eppendorf Microcentrifuge 5415D Eppendorf, Hauppauge, NY
Chemicals – Reagents – Commercial Solutions and -Kits
Ethyl alcohol, pure, 200 proof, for
molecular biology
Sigma-Aldrich Corp., St. Louis,
MO
Disposables
Feather Disposable Scalpel #21 Fisher Scientific, Hanover Park, IL
Sharps-A-GatorTMSharps Con-
tainer
Fisher Scientific, Hanover Park, IL
Additional Supplies
RNaseZap R© Life Technologies, Grand Island,
NY
Table 2.5: Materials – FFPE extraction.
• H&E stained slides: 1 H&E slide corresponding to one set of FFPE slides
Procedure
As described for tissue macrodissection of tumor samples (see 2.3.1), H&E stained
slides reviewed by a pathologist were used as guide slides for the FFPE slides to
determine which part of the sample could be extracted (area with 0% tumor con-
tent was encircled). Sample material of up to eight FFPE slides (10µm thickness
each) was combined depending on the part of the sample that could be used for
extraction (not more than 600mm2 total surface area were used for purification as
recommended by the kit).
The working area was cleaned with 70% ethanol and RNaseZap R©. The material
was scraped off of the FFPE slides using a new scalpel for every patient and col-
lected in a microcentrifuge tube filled with 100% ethanol. The tube was centrifuged
at 13,000rpm for 5 minutes at room temperature. The supernatant was carefully
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removed and the pellet was left to dry over night (12–20h) at room temperature in
the microcentrifuge tube (lid open). Subsequently, RNA and DNA were extracted
as described in 2.3.4.
2.3.4 Purification of DNA/RNA Derived from FFPE Tis-
sue Slides
Materials
See table 2.6 for the required materials. Unless otherwise specified the company
was located in the USA.
Item – Description Company
Equipment
Eppendorf Microcentrifuge 5415D Eppendorf, Hauppauge, NY
Dry Bath Incubator Fisher Scientific, Hanover Park, IL
Chemicals – Reagents – Commercial Solutions and -Kits
AllPrep DNA/RNA FFPE Kit QIAGEN Inc., Valencia, CA
Ethyl alcohol, pure, 200 proof, for
molecular biology
Sigma-Aldrich Corp., St. Louis,
MO
2-Propanol, for molecular biology,
99.5%
Sigma-Aldrich Corp., St. Louis,
MO
RNase A QIAGEN Inc., Valencia, CA
CitriSolvTMHybrid Solvent and
Clearing Agent, FisherbrandTM
Fisher Scientific, Hanover Park, IL
RNase A, DNase and protease-free
(10 mg/mL)
Life Technologies, Grand Island,
NY
Additional Supplies
RNaseZap R© Life Technologies, Grand Island,
NY
Table 2.6: Materials – DNA/RNA purification from FFPE tissue sections.
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Procedure
The AllPrep DNA/RNA FFPE kit was used to purify genomic DNA and total
RNA from the material extracted from FFPE slides as described in 2.3.3. The
working area was cleaned using 70% ethanol and RNaseZap R©. 100% isopropanol
was added to buffer FRN, 100% ethanol was added to buffers RPE, AW1, and
AW2 according to the instructions of the manufacturer. DNase I stock solution
was prepared by dissolving the lyophilized enzyme (provided with the kit) in 550µL
RNase-free water and gently inverting the vial to mix. All steps of the procedure,
including all centrifugation steps, were carried out at room temperature.
1mL CitriSolvTMwas added to each sample tube from the FFPE slide scraping step
(see 2.3.3) to remove paraffin from the samples. Tubes were closed, vortexed for 10
seconds, and centrifuged at 13,000rpm for 2 minutes. The supernatant was care-
fully removed by pipetting and the deparaffinization with CitriSolvTMwas repeated
up to three times until the pellets looked less fluffy. Subsequently, CitriSolvTMwas
removed and pellets were washed by adding 1mL 100% ethanol to remove residual
CitriSolvTMfrom the sample. Samples were vortexed, centrifuged at 13,000rpm
for 2 minutes, and the supernatant was removed by pipetting. The tubes were
kept on the benchtop (with the lid open) for approximately 30 minutes (or up
to 16 hours over night) to dry the pellets. Then, the pellet was resuspended in
150µL Buffer PKD. Tubes were flicked to loosen the pellet, 10µL proteinase K
were added and mixed by vortexing before incubating the samples at 56 ◦C for
15 minutes. Following lysis and proteinase K digest, samples were put on ice
for 3 minutes and centrifuged at 20,000g for 15 minutes to precipitate DNA and
pellet insoluble material. After transferring the RNA containing supernatant to a
fresh microcentrifuge tube, the DNA containing pellet was resuspended in 180muL
Buffer ATL, 40µL proteinase K were added and mixed by vortexing. Samples were
incubated at 56 ◦C for 1 hour followed by 90 ◦C for 2 hours. In the meantime, RNA
was purified.
The RNA containing supernatant that had been transferred to a fresh 2mL mi-
crocentrifuge tube was incubated at 80 ◦C for 15 minutes and briefly spun down
to collect liquid at the bottom of the tube. 320µL Buffer RLT were added and
mixed by pipetting. Then, 1120µL 100% ethanol were added and as well mixed
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by pipetting before 700µL of the sample were transfered to an RNeasy MinElute
spin column and centrifuged at 8,000g for 15 seconds. The flow-through was dis-
carded and the rest of the sample was applied to the column and centrifuged at
8,000g for 15 seconds. The flow-through was again discarded, 350µL Buffer FRN
were added to the spin column, which was centrifuged at 8,000g for 15 seconds,
then the flow-through was discarded. The DNase I master mix was prepared by
adding 10µL DNase I stock solution to 70µL Buffer RDD in a fresh microcen-
trifuge tube. The master mix containing tube was inverted to mix the enzyme
with the buffer and briefly spun down to collect liquid at the bottom of the tube.
The entire 80µL DNase I incubation mix were added to the spin column mem-
brane and incubated at room temperature on the benchtop for 15 minutes. 500µL
Buffer FRN were added to the column, the column was centrifuged at 8,000g for
15 seconds and the flow-through was not discarded but applied to the same col-
umn in a new collection tube, which was centrifuged at 8,000g for 15 seconds, the
flow-through was discarded. The spin column was washed twice with 500µL Buffer
RPE – centrifugation at 8,000g for 15 seconds – the flow-through was discarded
and after the second wash step the collection tube was discarded as well and the
column was placed into a new collection tube. The column was then centrifuged
with the lid open at 13,000rpm for 5 minutes to dry the spin column membrane,
flow-through and collection tube were discarded and the column was placed into
a fresh microcentrifuge tube. RNA was eluted by adding 30µL RNase-free water
to the membrane – incubation 1 minute at room temperature – and centrifuging
the column at 13,000rpm for 1 minute.
Following incubation at 90 ◦C, the microcentrifuge tubes containing the DNA were
briefly spun down to collect liquid at the bottom of the tube and left on the bench-
top to cool down to room temperature. 2µL RNase A (=̂100U) were added and
samples were incubated at room temperature for 2 minutes. A master mix contain-
ing 200µL Buffer AL and 200µL 100%ethanol per sample was prepared and 400µL
were added to each sample. Samples were vortexed, and the entire sample mix was
transfered to a QIAamp MinElute spin column in a collection tube and centrifuged
at 8,000g for 1 minute. The flow-through and the collection tube were discarded
and the column was placed into a new collection tube. 700µL Buffer AW1 were
added to the column which was centrifuged at 8,000g for 15 seconds. The flow-
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through was discarded and a second washing step was performed by transferring
700µL Buffer AW2 to the column and centrifuging it at 8,000g for 15 seconds. The
flow-through was discarded and 700µL 100% ethanol were added to the column fol-
lowed by centrifugation at 8,000g for 15 seconds. Collection tube and flow-through
were discarded, the column was placed into a new collection tube and centrifuged
at 13,000rpm for 5 minutes (with lid opened) to dry the spin column membrane.
Flow-through and collection tube were discarded and the spin column was placed
into a microcentrifuge tube for sample elution. Elution of DNA was performed by
adding 60µL Buffer ATE to the spin column membrane followed by an incubation
on the benchtop at room temperature for 5 minutes. The column was centrifuged
at 13,000rpm for 1 minute to elute DNA. Quality and quantity of the purified RNA
and DNA were determined by NanoDrop and Quant-iT PicoGreen measurements
– described in 2.3.6 and 2.3.7 and page 41 respectively.
2.3.5 Precipitation of DNA
Materials
See table 2.7 for the required materials. Unless otherwise specified the company
was located in the USA.
Procedure
DNA derived from blood (provided by the Department of Pathology at the Uni-
versity of Chicago) was concentrated and cleaned up by isopropanol precipitation.
Depending on the available volume, 170–400µL of the DNA solution were trans-
fered to a microcentrifuge tube and mixed with 0.7 volume isopropanol after adding
the respective volume 3M sodium acetate to reach a final concentration of 0.3M
sodium acetate. The mix was centrifuged at 15,000g for 30 minutes at 4 ◦C to
precipitate and pellet DNA. The supernatant was discarded and the DNA pel-
let was washed twice with 1mL 70% ethanol – centrifugation was performed at
15,000g for 30 minutes at 4 ◦C. After removing the supernatant, the DNA pellet
was dried (lid open) on a heat block at 40 ◦C for up to 1 hour depending on the
remaining volume of ethanol. DNA was resuspended in 100µL H2O/TE 1:1 mix.
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Item – Description Company
Equipment
Centrifuge 5424R, refridgerated Eppendorf, Hamburg, Germany
Dry Bath Incubator Fisher Scientific, Hanover Park, IL
Chemicals – Reagents – Commercial Solutions and -Kits
2-Propanol, for molecular biology,
99.5%
Sigma-Aldrich Corp., St. Louis,
MO
Sodium Acetate (3M), pH 5.5 Life Technologies, Grand Island,
NY
Ethyl alcohol, pure, 200 proof, for
molecular biology
Sigma-Aldrich Corp., St. Louis,
MO
HyCloneTM Water, Molecular Biol-
ogy Grade
Fisher Scientific, Hanover Park, IL
TE Buffer Life Technologies, Grand Island,
NY
Table 2.7: Materials – DNA precipitation.
Microcentrifuge tubes were left on the benchtop at room temperature over night
to ensure complete solubilization of DNA. If precipitate was still present on the
following day, the respective tubes were incubated at 50 ◦C for 4 hours to dissolve
DNA. Quant-iT PicoGreen and NanoDrop measurements were performed to assess
quantity and quality of DNA (see 2.3.6 and 2.3.7).
2.3.6 Quantification of Nucleic Acids
Materials
See table 2.8 for the required materials. Unless otherwise specified the company
was located in the USA.
2.3.6.1 NanoDrop – Procedure
RNA and DNA quantity were determined using a NanoDrop spectrophotometer,
which measures absorption of light by a compound in the ultraviolet and visible
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Item – Description Company
Equipment
Infinite M200 PRO Microplate
Reader
Tecan Group Ltd., Ma¨nnedorf,
Switzerland
NanoDrop 2000c UV-Vis Spec-
trophotometer
Thermo Fisher Scientific Inc.,
Waltham, MA
GeneMate Minifuge BioExpress, Kaysville, UT
Chemicals – Reagents – Commercial Solutions and -Kits
Quant-iTTMPicoGreen R©dsDNA
Assay Kit
Life Technologies, Grand Island,
NY
Disposables
Corning R©96 Well Clear Flat Bot-
tom Polystyrene Not Treated Mi-
croplate, with Lid, Sterile
Corning Inc., Corning, NY
Table 2.8: Materials – quantification of nucleic acids.
range. The amount of light which is absorbed by a particular substance can be de-
termined and used to calculate the concentration of the respective substance by ap-
plying LambertBeer law. Nucleic acids absorb light at a wavelength of 260nm. The
NanoDrop spectrophotometer and software calculate the concentration of RNA,
DNA and the corresponding purity ratios – 260/280nm and 260/230nm – indi-
cating the degree of contamination with proteins (280nm) or organic compounds
(230nm) or other molecules that absorb at these wavelengths and that potentially
interfere with downstream applications. Purity ratios greater or equal to 1.8 are
desired.
Samples or sample aliquots were briefly mixed by flicking the tubes, spun down
using the minifuge, and stored on ice while measurements were performed. The
pedestal surfaces of the instrument were wiped with distilled water to clean them
and the instrument was blanked with 1µL of the respective sample buffer. The
instrument was repeatedly blanked in between measurements (after every 6–8 sam-
ples) to ensure accuracy of the measurements. The pedestal surfaces were wiped
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after each measurement to remove blank buffer or sample. After blanking the in-
strument, the samples were measured by transferring 1µL of sample to the lower
pedestal surface. The lid (upper surface) was closed, absorbance was measured,
and concentration was calculated.
2.3.6.2 Quant-iT PicoGreen – Procedure
DNA concentrations were determined using Quant-iT PicoGreen. Quant-iT PicoGreen
is a fluorescent stain that binds double stranded DNA (dsDNA). Unlike absorbance
measurements at 260nm that cannot distinguish between dsDNA, single stranded
DNA (ssDNA), RNA, free nucleotides, or other molecules (contaminants) which
absorb at 260nm and hence tend to overestimate the actual DNA concentration,
Quant-iT PicoGreen exclusively binds dsDNA enabling exact and sensitive quan-
tification of dsDNA.
The lambda DNA standard (100µg/mL) was diluted 1:50 with buffer TE to pre-
pare 120µL of working solution #1 (2µg/mL). Working solution #1 was diluted
1:10 with buffer TE to prepare 10µL of working solution #2 (0.2µg/mL). The
PicoGreen assay dye was diluted 1:200 with buffer TE on the day of the assay and
kept protected from light to avoid photodegradation. DNA sample dilutions were
prepared in microcentrifuge tubes to obtain a final volume of 100µL DNA diluted
1:100 or 1:50 with buffer TE depending on the previously obtained NanoDrop read-
ings to fit in the scope of the standard curve. Five different concentrations of the
lambda DNA standard (STD) were prepared in microcentrifuge tubes following
the pipetting scheme in 2.9.
STD Buffer TE Lambda DNA STD PicoGreen in Final conc.
# (µL) (µL) TE 1:200 (µL) (ng/µL)
1 100 0 100 0 (blank)
2 99 1 (of STD #2) 100 0.001
3 99 1 (of STD #1) 100 0.01
4 90 10 (of STD #1) 100 0.1
5 0 100 (of STD #1) 100 1
Table 2.9: Quant-iT PicoGreen – pipetting scheme for lambda DNA standard.
100µL of the diluted PicoGreen assay dye were added to each standard or sam-
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ple in the microcentrifuge tubes and mixed well by pipetting. After 5 minutes of
incubation at room temperature on the benchtop (protected from light), 180µL of
each assay mix (samples and standards) were transfered to a well in the microplate
and measured in a plate reader using the settings listed in 2.10 (optimal gain for
standard with highest DNA concentration).
To calculate DNA concentrations, a standard curve was generated by plotting flu-
orescence intensity readings of the five standards versus DNA concentration after
subtracting the blank value from each assayed sample and standard.
Quant-iT PicoGreen – Plate Reader Settings
Mode Fluorescence Top Reading
Excitation Wavelength 480nm
Emission Wavelength 520nm
Excitation Bandwidth 9nm
Emission Bandwidth 20nm
Gain optimal
Number of Flashes 5
Integration time 20µs
Lag Time 0µs
Settle Time 0ms
Z-Position(Manual) 20000µm
Table 2.10: Quant-iT PicoGreen – plate reader settings.
2.3.7 Quality Control of Nucleic Acids
Quality of the purified nucleic acids was assessed using the NanoDrop 2000c UV-
Vis Spectrophotometer (RNA and DNA) as well as the Agilent 2100 Bioanalyzer
(RNA). As described previously in 2.3.6, the 260/280 and 260/230 purity ratios ac-
quired along with the concentration measurements using the NanoDrop instrument
give information about possible contamination of the RNA or DNA preparation
with proteins (280nm), organic compounds (230nm) or other molecules that ab-
sorb at these wavelengths. Purity ratios greater or equal to 1.8 were accepted for
downstream applications, minor exceptions were allowed for the 260/230 ratio. If
the 260/230 ratio in RNA samples was below 1.2, RNA was subjected to a column
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cleanup (see 2.3.8.3) followed by another RNA quantitation and quality control.
RNA samples were analyzed with an Agilent 2100 Bioanalyzer by the Genomics
Core Facility at the University of Chicago. The bioanalyzer measures the degree
of RNA degradation by analyzing the 18S and 28S ribosomal subunits of eukary-
otic RNA. An RNA integrity number (RIN) is received for each sample reflecting
the degree of total RNA degradation. A RIN of at least 7.5 (10 is best) was
required for downstream applications (microarray). Samples with a lower RIN
were excluded from further analysis. If DNA traces were visible in the obtained
electropherograms, RNA samples were either digested with DNase (see 2.3.8) or
re-extracted.
2.3.8 Removal of DNA from RNA Samples
Materials
See table 2.11 for the required materials. Unless otherwise specified the company
was located in the USA.
2.3.8.1 First Digest – Procedure
The TURBO DNA-freeTMkit contains recombinant, engineered DNaseI with a high
affinity for DNA which is bound and digested by the enzyme and thus removed
from the RNA preparation. In a subsequent step, the enzyme is inactivated and
removed along with divalent cations.
RNA samples were thawed on ice, mixed by flicking the tube and briefly spun
down to collect the liquid at the bottom of the tube. 0.1 volume 10X TURBO
DNase buffer and 1µL TURBO DNase were added to the RNA and mixed by
flicking the tubes. Samples were then incubated at 37 ◦C for 30 minutes in a heat
block. DNase inactivation reagent was resuspended by flicking the tube and 0.1
volume was added to the digested samples and intermixed by flicking the tubes
again. The samples were incubated at room temperature on the benchtop for 5
minutes and the tubes were repeatedly flicked to ensure an equal distribution of
the inactivation suspension. Following incubation, the samples were centrifuged
at 10,000g for 1.5 minutes and transferred to a fresh microcentrifuge tube without
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Item – Description Company
Equipment
Dry Bath Incubator Fisher Scientific, Hanover Park, IL
GeneMate Minifuge BioExpress, Kaysville, UT
Eppendorf Microcentrifuge 5415D Eppendorf, Hauppauge, NY
Chemicals – Reagents – Commercial Solutions and -Kits
TURBO DNA-freeTMKit Life Technologies, Grand Island,
NY
TRIS-HCL 1M pH 7.8 Fisher Scientific, Hanover Park, IL
Magnesium chloride solution, for
molecular biology, 1M in H2O
Sigma-Aldrich Corp., St. Louis,
MO
Calcium Chloride Dihydrate Fisher Scientific, Hanover Park, IL
HyCloneTM Water, Molecular Biol-
ogy Grade
Fisher Scientific, Hanover Park, IL
RNeasy MinElute Cleanup Kit QIAGEN Inc., Valencia, CA
Ethyl alcohol, pure, 200 proof, for
molecular biology
Sigma-Aldrich Corp., St. Louis,
MO
Table 2.11: Materials – removal of DNA from RNA samples.
transferring any traces of the inactivation reagent. Subsequently, RNA concen-
trations were measured (see 2.3.6) and RNA was subjected to quality control (see
2.3.7) and stored at −80 ◦C. If RNA quality was still not satisfactory regarding
its contamination with DNA, a second digest (see 2.3.8.2) followed by a column
cleanup (see 2.3.8.3) was performed and samples were quantified and subjected to
quality control again.
2.3.8.2 Second Digest – Procedure
First, the 10X TURBO DNA-free Second Digest Buffer with the following com-
position – 200mM Tris-HCl pH 7.5, 100mM MgCl2, 5mM CaCl2 – was prepared
using molecular biology grade water. Final pH of the buffer was 7.5. The buffer
was autoclaved twice in order to minimize the risk of contamination with RNase.
RNA samples previously digested with DNase (see 2.3.8.1) that had to be sub-
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jected to a second digest were partly transferred to a fresh microcentrifuge tube.
The procedure for the second digest was the same as described for the first digest
in 2.3.8.1 with the exception that 0.1 volume 10X TURBO DNA-free Second Di-
gest Buffer was used (instead of 10X TURBO DNase buffer). Following second
digest, a column cleanup was performed (see 2.3.8.3) to minimize salt carryover
that could compromise microarray results.
2.3.8.3 Column Cleanup – Procedure
Ethanol was added to buffer RPE according to the instructions of the manufac-
turer. The volume of the digested RNA was adjusted to 100µL using RNase-free
water. 350µL buffer RLT were added and mixed by pipetting. 250µL of 100%
ethanol were added and mixed by pipetting before the entire sample was loaded
on an RNeasy MinElute spin column in a collection tube. The spin column with
the sample was centrifuged at 8,000g for 15 seconds and the flow-through was dis-
carded. The spin column was assembled with a new collection tube, 500µL buffer
RPE were added, and the column was spun again at 8,000g for 15 seconds, the
flow-through was discarded. 500µL of 80% ethanol were added to the spin column,
which was then centrifuged at 8,000g for 2 minutes. Flow-through and collection
tube were discarded, the spin column was assembled with a new collection tube,
and centrifuged at 13,000rpm for 5 minutes to dry the membrane (lid of the spin
column was kept open during centrifugation). The spin column was placed in a
fresh microcentrifuge tube and 14µL RNase-free water were added to the mem-
brane. The lid was closed and the RNA was eluted by centrifugation at 13,000rpm
for 1 minute. RNA concentrations were measured (see 2.3.6), RNA was subjected
to quality control (see 2.3.7) and stored at −80 ◦C.
2.3.9 Removal of RNA from DNA Samples
Materials
See table 2.12 for the required materials. Unless otherwise specified the company
was located in the USA.
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Item – Description Company
Equipment
Dry Bath Incubator Fisher Scientific, Hanover Park, IL
Eppendorf Microcentrifuge 5415D Eppendorf, Hauppauge, NY
GeneMate Minifuge BioExpress, Kaysville, UT
Chemicals – Reagents – Commercial Solutions and -Kits
RNase I (10U/µL) Thermo Fisher Scientific Inc.,
Waltham, MA
QIAquick PCR Purification Kit QIAGEN Inc., Valencia, CA
Ethyl alcohol, pure, 200 proof, for
molecular biology
Sigma-Aldrich Corp., St. Louis,
MO
Table 2.12: Materials – removal of RNA from DNA samples.
2.3.9.1 Digest with RNaseI – Procedure
The respective volume was taken from each sample and transferred to a fresh
microcentrifuge tube. If less than 20µL of the sample were used, the volume
was adjusted to 20µL using Qiagen buffer EB (= 10mM TrisCl, pH 8.5). 1µL of
RNase I (=̂ 10 Units) was added, the tubes were flicked to mix, and briefly spun
down with the minifuge. Samples were incubated at 37 ◦C for 1.5 hours in a heat
block. Following digest with RNase I, a column cleanup was performed to remove
the enzyme – here, the Qiaquick PCR purification kit was used for cleanup, since
the DNA to be cleaned was already sheared to 300bp length.
2.3.9.2 Column Cleanup – Procedure
The Qiaquick PCR purification kit was used according to the instructions of the
manufacturer. Ethanol was added to Buffer PE before starting the procedure.
Centrifugation steps were performed at 13,000rpm at room temperature.
5 volumes Buffer PB (=̂ 500µL, if samples were cleaned after shearing, which
was performed in a volume of 100µL) were added to each sample and mixed by
pipetting. A Qiaquick column was placed into a collection tube, the sample was
transferred to the spin column and centrifuged for 60 seconds. The flow-through
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was discarded and the spin column was reassembled with its collection tube. 750µL
Buffer PE were added to the spin column (washing step), which was subsequently
centrifuged for 60 seconds, flow-through was discarded. The column was cen-
trifuged again for 1 minute to dry the sample, the collection tube was discarded
and the column was placed into a fresh microcentrifuge tube for sample elution. To
elute DNA, 50µL of molecular biology grade water were added to the spin column
membrane and the column was centrifuged for 1 minute.
2.3.10 Determination of HPV Status – HPV PCR
HPV detection and typing was done by E6 nested multiplex PCR modified after
Sotlar et al. who developed a nested PCR assay to increase sensitivity of HPV
detection by amplifying DNA of all known mucosal HPV types in a first round,
while using type specific primers for 18 different HPV genotypes in a second round
of multiplex PCR and distinguishing the different HPV types according to their
PCR fragment size on an agarose gel [121].
Materials
See table 2.13 for the required materials. Unless otherwise specified the company
was located in the USA.
Procedure
As HPV-positive HNSCC is mainly caused by infections with HPV type 16 or
18 [119], the protocol by Sotlar et al. was slightly adjusted. In a first round,
samples were subjected to E6 PCR (PCR volume 20µL) and 10µL of the am-
plification products were analyzed on an agarose gel (see 2.3.11). Depending on
sample specific differences as well as the amount of starting material that can be
used, E6 PCR results can appear negative even though HPV infection is present
and detected after HPV type specific PCR. Therefore, all samples were subjected
to group I type specific multiplex PCR (HPV types 16, 18, 31, 59, 45) regard-
less of their E6 PCR result. 10µL of the amplification products were analyzed on
an agarose gel to determine the exact HPV type. Only if E6 PCR results indi-
cated HPV infection and group I type specific PCR was negative, the respective
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Item – Description Company
Equipment
C1000 Thermal Cycler Bio-Rad Laboratories Inc., Her-
cules, CA
GeneMate Minifuge BioExpress, Kaysville, UT
Chemicals – Reagents – Commercial Solutions and -Kits
AmpliTaq Gold R© DNA Poly-
merase with Buffer II and MgCl2
Life Technologies, Grand Island,
NY
dNTP Mix (10mM) Life Technologies, Grand Island,
NY
Primers for E6 PCR and type spe-
cific PCR [121] (sequences are
listed in A.1)
Integrated DNA Technologies Inc.,
Coralville, IA
HyCloneTM Water, Molecular Biol-
ogy Grade
Fisher Scientific, Hanover Park, IL
Disposables
0.2mL PCR 8-tube FLEX-FREE
strip, attached clear flat caps
USA Scientific, Inc., Ocala, FL
Table 2.13: Materials – HPV PCR.
samples were subjected to group II (HPV types 33, 6/11, 58, 52, 56), group III
(HPV types 35, 42, 43, 44), and group IV (HPV types 68, 39, 51, 66) type specific
PCRs (PCR volume 10–20µL). Samples were defined as HPV-positive or HPV-
negative according to the results received with the above described methodology.
Positive control samples (DNA from cell lines) were available for HPV16 (SCC2)
and HPV18 (HeLa), HPV-negative cell line SCC151 was used as negative control
sample and water as no template control. Repeat runs were performed to confirm
the results obtained in the first run of HPV PCR.
The working area was cleaned with 70% ethanol. Sample genomic DNA, cell line
genomic DNA serving as positive and negative controls, primers (see A.1) and
reagents – except for DNA polymerase – were thawed on ice, tubes were flicked to
mix and spun down using the minifuge. DNA dilutions for samples and controls
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were prepared using molecular biology grade water and concentrations were ad-
justed to 100ng/µL (at least 20ng/µL) for samples and 50ng/µL for controls. A
master mix for the E6 PCR (see table 2.14) was set up for the respective number
of samples and cell line controls as well as the no template control and one addi-
tional sample to account for dead volume. Setup was done in a microcentrifuge
tube at room temperature directly before use. DNA polymerase was taken out of
the −20 ◦C freezer, added to the master mix, and immediately put back into the
freezer. Components of the master mix were mixed homogeneously by flicking the
tube, and spun down using the minifuge. PCR tubes were preloaded with 19µL
of master mix, then 1µL of sample or control genomic DNA or water for the no
template control was added to the respective well. Master mix and DNA were
mixed homogeneously by flicking the PCR reaction tubes, spun down using the
minifuge and processed in the PCR cycler applying the temperature protocol in
table 2.14. After finishing the PCR, the samples were either kept on ice (if further
processed on the same day) or frozen at −20 ◦C.
Following E6 PCR, 10µL of the amplification products were subjected to agarose
gel electrophoresis (see 2.3.11) to visualize the results of the E6 PCR. Subsequently,
HPV type specific (TS) PCR targeting HPV16, 18, 31, 59, and 45 in one multi-
plex reaction (group I according to Sotlar et al. [121]) was performed using 2µL
of E6 PCR product as template – even if E6 PCR did not indicate the presence
of an HPV infection. The remainder of E6 PCR product was stored at −20 ◦C
for future usage. Type specific PCR was set up as described for E6 PCR, yet
following the master mix and temperature directions in table 2.15. Since the total
volume per PCR reaction was only 10µL for the type specific PCR, PCR tubes
were preloaded with 8µL of master mix, to which 2µL of E6 PCR amplification
product were added. An additional no template control besides the no template
control product from the E6 PCR was included as well.
As described for the E6 PCR, 10µL of the amplification products were subjected
to agarose gel electrophoresis (see 2.3.11) to visualize the results and to determine
the HPV type, where applicable. Samples showing a positive E6 PCR and a
negative type specific PCR concurrently were subjected to additional type specific
PCRs (groups II–IV according to Sotlar et al. [121]) using the remaining E6 PCR
product – for master mix and temperature protocol see table 2.15, for primers
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E6 PCR – Master Mix
Component Volume Final Concentration
10X PCR Buffer II 2.0µL 1x
25mM MgCl2 1.2µL 1.5mM
10mM dNTP mix 0.4µL 200µM
10µM Primer E6-3F 0.6µL 6pmol
10µM Primer E6-5R 0.6µL 6pmol
10µM Primer E6-6R 0.6µL 6pmol
H2O 13.4µL
AmpliTaq Gold R©DNA Polymerase 0.2µL 1 Unit
Total volume 19.0µL
E6 PCR – Temperature Protocol
Temperature Time Description
94 ◦C 10min Activation (hot-start enzyme)
40 cycles:
94 ◦C 1min Denaturation
40 ◦C 1min Annealing
72 ◦C 2min Elongation
72 ◦C 10min Final extension
4 ◦C Final hold
Table 2.14: E6 PCR – master mix and temperature protocol.
Primer sequences for the E6 PCR primers [121] are listed in A.1.
see table 2.16, for primer sequences see A.1. Additional molecular biology grade
water was added to the master mix for groups III and IV to account for the missing
volume due to usage of four instead of five primer pairs. No positive controls were
available for these additional type specific PCRs.
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Type Specific PCR – Master Mix
Component Volume Final Concentration
10X PCR Buffer II 1.0µL 1x
25mM MgCl2 0.6µL 1.5mM
10mM dNTP mix 0.2µL 200µM
10µM Primer HPV16 forward 0.3µL 3pmol
10µM Primer HPV16 reverse 0.3µL 3pmol
10µM Primer HPV18 forward 0.3µL 3pmol
10µM Primer HPV18 reverse 0.3µL 3pmol
10µM Primer HPV31 forward 0.3µL 3pmol
10µM Primer HPV31 reverse 0.3µL 3pmol
10µM Primer HPV59 forward 0.3µL 3pmol
10µM Primer HPV59 reverse 0.3µL 3pmol
10µM Primer HPV45 forward 0.3µL 3pmol
10µM Primer HPV45 reverse 0.3µL 3pmol
H2O 3.0µL
AmpliTaq Gold R©DNA Polymerase 0.2µL 1 Unit
Total volume 8.0µL
Type Specific PCR – Temperature Protocol
Temperature Time Description
94 ◦C 10min Activation (hot-start enzyme)
35 cycles:
94 ◦C 30s Denaturation
56 ◦C 30s Annealing
72 ◦C 45s Elongation
72 ◦C 4min Final extension
4 ◦C Final hold
Table 2.15: Type specific PCR – master mix and temperature protocol.
Primer sequences for the type specific PCR primers [121] are listed in A.1. The volume
used for the fifth primer pair – 0.6µL – was replaced by water in the master mix for
type specific PCRs group III and IV.
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Primers Type Specific PCR – Group 2
Primer HPV33 forward and reverse
Primer HPV6/11 forward and reverse
Primer HPV58 forward and reverse
Primer HPV52 forward and reverse
Primer HPV57 forward and reverse
Primers Type Specific PCR – Group 3
Primer HPV35 forward and reverse
Primer HPV42 forward and reverse
Primer HPV43 forward and reverse
Primer HPV44 forward and reverse
Primers Type Specific PCR – Group 4
Primer HPV68 forward and reverse
Primer HPV39 forward and reverse
Primer HPV51 forward and reverse
Primer HPV66 forward and reverse
Table 2.16: Type specific PCR – primers for groups 2–4.
100µM stock solutions of all primers were prepared using buffer TE. 10µM work solu-
tions were prepared by diluting the stock solutions 1:10 with molecular biology grade
water. Primer sequences [121] are listed in A.1.
2.3.11 Agarose Gel Electrophoresis
Materials
See table 2.17 for the required materials. Unless otherwise specified the company
was located in the USA.
Procedure
Agarose gel electrophoresis was performed to visualize the respective PCR results
or to assert that the PCR had worked and the concentration of PCR product was
sufficient for subsequent Sanger sequencing. Additionally, it was used to check iso-
form expression and to purify differently sized amplification products after FGFR3
RT-PCR (see 2.3.21). Samples were thawed or taken out of the PCR cycler, briefly
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Item – Description Company
Equipment
Microwave Sanyo
Universal Hood II Bio-Rad, Hercules, CA
PowerPacTMHC High-Current
Power Supply
Bio-Rad, Hercules, CA
Wide Mini-Sub Cell GT Elec-
trophoresis Cell
Bio-Rad, Hercules, CA
Mini-Gel Caster Bio-Rad, Hercules, CA
Sub-Cell GT UV-Transparent
Wide Mini-Gel Tray
Bio-Rad, Hercules, CA
Combs, different sizes Bio-Rad, Hercules, CA
Accu-224 Balance Fisher Scientific, Hanover Park, IL
Pyrex R© Erlenmeyer flasks, Mea-
suring Cylinders, Beakers
Corning Inc., Corning, NY
GeneMate Minifuge BioExpress, Kaysville, UT
Chemicals – Reagents – Commercial Solutions and -Kits
UltraPureTMAgarose Life Technologies, Grand Island,
NY
TAE Buffer 10X, Promega Fisher Scientific, Hanover Park, IL
HyCloneTM Water, Molecular Biol-
ogy Grade
Fisher Scientific, Hanover Park, IL
Thermo ScientificTM GeneRulerTM,
100bp Plus DNA Ladder, supplied
with 6X DNA Loading Dye
Fisher Scientific, Hanover Park, IL
Ethidium Bromide, 1% Solution,
Molecular Biology-Grade
Fisher Scientific, Hanover Park, IL
Disposables
Curwood Parafilm MTM Fisher Scientific, Hanover Park, IL
0.2mL PCR 8-tube FLEX-FREE
strip, attached clear flat caps
USA Scientific, Inc., Ocala, FL
Table 2.17: Materials – agarose gel electrophoresis.
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mixed by flicking the tubes, spun down using the minifuge, and put back on ice.
DNA ladder and loading dye were as well thawed, mixed, and spun down. The
working area was cleaned with 70% ethanol, TAE buffer was diluted to 1X con-
centration with molecular biology grade water.
A 100mL gel was cast taking the respective amount of agarose and TAE buffer.
Agarose and TAE buffer were mixed in an Erlenmeyer flask and heated in the
microwave until agarose was completely melted. After the liquid had cooled down,
2.5µL ethidium bromide were added and intermixed. The mixture was then poured
into a gel casting tray and the desired comb was stuck into the gel. Bubbles were
removed using a pipette tip. After polymerization of the gel, the comb was removed
and the gel in its tray was put into the running chamber filled with sufficient TAE
buffer, and connected to the power supply. To prepare and load samples, a piece of
parafilm was attached to the benchtop for sample preparation and preloaded with
the respective amount of loading dye per sample. If required, molecular biology
grade water was as well added to the loading dye droplet on parafilm. The desired
amount of sample was added to each of the loading dye/water droplets and mixed
by pipetting up and down. Subsequently, the samples and the respective amount
of 100bp Plus DNA Ladder (same volume as sample/dye/water mix) were loaded
on the gel and electrophoresis was started. If parts of the sample were supposed
to be cut and purified from the gel, sample preparation was performed in 0.2mL
PCR reaction tubes instead of parafilm. An overview over the different gel compo-
sitions, electrophoresis conditions, and gel loading volumes following the different
PCRs is given in table 2.18.
Immediately after finishing the run, the electrophoresis gels were imaged and
pictures were taken and analyzed. If required (e.g. after FGFR3 RT-PCR, see
2.3.21), samples were cut and purified from the gel (see 2.3.22 and 2.3.23 respec-
tively).
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Agarose in Volume Vol. Vol.
PCR TAE (w/v) Voltage Time sample 6X dye H2O
HPV E6 PCR 2% 100V 45–60min 10µL 2µL —
HPV TS PCR 2% 100V 40-45min 10µL 2µL —
REPLI-g WGA 0.5% 100V 70min 2µL 1µL 3µL
GenomePlex R©
WGA 1.5% 120V 60min 5µL 1µL —
FGFR3 PCR 2% 100V 40min 2µL 1µL 3µL
FGFR3 RT-PCR 2% 100V 45–60min 2µL 1µL 3µL
Gel Excision 2% 100V 45min 8µL 2µL 2µL
Gel Purification 2% 100V 45min 2µL 1µL 3µL
FGFR3/TACC3 2% 100V 45–60min 2µL 1µL 3µL
Maxiprep 0.8% 100V 30min 2µL 1µL 3µL
Table 2.18: Agarose gel electrophoresis – overview.
Different sample preparations and conditions used for agarose gel electrophoresis fol-
lowing the different PCRs.
2.3.12 Expression Microarrays
RNA used for expression microarrays is required to be of excellent quality in order
to get meaningful results. RNA quality control was performed as described in
2.3.7. Only samples with an RNA integrity number (RIN) ≥7.5 were used for ex-
pression microarrays without any exception. Purity ratios (260/280 and 260/230)
≥1.8 were accepted for downstream applications, minor exceptions were allowed
for the 260/230 ratio in a few samples. Following RNA QC and quantification,
samples were labeled for expression microarrays. Labeled RNA samples were sent
to the Argonne National Laboratories (Argonne, IL, USA) for the expression ar-
rays to be performed (in ozone controlled atmosphere, with liquid handler).
2.3.12.1 Labeling
Materials See table 2.19 for the required materials. Unless otherwise specified
the company was located in the USA.
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Item – Description Company
Equipment
Isotemp 205 Digital Water Bath Fisher Scientific, Hanover Park, IL
Dry Bath Incubator Fisher Scientific, Hanover Park, IL
C1000 Thermal Cycler Bio-Rad Laboratories Inc., Her-
cules, CA
NanoDrop 2000c UV-Vis Spec-
trophotometer
Thermo Fisher Scientific Inc.,
Waltham, MA
GeneMate Minifuge BioExpress, Kaysville, UT
Chemicals – Reagents – Commercial Solutions and -Kits
Quick Amp Labeling Kit, one-color Agilent Technologies, Santa Clara,
CA
RNA Spike-In Kit, one-color Agilent Technologies, Santa Clara,
CA
Human GE 4x44K v2 Microarray
Kit
Agilent Technologies, Santa Clara,
CA
RNeasy Mini Kit QIAGEN Inc., Valencia, CA
Ethyl alcohol, pure, 200 proof, for
molecular biology
Sigma-Aldrich Corp., St. Louis,
MO
HyCloneTM Water, Molecular Biol-
ogy Grade
Fisher Scientific, Hanover Park, IL
Disposables
0.2mL PCR 8-tube FLEX-FREE
strip, attached clear flat caps
USA Scientific, Inc., Ocala, FL
Additional Supplies
RNaseZap R© Life Technologies, Grand Island,
NY
Table 2.19: Materials – labeling.
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Procedure Labeling was performed using the Agilent Quick Amp Labeling Kit
one-color according to the instructions of the manufacturer with the one excep-
tion that all the reaction volumes were halved. 200ng of total RNA were used as
starting material.
The kit produces fluorescent complementary RNA (cRNA) by incorporating CTP
labeled with the fluorescent dye cyanine 3. In a first step, the T7 oligo dT pro-
moter primer and the template (sample total RNA) are mixed and denatured.
The T7 oligo dT promoter primer subsequently binds to the poly–A tail of mRNA
and cDNA synthesis by MMLV–RT (Moloney Murine Leukemia Virus Reverse
Transcriptase) is performed in the second step. Following cDNA synthesis, the T7
RNA Polymerase is used to transcribe the cDNA into cRNA and to incorporate
cyanine 3 labeled CTP during transcription. RNA is amplified at least by factor
100 during the labeling process.
The working area was cleaned with 70% ethanol and RNaseZap R©, working mate-
rials were as well cleaned with RNaseZap R©. Dilutions of the purified tumor RNA
(50ng/µL or 100ng/µL for most RNA samples) were prepared using molecular
biology grade water. After use, RNA dilutions were stored at −80 ◦C. Dilutions
of the RNA Spike-In Kit (internal positive control to normalize data during anal-
ysis) were prepared. The dilution buffer was thawed on ice, briefly mixed and
centrifuged. The spike mix stock solution was thawed on ice, vortexed thoroughly,
heated at 37 ◦C for 5 minutes, again mixed on a vortex mixer and briefly spun
down to collect liquid at the bottom of the tube. Dilutions were prepared ac-
cording to the amount of starting material used (200ng of RNA) as recommended
by the manufacturer. For the first dilution (1:20) 2µL of the concentrated spike
mix were added to a fresh microcentrifuge tube together with 38µL of dilution
buffer. The tube was closed and contents were vortexed to mix and briefly spun
down. For the second dilution (1:25) 2µL of the first dilution were added to a fresh
microcentrifuge tube together with 48µL of dilution buffer. Again contents were
mixed thoroughly on a vortex mixer and spun down. For the third dilution (1:10)
4µL of the second dilution were added to a fresh microcentrifuge tube together
with 36µL of dilution buffer (or 16µL of dilution buffer yielding a 1:5 dilution).
Contents were mixed thoroughly on a vortex mixer and briefly spun down. 2µL of
the third dilution (or 1µL of the third dilution 1:5) were used for 200ng of sample
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total RNA in the subsequent labeling reactions. After use, the second and third
dilutions were discarded, the first dilution was stored no longer than two months
at −80 ◦C and reused up to eight times for labeling reactions.
Reagents were thawed on ice. 200ng of total RNA, i.e. 2µL of the 100ng/µL dilu-
tion (or 4µL of the 50ng/µL dilution) were pipetted into a PCR tube. 0.6µL of T7
Promotor Primer and 2µL of the spike mix third dilution (or 1µL of the spike mix
third dilution 1:5) were added to the RNA. 1.15µL (or 0.15µL) of nuclease free
water were added to reach a total reaction volume of 5.75µL. Template and T7
promoter primer mix were mixed by flicking the tubes and briefly spinning down
the contents. Primer and template RNA were denatured at 65 ◦C for 10 minutes
in a PCR cycler. Following incubation time, the tubes were taken out and placed
on ice for at least 5 minutes.
In the meantime, the cDNA master mix was prepared (immediately before use)
at room temperature. Therefore, the 5X first strand buffer was prewarmed at
80 ◦C in a heat block for 4 minutes, vortexed, and briefly spun down (kept at room
temperature until needed). The other components were thawed on ice, mixed by
inverting or flicking the tube, and briefly spun down to collect liquid at the bot-
tom. MMLV-RT and RNaseOut were kept on ice and added to the cDNA master
mix immediately before use. Components of the cDNA master mix were pipetted
into a microcentrifuge in the order indicated in table 2.20, mixed by inverting the
tube, and briefly centrifuged. Sample tubes were briefly spun down as well and
4.25µL of cDNA master mix were added to each sample and mixed by pipetting
up and down. Samples were incubated using the temperature protocol in table
2.20.
Following incubation, samples were briefly spun down and put on ice. Shortly
before the end of the incubation time the transcription master mix was pipetted
into a microcentrifuge tube at room temperature in the order indicated in table
2.21. The 50% PEG solution was prewarmed at 40 ◦C for 1 minute, vortexed, spun
down, and kept at room temperature. RNaseOut, inorganic pyrophosphatase, and
T7 RNA polymerase were kept on ice and added to the transcription master mix
immediately before use. After addition of cyanine 3–CTP, the subsequent steps
were performed protected from light. Components of the transcription master mix
were mixed by gently inverting the tube, which was then briefly spun to collect
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Labeling – cDNA Master Mix
Component Volume
5X First Strand Buffer 2.00µL
0.1M DTT 1.00µL
10mM dNTP mix 0.50µL
MMLV-RT 0.50µL
RNaseOut 0.25µL
Total Volume 4.25µL
Labeling – Temperature Protocol
Temperature Time
40 ◦C 2h
65 ◦C 15min
4 ◦C ≥ 5min (Final hold)
Table 2.20: Labeling – cDNA master mix and temperature protocol.
liquid at the bottom of the tube. 30µL of transcription master mix were added to
each sample and mixed carefully by pipetting up and down. Samples were incu-
bated using the temperature protocol in table 2.21.
Labeling – Transcription Master Mix
Component Volume
Nuclease free water 7.65µL
4X Transcription Buffer 10.00µL
0.1M DTT 3.00µL
NTP mix 4.00µL
50% PEG 3.20µL
RNaseOut 0.25µL
Inorganic pyrophosphatase 0.30µL
T7 RNA Polymerase 0.40µL
Cyanine 3–CTP 1.20µL
Total Volume 30.00µL
Labeling – Temperature Protocol
Temperature Time
40 ◦C 2h
4 ◦C Final hold
Table 2.21: Labeling – transcription master mix and temperature protocol.
Purification of the labeled and amplified cRNA was done using the RNeasy
mini spin columns. Ethanol was added to buffer RPE of the kit as recommended
by the manufacturer. Purification of cRNA was performed in the cold room at
4 ◦C and protected from light. 60µL of molecular biology grade water were added
to each cRNA sample to reach a total volume of 100µL. 350µL of buffer RLT were
added and mixed by pipetting. Then, 250µL of ethanol were added and as well
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mixed by pipetting. The total of 700µL cRNA mix were transfered to an RNeasy
spin column in a collection tube. The sample was centrifuged for 30 seconds at
13,000rpm (4 ◦C), flow-through and collection tube were discarded and the spin
column was put into a fresh collection tube. 500µL of buffer RPE were added,
samples were centrifuged for 30 seconds at 13,000rpm (4 ◦C), the flow-through was
discarded and another 500µL of buffer RPE were added to the spin column. Sam-
ples were centrifuged for 1 minute at 13,000rpm (4 ◦C), flow-through and collection
tube were discarded and the spin column was assembled with a new collection tube.
Samples were spun again for 30 seconds at 13,000rpm (4 ◦C) to dry the column.
The collection tube was discarded and the spin column was put into a microcen-
trifuge tube. 30µL molecular biology grade water were added to the spin column
membrane, incubated for 1 minute, and centrifuged for 30 seconds at 13,000rpm
(4 ◦C) to elute the labeled cRNA.
cRNA was kept on ice and subjected to quantification using a NanoDrop spec-
trophotometer and the microarray measurement tab. The pedestal surfaces of the
NanoDrop were cleaned prior to taking measurements. RNA-40 was selected as
sample type and the instrument was blanked using 1µL of molecular biology grade
water before starting and reblanked every 6 measurements. Subsequently, 1µL of
each sample was used to quantitate the cRNA, determine the dye concentration,
and the 260/280 ratio. Yield and specific activity of each sample were calculated
as follows.
Concentration of cRNA (ng/µL) ∗ 30µL (elution volume)
1000
= µg of cRNA
Concentration of Cy3 (pmol/µL)
Concentration of cRNA (ng/µL)
∗ 1000 = pmol Cy3 per µg cRNA
Only cRNA samples with a yield ≥1.20 and a specific activity ≥6.7 were used
for expression microarrays. The 260/280 ratio of the labeled samples was >1.8 for
all samples. If the labeled cRNA did not meet these requirements, cRNA prepa-
ration was repeated.
60 CHAPTER 2. MATERIALS AND METHODS
2.3.13 Nanostring Copy Number Assay
The Nanostring copy number assay (nCounter CNV Assay) is a medium-throughput
method to determine copy number variation in up to 12 different samples and 800
locations in the human genome in one run. Genomic DNA is fragmented, dena-
tured to single strands, and then hybridized with so called nCounter probe pairs,
which are molecular barcodes, that can be counted by a digital analyzer during
the data collection step. The nCounter CNV Assay was performed following the
instructions of the manufacturer with the modification that DNA was fragmented
through ultrasonication instead of restriction enzyme digest.
Materials
See table 2.22 for the required materials. Unless otherwise specified the company
was located in the USA.
Procedure
The working area was cleaned with 70% ethanol and RNaseZap R©. Sample ge-
nomic DNA was thawed, mixed by flicking the tube, and briefly spun down. DNA
quantity and quality were determined with Quant-iT PicoGreen and a NanoDrop
spectrophotometer (see 2.3.6 and 2.3.7 respectively).
Typically, ≥300ng of fragmented DNA were used for the assay – less DNA was
used if sample was exhausted, but at least 100ng. In terms of DNA quality the re-
quired 260/280 and 260/230 ratios of ≥1.7 and ≥1.3 respectively were met. DNA
was sheared to a fragment length of 300bp in a volume of 100µL as described in
2.3.15. 300ng of sheared DNA were transferred to a fresh microcentrifuge tube
and the volume was reduced to 5–10µL using a SpeedVac centrifugal evaporator.
If reduction of sample volume by SpeedVac centrifugation would have led to con-
centration of buffer components (calculated considering the initial sample volume
taken for shearing and the volume of sheared DNA taken as starting material for
the Nanostring assay), the sheared sample was subjected to a column cleanup
using the Qiaquick PCR purification Kit (see 2.3.9.2). Quant-iT PicoGreen and
NanoDrop measurements were repeated before reducing the volume of the sample
with the SpeedVac to 5–10µL and using it for the Nanostring CNV assay.
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Item – Description Company
Equipment
nCounter Prep Station NanoString Technologies Inc.,
Seattle, WA
nCounter Digital Analyzer NanoString Technologies Inc.,
Seattle, WA
Memory Stick NanoString Technologies Inc.,
Seattle, WA
C1000 Thermal Cycler Bio-Rad Laboratories Inc., Her-
cules, CA
GeneMate Minifuge BioExpress, Kaysville, UT
Savant DNA120 SpeedVac R© Con-
centrator
Thermo Fisher Scientific Inc.,
Waltham, MA
Dry Bath Incubator Fisher Scientific, Hanover Park, IL
Chemicals – Reagents – Commercial Solutions and -Kits
nCounter CNV CodeSet NanoString Technologies Inc.,
Seattle, WA
nCounter Master Kit NanoString Technologies Inc.,
Seattle, WA
nCounter CNV DNA Prep Kit NanoString Technologies Inc.,
Seattle, WA
Additional Supplies
RNaseZap R© Life Technologies, Grand Island,
NY
Table 2.22: Materials – Nanostring copy number assay.
If required, DNA was treated with RNase I to remove RNA (see 2.3.9) and sheared
to 300bp (see 2.3.15) followed by a subsequent column cleanup using the Qiaquick
PCR purification Kit to remove RNase I (see 2.3.9.2). Subsequently, Quant-iT
PicoGreen and NanoDrop measurements were repeated and the volume of the
sample was reduced to 5–10µL using the SpeedVac.
Normal DNA samples (obtained from the Department of Pathology at the Univer-
sity of Chicago) derived from blood of four patients of this cohort were cleaned up
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through precipitation (see 2.3.5) and included in the assay to be used as reference.
Generally ≥300ng of sheared tumor DNA in up to 10µL volume and 400–800ng
normal DNA were used for the copy number assay, which was performed according
to the instructions of the manufacturer.
Aliquots of the Reporter CodeSet and the Capture CodeSet were thawed at room
temperature on the benchtop, gently inverted to mix components, and briefly spun
down (not more than 1,000rpm) using a minifuge. 130µL of hybridization buffer
were added to the Reporter CodeSet tube to create a master mix containing 130µL
of hybridization buffer and 130µL of Reporter CodeSet. The tube was gently in-
verted to mix and briefly spun down. A 12 tube strip (provided with the kit) was
labeled and cut in half. 20µL of master mix were added to each of the tubes.
A PCR cycler was preheated to 65 ◦C (heated lid turned on and ”forever” time
setting). The prepared aliquots of sheared DNA in microcentrifuge tubes were
denatured at 95 ◦C for 5 minutes in the heat block. The denatured DNA was
taken out of the heat block and immediately put on ice for ≥2 minutes. DNA
tubes were briefly spun down to collect liquid at the bottom of the tube. The
DNA (generally 5µL but up to 10µL for some samples) was added to the 12 tubes
containing the hybridization master mix. 5µL of Capture ProbeSet were added
to each tube (immediately before placing reactions at 65 ◦C). Tubes were closed,
flicked to mix components, briefly spun down, and immediately put into the PCR
cycler preheated to 65 ◦C. Hybridization reactions were incubated for at least 16
hours (16–20hours).
One nCounter Cartridge was taken out of the freezer and two nCounter Prep
Plates were taken out of the fridge and kept at room temperature on the benchtop
for 20 minutes before proceeding with sample processing. The Prep Plates were
centrifuged at 670g for 2 minutes (brake off to decelerate slowly) to collect liquid
at the bottom of the wells. The plastic lids were removed from the Prep Plates and
plates were placed into the Prep Station. Tips and foil piercers, tip sheaths, empty
strip tubes, waste containers and cartridge were placed into the Prep Station as
well. The lid for the empty strip tubes and the electrode fixture for the cartridge
were closed carefully. Reactions were removed from the PCR cycler (immediately
before continuing with the post-hybridization processing), and placed (without the
caps) on the nCounter Prep Station in a way that tube 1 aligned with position 1.
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The instrument was started and samples were processed.
Immediately after post-hybridization processing the cartridge was removed and
sealed to prevent evaporation. The cartridge was put into the nCounter Digital
Analyzer to collect the data (Field of View (FOV) counts: 1155) and stored at
4 ◦C protected from light once data acquisition was complete.
2.3.14 Whole Genome Amplification (WGA)
12 of the normal DNA samples were subjected to whole genome amplification
(WGA), since DNA yield after purification, as determined by PicoGreen measure-
ments, was too low for subsequent sequencing library preparation. The REPLI-g
Mini Kit was used on normal DNA derived from frozen OCT blocks (n=7) or
blood (n=1), whereas the GenomePlex R©Complete Whole Genome Amplification
Kit was used to amplify normal DNA extracted from FFPE slides (n=4).
Materials
See table 2.23 for the required materials. Unless otherwise specified the company
was located in the USA.
2.3.14.1 REPLI-g – Procedure
Whole genome amplification was performed on eight normal DNA samples using
the REPLI-g Mini Kit and following the instructions of the manufacturer. If possi-
ble, more than 10ng of purified genomic DNA (quantified with PicoGreen) in 5µL
volume were used as starting material (10–15ng), otherwise the amount of input
material was lower (3–8.5ng). 6ng of male human gDNA were used as positive
control, molecular biology grade water was used as no template control.
Reagents were handled and buffers were prepared as recommended by the man-
ufacturer: Components of the kit were thawed at room temperature, except for
REPLI-g Mini DNA Polymerase, which was thawed on ice. Buffer DLB was pre-
pared by adding 500µL nuclease free water followed by mixing of the components
and briefly centrifuging the tube. Buffers and reagents were vortexed and briefly
spun down before use.
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Item – Description Company
Equipment
C1000 Thermal Cycler Bio-Rad Laboratories Inc., Her-
cules, CA
GeneMate Minifuge BioExpress, Kaysville, UT
Eppendorf Microcentrifuge 5415D Eppendorf, Hauppauge, NY
Chemicals – Reagents – Commercial Solutions and -Kits
REPLI-g Mini Kit QIAGEN Inc., Valencia, CA
GenomePlex R©Complete Whole
Genome Amplification (WGA) Kit
Sigma-Aldrich Corp., St. Louis,
MO
Promega Human Genomic DNA,
Male, 100µg
Fisher Scientific, Hanover Park, IL
HyCloneTM Water, Molecular Biol-
ogy Grade
Fisher Scientific, Hanover Park, IL
Ethyl alcohol, pure, 200 proof, for
molecular biology
Sigma-Aldrich Corp., St. Louis,
MO
TE Buffer Life Technologies, Grand Island,
NY
QIAquick PCR Purification Kit QIAGEN Inc., Valencia, CA
Disposables
0.2mL PCR 8-tube FLEX-FREE
strip, attached clear flat caps
USA Scientific, Inc., Ocala, FL
Table 2.23: Materials – WGA.
Denaturation buffer (Buffer D1) was prepared for 10 reactions using 12.86µL re-
constituted Buffer DLB and 45.7µL nuclease free water to prepare 58.56µL of
Buffer D1. A total of 114.24µL neutralization buffer (Buffer N1) were prepared
using 17.14µL stop solution and 97.1µL nuclease free water. 5µL (=̂3–15ng) of
each sample were transferred to a fresh PCR tube. 6ng (in 5µL volume) of male
human gDNA and 5µL molecular biology grade water were as well added to fresh
PCR tubes to be used as positive and no template controls respectively. 5µL
Buffer D1 were added, samples were vortexed, briefly spun down to collect liquid
at the bottom of the tube, and incubated on the benchtop at room temperature
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for 3 minutes. 10µL Buffer N1 were added and samples were vortexed and briefly
centrifuged. A master mix was prepared on ice by mixing 29µL REPLI-g Mini
Reaction Buffer with 1µL REPLI-g Mini DNA Polymerase per sample. 30µL of
that master mix were added to each sample and control tube. Reactions were
incubated in a PCR cycler at 30 ◦C for 16 hours followed by an inactivation step
at 65 ◦C for 3 minutes (lid temperature was 70 ◦C).
The amplified DNA was purified as described in the supplementary protocols of
the manufacturer. The inactivated reaction mix was transferred to a fresh mi-
crocentrifuge tube. 150µL 100% ethanol were added, tubes were flicked to mix
components, and centrifuged at 13,000rpm for 2 minutes. The supernatant was
removed by pipetting and 100µL 70% ethanol were added to the pellet. After
another centrifugation step at 13,000rpm for 2 minutes, the supernatant was re-
moved by pipetting and centrifugation was repeated to collect liquid at the bottom
of the tube. The residual supernatant was carefully removed and the pellet was
dried at room temperature for 10 minutes. 50µL buffer TE were added, tubes were
flicked to mix and incubated at room temperature for 2 hours to dissolve precipi-
tated DNA. Quantity and quality of the amplified DNA were determined through
PicoGreen and NanoDrop measurements (see 2.3.6 and 2.3.7) as well as agarose gel
electrophoresis (see 2.3.11). 2µL of the precipitated WGA product were used for
electrophoresis. Positive and no template controls were not subjected to precipita-
tion, thus 5µL of the unprecipitated WGA product were used for electrophoresis.
Since amplified DNA was visible in the no template control after WGA, two of
the samples as well as the positive and no template WGA controls and a new no
template PCR control (H2O) were subjected to a standard PCR for a human gene
(ARID1A). Amplification was present in the two samples and the positive WGA
control, but no amplification was visible in any of the no template controls. Hence
the product seen before in the WGA no template control is most likely attributable
to extended primer dimers produced by the Phi29 polymerase.
2.3.14.2 GenomePlex R©– Procedure
Whole genome amplification with the GenomePlex R© Complete WGA Kit was
performed according to the instructions of the manufacturer on four normal DNA
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samples derived from FFPE slides. Since the recommended amount of starting
material is 25–100ng DNA, if degraded DNA is used as a template, a minimum of
30ng and a maximum of 99ng sample DNA were subjected to WGA (quantified
by spectrophotometric/NanoDrop measurements). 10ng of human genomic DNA
(provided with the kit) were used as positive control and molecular biology grade
water was used as no template control.
Reagents were thawed on ice. 10µL of template DNA were used for DNA con-
centrations ≤10ng/µL. If DNA concentration was >10ng/µL, 100ng of DNA were
used as template and the volume was adjusted to 10µL using molecular biology
grade water. 10µL of template DNA (or diluted template DNA) were transferred
to a fresh PCR tube. 1µL of 10X Fragmentation Buffer was added, mixed, and
tubes were incubated in a PCR cycler at 95 ◦C for exactly 4 minutes. Tubes were
taken out, cooled on ice and briefly centrifuged to collect liquid at the bottom.
2µL of 1X Library Preparation Buffer and 1µL of Library Stabilization Solution
were added. Tubes were vortexed, briefly centrifuged, incubated in a PCR cycler
at 95 ◦C for 2 minutes, and cooled on ice. Tubes were briefly spun to collect liq-
uid at the bottom and placed back on ice. 1µL of Library Preparation Enzyme
was added, tubes were vortexed to mix, and briefly centrifuged. Samples were
incubated in a PCR cycler using the temperature protocol in table 2.24.
Temperature Time
16 ◦C 20min
24 ◦C 20min
37 ◦C 20min
75 ◦C 5min
4 ◦C Final hold
Table 2.24: GenomePlex R© WGA – temperature protocol.
Samples were taken out of the PCR cycler, briefly centrifuged, and put on ice
while the master mix for amplification was prepared as described in table 2.25.
60µL of the master mix were transferred to each sample, mixed by vortexing
and briefly spun down before starting amplification. The temperature protocol
described in table 2.25 was used for the amplification step.
Agarose gel electrophoresis as described in 2.3.11 was performed to check quality
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GenomePlex R© WGA – Amplification Master Mix
Component Volume
10X Amplification Master Mix 7.5µL
Molecular Biology Grade Water 47.5µL
WGA DNA Polymerase 5.0µL
Total volume 60.0µL
GenomePlex R© WGA – Temperature Protocol
Temperature Time Description
95 ◦C 3min Initial Denaturation
14 cycles:
94 ◦C 15s Denaturation
65 ◦C 5min Annealing/Elongation
4 ◦C Final hold
Table 2.25: GenomePlex R©WGA – amplification master mix and temperature
protocol.
of the WGA DNA before samples were subjected to purification. Samples were
purified using the QIAquick PCR Purification Kit according to the instructions of
the manufacturer and as described in 2.3.9.2 with the exception that 375µL Buffer
PB were used, since the total reaction volume was 75µL, and that 50µL Buffer EB
were used for elution of the purified DNA. Quantity and quality of the amplified
DNA were determined through PicoGreen and NanoDrop measurements (see 2.3.6
and 2.3.7).
2.3.15 Fragmentation of DNA
DNA was sheared into fragments of a length of approximately 300 base pairs
(bp) to be used for the Nanostring copy number assay (see 2.3.13) as well as for
the preparation of sequencing libraries for next generation sequencing (NGS) (see
2.3.16).
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Materials
See table 2.26 for the required materials. Unless otherwise specified the company
was located in the USA.
Item – Description Company
Equipment
S220 Focused-ultrasonicator Covaris, Inc., Woburn, MA
S-Series microTUBE Holder Covaris, Inc., Woburn, MA
microTUBE AFA Fiber Pre-Slit
Snap-Cap 6x16mm
Covaris, Inc., Woburn, MA
Chemicals – Reagents – Commercial Solutions and -Kits
HyCloneTM Water, Molecular Biol-
ogy Grade
Fisher Scientific, Hanover Park, IL
Table 2.26: Materials – fragmentation of DNA.
Procedure
The water bath tank of the Covaris ultrasonicator was filled with ultrapure water
to be prechilled and degased before use. Sample DNA was kept on ice during the
procedure. The amount of DNA that was supposed to be subjected to shearing
(up to 2µg) was transferred to a fresh microcentrifuge tube and the volume was
adjusted to 100µL with molecular biology grade water. The entire sample volume
of 100µL was transferred to a Covaris microTUBE and sheared to ≈300bp by
ultrasonication – duty cycle 10%, Intensity 4, cycles per burst 200, time 120s. The
sheared DNA was then transferred back to the same microcentrifuge tube.
2.3.16 Preparation of Sequencing Libraries
Preparation of sequencing libraries with subsequent target capture was performed
following previously published protocols [49,85]. DNA was sheared into fragments
of approximately 300bp length. The ends of the fragments were blunted (5’-ends
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were filled and 3’-ends were removed), 5’-phosphates were attached and two dif-
ferent adapters were ligated with the 5’-ends of the blunted fragments. In a sub-
sequent reaction the overhanging adapters were filled and the 3’-end nicks were
removed. Full length adapter sequences and indices were added during a PCR
reaction using primers IS4 and an indexing primer each partly complementary to
one of the adapters. Indexed libraries were pooled and subjected to target cap-
ture. After capture, libraries were eluted from the slide, cleaned up/concentrated,
amplified, and sequenced.
Sequencing libraries of tumor (n=120) and matching normal (n=120) DNA for
next generation sequencing (NGS) on Illumina HiSeq 2000/2500 sequencers were
prepared following the protocol published by Meyer and Kircher with minor modi-
fications [85]. DNA was fragmented to 300bp through ultrasonication as described
before (see 2.3.15), adapter tagged libraries were size selected using an e-gel fol-
lowed by a cleanup step and indexed in four parallel PCR reactions followed by
quality control with an Agilent 2100 Bioanalyzer (Bioanalyzer QC was performed
by the Genomics Core Facility at the University of Chicago). Further modifica-
tions were an additional ethanol precipitation for concentration and cleanup of the
material eluted from the capture slide as well as reduction of cycle number during
bulk amplification after capture to 13 or 14 cycles.
The amount of starting material used for library building varied between 100ng
and 1000ng DNA as determined by PicoGreen measurements (see 2.3.6) and was
300–500ng DNA for most sequencing libraries. Primer and adapter stock solutions
were prepared using buffer TE, dilutions were prepared using molecular biology
grade water, concentrations were prepared as required and indicated in the proto-
col [85] (see below in the respective procedures).
Materials
See tables 2.27, 2.28 and 2.29, page 71, and page 72 for the required materials.
Unless otherwise specified the company was located in the USA.
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Item – Description Company
Equipment
C1000 Thermal Cycler Bio-Rad Laboratories Inc., Her-
cules, CA
GeneMate Minifuge BioExpress, Kaysville, UT
Beckman Coulter 3P SPRIPlate
Super96 Magnet Plate
Fisher Scientific, Hanover Park, IL
E-Gel R© iBaseTM Power System Life Technologies, Grand Island,
NY
DynaMagTM-2 Magnet Life Technol., Grand Island, NY
DynaMagTM-Spin Magnet Life Technol., Grand Island, NY
Savant DNA120 SpeedVac R© Con-
centrator
Thermo Fisher Scientific Inc.,
Waltham, MA
Dry Bath Incubator Fisher Scientific, Hanover Park, IL
SureHyb Microarray Hybridization
Chamber
Agilent Technologies, Santa Clara,
CA
Microarray Hybridization Oven Agilent Technologies, Santa Clara,
CA
GeneMate Rocker, Variable Speed BioExpress, Kaysville, UT
Isotemp 205 Digital Water Bath Fisher Scientific, Hanover Park, IL
ArrayIt R© Microarray High-Speed
Centrifuge
Arrayit Corporation, Sunnyvale,
CA
Centrifuge 5424R, refridgerated Eppendorf, Hamburg, Germany
Disposables
0.2mL PCR 8-tube FLEX-FREE
strip, attached clear flat caps
USA Scientific, Inc., Ocala, FL
Hybridization Gasket Slide Kit (1
microarray per slide format)
Agilent Technologies, Santa Clara,
CA
SA2260–SecureSeal adhesive hy-
bridization chambers
Grace Bio-Labs Inc., Bend, OR
Thermo ScientificTM NuncTM50mL
Conical Sterile Polypropylene Cen-
trifuge Tube
Fisher Scientific, Hanover Park, IL
Table 2.27: Materials – preparation of sequencing libraries.
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Item – Description Company
Chemicals – Reagents – Commercial Solutions and -Kits
TE Buffer Life Technol., Grand Island, NY
HyCloneTM Water, for mol. bio. Fisher Scientific, Hanover Park, IL
Sodium Chloride Fisher Scientific, Hanover Park, IL
Tris Base Fisher Scientific, Hanover Park, IL
EDTA, Disodium Salt Dihydrate Fisher Scientific, Hanover Park, IL
Sodium Hydroxide Fisher Scientific, Hanover Park, IL
Tango Buffer (10X) Life Technol., Grand Island, NY
dNTP Mix (25mM each) Life Technol., Grand Island, NY
ATP Solution (100mM) Life Technol., Grand Island, NY
T4 Polynucleotide Kinase
(10U/µL)
Life Technol., Grand Island, NY
T4 DNA Polymerase (5U/µL) Life Technol., Grand Island, NY
Agencourt AMPure XP, 60mL Beckman Coulter R©Inc., Brea, CA
Ethyl alcohol, pure, 200 proof, for
molecular biology
Sigma-Aldrich Corp., St. Louis,
MO
Buffer EB QIAGEN Inc., Valencia, CA
T4 DNA Ligase (5U/µL) Life Technol., Grand Island, NY
Bst DNA Polymerase, Large Frag-
ment, (8U/µL)
New England Biolabs R© Inc., Ip-
swich, MA
E-Gel R© SizeSelectTMAgarose Gel,
2%
Life Technol., Grand Island, NY
100bp DNA Ladder Promega Corp., Madison, WI
QIAquick PCR Purification Kit QIAGEN Inc., Valencia, CA
Phusion Hot Start II High-Fidelity
DNA Polymerase (2U/µL)
Thermo Fisher Scientific Company,
Pittsburgh, PA
Human Cot-1 DNA R© Life Technol., Grand Island, NY
Oligo aCGH/ChIP-on-Chip Hy-
bridization Kit
Agilent Technologies, Santa Clara,
CA
Custom SurePrint G3 CGH Mi-
croarray 1x1M
Agilent Technologies, Santa Clara,
CA
Oligo aCGH/ChIP-on-Chip Wash
Buffer Kit
Agilent Technologies, Santa Clara,
CA
Ammonium Acetate (5M) Life Technol., Grand Island, NY
Glycogen (5mg/mL) Life Technol., Grand Island, NY
Table 2.28: Materials – preparation of sequencing libraries – continued from
2.27.
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Oligos
Name Description
IS1 adapter P5.F
IS2 adapter P7.F
IS3 adapter P5+P7.R
IS4 primer indPCR.P5
Index Primers 1–24 primer indPCR.P7
BO1 blocking oligo hyb.P5.F
BO2 blocking oligo hyb.P5.R
BO3 blocking oligo hyb.P7.part1.F
BO4 blocking oligo hyb.P7.part1.R
BO5 blocking oligo hyb.P7.part2.F
BO6 blocking oligo hyb.P7.part2.R
IS5 primer bulkamp.P5
IS6 primer bulkamp.P7
Table 2.29: Oligos – preparation of sequencing libraries.
The exact same oligos as recommended by Meyer and Kircher [85] were used. Sequences
and modifications (e.g. PTO bond, 3’-phosphate) are listed in A.1 in the appendix.
Oligos were ordered from Sigma-Aldrich (Sigma-Aldrich Corp., St. Louis, MO) or
Invitrogen (Life Technologies, Grand Island, NY) at 0.2µmol synthesis scale and HPLC
purified. All oligos were resuspended in buffer TE to prepare 100µM (IS4, index primers,
IS5, IS6), 200µM (BO1–BO6) or 500µM (IS1–IS3) stock solutions. For the primers (IS4,
index primers, IS5, IS6) 10µM dilutions were prepared using molecular biology grade
water (see the respective protocols below).
2.3.16.1 Preparation of Adapter Mix – Procedure
The 10X oligo hybridization buffer – 500mM NaCl, 10mM Tris-HCl (pH 8), and
1mM EDTA (pH 8) – was prepared and autoclaved. The 500µM adapter stock
solutions were prepared using buffer TE. The hybridization mix for adapter P5
and the hybridization mix for adapter P7 were each pipetted in two separate PCR
tubes – the composition of both P5 and P7 is described in table 2.30. Both tubes
were incubated in a PCR cycler at 95 ◦C for 10 seconds before the temperature
was ramped down to 12 ◦C at a rate of 0.1 ◦C per second. Subsequently, the P5
and the P7 mix were combined to have one adapter mix containing each adapter
at a concentration of 100µM. Aliquots of the adapter mix were frozen at −20 ◦C.
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Hybridization Mix – P5
Component Volume Final Concentration
500µM IS1 (adapter P5.F) 40.0µL 200µM
500µM IS3 (adapter P5+P7.R) 40.0µL 200µM
10X oligo hybridization buffer 10.0µL 1X
H2O 10.0µL
Total volume 100.0µL
Hybridization Mix – P7
Component Volume Final Concentration
500µM IS2 (adapter P7.F) 40.0µL 200µM
500µM IS3 (adapter P5+P7.R) 40.0µL 200µM
10X oligo hybridization buffer 10.0µL 1X
H2O 10.0µL
Total volume 100.0µL
Table 2.30: Preparation of sequencing libraries – composition of adapter mix
P5 and P7.
Adapter sequences [85] are listed in appendix A.1.
2.3.16.2 Blunt End Repair – Procedure
Library building was started using 100–1000ng – mostly 300–500ng – of DNA
fragmented to a length of 300bp. A maximum of 50µL sample DNA was transferred
to each PCR tube. If less than 50µL DNA were used, the volume was adjusted
to 50µL using molecular biology grade water. A master mix for the respective
number of samples was prepared in a fresh microcentrifuge tube as described in
table 2.31. The master mix was prepared on ice, mixed by flicking the tube, and
briefly spun down. 20µL of master mix were immediately added to each PCR
tube containing 50µL of sample DNA and gently mixed by pipetting. Tubes were
incubated in a PCR cycler using the temperature protocol described in table 2.31.
Following blunt end repair, a reaction cleanup was done as described in 2.3.16.3.
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Blunt End Repair – Master Mix
Component Volume Final Concentration
H2O 7.12µL
10X Buffer Tango 7.00µL 1X
25mM (each) dNTP mix 0.28µL 100µM each
100mM ATP 0.70µL 1mM
T4 polynucleotide kinase (10U/µL) 3.50µL 0.5U/µL
T4 DNA polymerase (5U/µL) 1.40µL 0.1U/µL
Total volume 20.00µL
Blunt End Repair – Temperature Protocol
Temperature Time
25 ◦C 15min
12 ◦C 5min
4 ◦C Final hold
Table 2.31: Blunt end repair – master mix and temperature protocol.
2.3.16.3 Purification – Procedure
Reaction cleanup was done at room temperature using solid phase reversible im-
mobilization (SPRI) magnetic beads and a 96–well magnetic plate. Before use, the
SPRI bead solution (AMPure beads) was equilibrated to room temperature and
resuspended by vortexing and inverting the bottle. The reactions to be cleaned
were taken out of the PCR cycler, briefly spun down, and placed on the magnetic
plate. 1.8 volumes of AMPure beads were added to each reaction (e.g. 126µL
were added to a 70µL reaction). The lid was closed and the sample-beads-mix was
vortexed thoroughly to suspend the SPRI beads. Sample tubes were incubated
on the benchtop at room temperature for 5 minutes (far enough away from the
magnetic plate). Following incubation, samples were briefly centrifuged (up to
2000g) to collect liquid at the bottom of the tube, placed on the magnetic plate,
and incubated for 5 minutes. The supernatant was discarded and beads were
washed twice using 150µL of freshly prepared 70% ethanol, i.e. ethanol was added,
incubated for 1 minute, and discarded. After the second washing step, all residual
traces of ethanol were carefully removed by pipetting and beads were air-dried for
20 minutes (room temperature, lids open). The purified DNA was subsequently
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eluted. 20µL of Buffer EB were added to each tube. Lids were closed, tubes were
removed from the magnetic rack, vortexed to resuspend the beads, and incubated
on the benchtop for 1 minute prior to a brief centrifugation to collect liquid at the
bottom of the tubes. Tubes were placed back on the magnetic plate, incubated for
1 minute, and the eluted DNA was removed by pipetting and transferred to a new
PCR tube. Subsequently, samples were either processed immediately or frozen at
−20 ◦C until the next step could be performed.
2.3.16.4 Adapter Ligation – Procedure
A master mix was prepared in a fresh microcentrifuge tube as described in table
2.32 using the adapter mix prepared before (see 2.3.16.1). Before adding the
T4 DNA ligase, components of the master were mixed by vortexing to ensure
homogeneous distribution of PEG. The tube was briefly centrifuged, T4 DNA
ligase was added and mixed by pipetting. 20µL of the master mix were added
to each sample and mixed by pipetting. Tubes were placed in a PCR cycler and
processed applying the temperature protocol in table 2.32.
Following adapter ligation, samples were purified as described in 2.3.16.3.
Adapter Ligation – Master Mix
Component Volume Final Concentration
H2O 10.0µL
10X T4 DNA Ligase Buffer 4.0µL 1X
50% PEG-4000 Solution 4.0µL 5%
Adapter mix (100µM each)* 1.0µL 2.5µM each
T4 DNA Ligase (5U/µL) 1.0µL 0.125U/µL
Total volume 20.0µL
Adapter Ligation – Temperature Protocol
Temperature Time
22 ◦C 30–60min
4 ◦C Final hold
Table 2.32: Adapter ligation – master mix and temperature protocol.
*This is the adapter mix that was prepared before – see 2.3.16.1.
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2.3.16.5 Adapter Fill-In – Procedure
Following purification, the adapter fill-in was performed. A master mix was pre-
pared in a fresh microcentrifuge tube with the ingredients described in table 2.33.
The master mix was mixed by pipetting and briefly spun down before 20µL of
master mix were added to each sample. Samples were mixed by pipetting and in-
cubated in a PCR cycler at 37 ◦C for 20 minutes (see 2.33). Following the reaction,
another cleanup using the SPRI beads was performed as described in 2.3.16.3 and
samples were either processed further immediately or frozen at −20 ◦C.
Adapter Fill-In – Master Mix
Component Volume Final Concentration
H2O 14.1µL
10X ThermoPol reaction buffer 4.0µL 1X
25mM (each) dNTP mix 0.4µL 250µM each
Bst DNA Polymerase, Large Fragment
(8U/µL) 1.5µL 0.3U/µL
Total volume 20.0µL
Adapter Fill-In – Temperature Protocol
Temperature Time
37 ◦C 20min
4 ◦C Final hold
Table 2.33: Adapter fill-in – master mix and temperature protocol.
2.3.16.6 Size Selection and Column Cleanup – Procedure
Size selection was performed using an E-Gel R© SizeSelectTM Gel, which is specifi-
cally designed for the purification of DNA sequencing libraries. DNA libraries and
a ladder are loaded in the upper row of wells on the precast gel, electrophoresis
is run, and the desired fraction of the library is recovered by pipetting from the
lower row of wells allowing for a small size range and efficient DNA recovery.
DNA library fractions of three different sizes were selected and extracted from
the gel – 250bp, 300bp, 350bp. Two fractions (300bp and 350bp) were stored at
−20 ◦C as spare material, the 250bp fraction was purified using a QIAquick PCR
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Purification Kit and further processed to be subjected to sequencing. The optimal
size to be selected (=250bp) was calculated considering the maximum read length
of the sequencing reaction (150bp – 75bp from each end) and the total length
of the adapters ligated to the sample DNA (67bp – 33bp adapter P5 and 34bp
adapter P7).
The E-Gel R© SizeSelectTM Gel was run using the E-Gel R© iBaseTM Power System.
The empty gel was placed on the base and run for 2 minutes with the pre-run
program. Subsequently, the upper row of wells, which contains 8 wells for sample
material and 1 well for the ladder, was filled with the complete sample volume ob-
tained after the last purification step (= 20µL) or molecular biology grade water
if less than 8 samples were processed. The well for the ladder was filled with 5µL
100bp DNA ladder. The bottom wells were all filled with molecular biology grade
water – 25µL in the sample wells and 10µL in the ladder well. Program 3 was used
to run the gel. When the DNA library fractions of the desired size had reached the
bottom wells, the program was stopped and the DNA was extracted from the bot-
tom wells in the gel by pipetting and transferred to a fresh microcentrifuge tube.
Wells were refilled with water and the procedure was continued until all the desired
fractions had been extracted into separate microcentrifuge tubes. The 300bp and
350bp fractions were stored at −20 ◦C to have spare material (the 300bp fractions
were later used for validation experiments to confirm NGS results, see 2.3.17). The
250bp fraction was cleaned up using a QIAquick PCR Purification Kit following
the instructions of the manufacturer (method is described in 2.3.9.2) with the ex-
ception that elution of DNA libraries was performed using 30µL Buffer EB. After
cleanup, samples were either subjected to the indexing PCR immediately or frozen
at −20 ◦C.
2.3.16.7 Indexing PCR – Procedure
The adapter ligated DNA libraries were amplified using primer IS4 and an index-
ing primer to add full length adapter sequences and indexes to the DNA libraries.
Each indexing primer contains a barcode, a unique combination of 7 specific bases,
embedded in the primer sequence allowing for multiplexing of samples and iden-
tification of the sample during sequencing. The entire DNA library (in 30µL EB)
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received after the previous cleanup step was indexed. Indexing PCR for one li-
brary was carried out in 4 parallel reactions using 7µL of template per reaction. 18
cycles were sufficient to amplify enough material for the subsequent multiplexed
target capture. Index primers 1–24 as published by Meyer and Kircher [85] were
used sequentially for all 240 samples (120 tumor samples and 120 matching normal
samples). Each template DNA was split into four parts, i.e. 7µL of template DNA
were transferred to each PCR tube. Indexing primers were added to the template
DNA libraries. A master mix was prepared as described in table 2.34 (without
template DNA and indexing primer). 42µL of master mix were added to each re-
action tube containing the template DNA and the indexing primer (total reaction
volume=50µL) and mixed by pipetting. Samples were processed in a PCR cycler
applying the temperature protocol described in table 2.34.
Indexing PCR – Master Mix
Component Volume Final Concentration
H2O 30.1µL
5X Phusion HF Buffer 10.0µL 1X
25mM (each) dNTP mix 0.4µL 200µM each
10µM Primer IS4 1.0µL 200nM
Phusion Hot Start II HighFidelity
DNA Polymerase (2U/µL) 0.5µL 0.02U/µL
10µM Indexing Primer 1.0µL 200nM
DNA Library (Template DNA) 7.0µL
Total volume 50.0µL
Indexing PCR – Temperature Protocol
Temperature Time Description
98 ◦C 30s Initial Denaturation
18 cycles:
98 ◦C 10s Denaturation
60 ◦C 20s Annealing
72 ◦C 20s Elongation
72 ◦C 10min Final extension
4 ◦C Final hold
Table 2.34: Indexing PCR – master mix and temperature protocol.
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Following indexing PCR, the four parallel reactions were pooled in a microcen-
trifuge tube and a cleanup using the SPRI beads and one of the DynaMag magnets
was performed (see 2.3.16.3) with the exception that libraries were eluted in 100–
150µL molecular biology grade water. Libraries were quantified using NanoDrop
measurements (see 2.3.6) and the quality of the indexed libraries was analyzed
using an Agilent 2100 Bioanalyzer (Bioanalyzer measurements were performed by
the Genomics Core Facility at the University of Chicago). 260/280 and 260/230
ratios of all libraries determined through NanoDrop measurements were ≥1.8 and
≥1.5 respectively (260/230 ratio was ≥1.8 for most libraries).
2.3.16.8 Pooling – Procedure
Following quantification and quality control, 12 indexed libraries were pooled in
equimolar ratios based on NanoDrop measurements to be processed in one multi-
plexed (12plex) target capture. 1.67µg of each of the 12 libraries to be processed
together were transferred to a fresh microcentrifuge tube to reach a total of 20µg
that was needed per capture slide as recommended in the protocol by Hodges et
al. [49]. Since the required volume to be used for the capture was 128µL, the vol-
ume of the 12plex library was reduced to 100–120µL using a SpeedVac vacufuge
(medium temperature, 3–4 hours) and subsequently adjusted to exactly 128µL
with molecular biology grade water.
2.3.16.9 Target Capture/Hybridization – Procedure
Target capture of 617 cancer-associated genes was performed following the proto-
col by Hodges et al. [49] applying the modifications recommended by Meyer and
Kircher [85], i.e. blocking oligos BO1–BO6 were used (see table 2.29, sequences as
published by Meyer and Kircher [85] are listed in appendix A.1). The 10X Agilent
Blocking Agent was prepared by adding 1350µL of molecular biology grade water
to the lyophilized pellet. The tube was vortexed, incubated at 37 ◦C for 5 minutes
to dissolve the pellet, and stored at −20 ◦C. Reagents were thawed on ice, tubes
were flicked to mix, and briefly spun down. The 10X Agilent Blocking Agent was
vortexed after thawing and briefly spun down. The 2x hybridization buffer was
carefully inverted to mix. The hybridization mix was prepared in a fresh micro-
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centrifuge tube by adding the components listed in table 2.35 in the given order.
As described in 2.3.16.8 12 indexed libraries had been pooled to be processed and
hybridized together on one capture slide (12plex capture).
Target Capture – Hybridization Mix
Component Volume Final Concentration
20µg DNA (pooled indexed libraries) 128µL ≈ 38.5ng/µL
200µM BO1 5µL ≈ 2µM
200µM BO2 5µL ≈ 2µM
200µM BO3 5µL ≈ 2µM
200µM BO4 5µL ≈ 2µM
200µM BO5 5µL ≈ 2µM
200µM BO6 5µL ≈ 2µM
1mg/mL Cot-1 DNA 50µL ≈ 0.01mg/mL
10X Agilent Blocking Agent 52µL 1X
2X Agilent Hybridization Buffer 260µL 1X
Total volume 520µL
Table 2.35: Target capture – hybridization mix.
Hybridization of the 12plex libraries was performed following the protocol by Hodges
et al. [49] following the modifications recommended by Meyer and Kircher [85].
The hybridization mix was inverted to mix, briefly spun down, and incubated
in a heat block at 95 ◦C for 3 minutes to denature the samples. After denaturation,
the tubes were immediately transfered to a second heat block at 37 ◦C and incu-
bated for 30–60 minutes. The tubes were centrifuged at 13,000rpm for 1 minute
and the hybridization was set up.
The hybridization oven was preheated to 65 ◦C. A new gasket slide was placed
into the hybridization chamber base (rubber seal up). The hybridization mix was
removed from the 37 ◦C heat block and 490µL of the hybridization mix were pipet-
ted onto the gasket slide. The SurePrint G3 CGH microarray slide was placed onto
the gasket slide (side with numeric code facing up) and the hybridization chamber
was closed and placed into the hybridization oven. Hybridization was carried out
at 65 ◦C and 12rpm for 65–70 hours.
Following hybridization, the hybridization chambers were removed from the oven.
The slide sandwich was taken out of the chambers, a plastic tray was filled with
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oligo aCGH/CoC wash buffer I (at room temperature), and array slide and gasket
slide were submerged in wash buffer I while being disassembled. The array slide
was quickly put in a 50mL conical tube filled with oligo aCGH/CoC wash buffer I.
The conical tube was put in a tube rack on a rocker to wash the array slide for 10
minutes at medium speed. The array slide was then transferred to another conical
tube filled with oligo aCGH/CoC wash buffer II prewarmed to 37 ◦C and washed
on the rocker for 5 minutes. The array slide was removed and dried by brief cen-
trifugation in a microarray slide centrifuge. A SecureSeal adhesive hybridization
chamber was placed on top of the microarray slide, one port was sealed. The new
slide sandwich was filled with ≈ 1mL buffer EB preheated to 95 ◦C, and placed on
a heat block at 95 ◦C for 5 minutes to elute the captured DNA libraries. The eluate
was split and collected in two fresh microcentrifuge tubes and the slide sandwich
was again filled with ≈ 1mL buffer EB to repeat the elution step. The eluate
from the second elution was as well split and collected in two new microcentrifuge
tubes.
2.3.16.10 DNA Precipitation after Target Capture – Procedure
Ethanol precipitation of the DNA libraries was performed following elution from
the capture slide. Therefore, the eluate obtained after slide elution was parted
into 5 microcentrifuge tubes each containing 400µL (or 4 tubes with 500µL each).
0.15 volumes 5M Ammonium Acetate, 0.04 volumes 5mg/mL Glycogen, and 2.2–
2.5 volumes 100% cold ethanol were added to each tube to precipitate the eluted
DNA libraries (see 2.36). Tubes were inverted to mix and incubated at −80 ◦C
over night.
DNA Precipitation after Target Capture
Component Volume
Eluted DNA in buffer EB 400–500µL
5M Ammonium Acetate 60–75µL
5mg/mL Glycogen 16–20µL
100% Ethanol (cold) 1000–1100µL
Total volume 1476–1695µL
Table 2.36: DNA precipitation after target capture.
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Following incubation, the tubes were centrifuged at 12,000rpm and 4 ◦C for
60 minutes to pellet the precipitated DNA. The supernatant was discarded and
the pellets were washed with 750µL 75% cold ethanol. Tubes were centrifuged
at 12,000rpm and 4 ◦C for 10 minutes. The supernatant was discarded and the
washing step was repeated. After centrifugation, the supernatant was discarded,
residual ethanol was removed by letting the samples air-dry on the benchtop for
approximately 60 minutes. Alternatively, the supernatant was discarded leaving
approximately 100µL of ethanol on the sample before reducing the volume by
centrifugation in a SpeedVac vacufuge at medium heat and subsequently letting
the samples air-dry on the benchtop. The dried pellets were resuspended in 10µL
buffer EB each and incubated on the benchtop at room temperature for 60 minutes
to completely dissolve the DNA. The 5 tubes containing DNA previously eluted
from the same capture slide were pooled to yield a final volume of 50µL per 12plex
library. The 12plex libraries were either processed immediately or frozen at−20 ◦C.
2.3.16.11 Amplification of Libraries after Target Capture – Procedure
The captured 12plex libraries that had been precipitated and cleaned up in the
previous step were amplified for sequencing using the PCR protocol described in
2.3.16.7 with the exception that primer IS5 and IS6 were used as suggested by
Meyer and Kircher [85]. The samples were split into 5 (or 4) PCR tubes at 10µL
each to perform 5 parallel reactions of bulk amplification. A PCR master mix
was prepared as described in table 2.37 and 40µL of the master mix were added
to each reaction, mixed by pipetting, and processed in a PCR cycler using the
temperature protocol in table 2.37. 13 to 14 cycles were run.
Following amplification, the 5 (or 4) parallel reactions were pooled in one mi-
crocentrifuge tube and subjected to a cleanup step that was performed using one of
the DynaMag magnets and SPRI beads as described in 2.3.16.3 – with the excep-
tion that elution was performed using 60µL buffer EB. Subsequently, NanoDrop
(see 2.3.6) and Bioanalyzer measurements were performed (Bioanalyzer measure-
ments were performed by the Genomics Core Facility at the University of Chicago)
to determine quantity and quality of the 12plex captured DNA sequencing libraries
before submitting them for sequencing.
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Bulk amplification – Master Mix
Component Volume Final Concentration
H2O 27.1µL
5X Phusion HF Buffer 10.0µL 1X
25mM (each) dNTP mix 0.4µL 200µM each
10µM Primer IS5 1.0µL 200nM
10µM Primer IS6 1.0µL 200nM
Phusion Hot Start II HighFidelity
DNA Polymerase (2U/µL) 0.5µL 0.02U/µL
Total volume 40.0µL
Bulk amplification – Temperature Protocol
Temperature Time Description
98 ◦C 30s Initial Denaturation
13–14 cycles:
98 ◦C 10s Denaturation
60 ◦C 20s Annealing
72 ◦C 20s Elongation
72 ◦C 10min Final extension
4 ◦C Final hold
Table 2.37: Bulk amplification – master mix and temperature protocol.
2.3.17 Sequencing – Validation
Next generation sequencing (NGS) of tumor/normal pairs was performed on Il-
lumina HiSeq 2000/2500 sequencers by the Institute for Genomics and Systems
Biology (IGSB) High-throughput Genome Analysis Core (HGAC) at the Univer-
sity of Chicago.
For validation of the obtained sequencing results, a solution phase target cap-
ture approach was applied. Therefore, the 300bp fraction of adapter ligated DNA
(n=240, 120 tumor and matching normal samples) that was obtained when per-
forming size selection with the e-gel and kept as spare material (see 2.3.16.6) was
used. The 300bp fractions were thawed and processed as described – column
cleanup following e-gel size selection (see 2.3.16.6), indexing PCR (see 2.3.16.7),
however, using indexes 1–75 as published by Meyer and Kircher [85] (see table A.1
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in the appendix), and SPRI beads cleanup (see 2.3.16.3). Samples were indexed
in a different order and using different indexes as before, e.g. if samples A–X were
indexed with indices 1–24 for solid phase capture, they were now indexed with
different indices and the order was scrambled. Pooling was performed as described
(see 2.3.16.8) but multiplexing the samples 75plex and hence using a different
amount per sample. Pooling and solution phase capture were performed by Dr.
Arun Khattri following the protocol of the manufacturer (Nimblegen EZ Choice,
Madison, WI). Dr. Khattri also helped to index and clean up some of the samples
for solution phase capture.
Copy number aberrations derived from NGS data were validated using results
from the Nanostring copy number assay (see 2.3.13).
2.3.18 FGFR3 PCR
Materials
See table 2.38 for the required materials. Unless otherwise specified the company
was located in the USA. Primers targeting exon 7 of FGFR3 and thus flanking the
S249C mutation as described by Jebar et al. [57] were used for PCR and direct
sequencing.
Procedure
Primers were dissolved in buffer TE to a concentration of 100µM to prepare a stock
solution. A work solution of 10µM was prepared by diluting the stock solution 1:10
with molecular biology grade water. Both stock and work solution were stored at
−20 ◦C. Primers were tested and the conditions for PCR were optimized.
The working area was cleaned with 70% ethanol. Sample genomic DNA, primers
(primer sequence list) and reagents – except for DNA polymerase – were thawed
on ice, tubes were flicked to mix and spun down using the minifuge. DNA dilutions
for samples were prepared using molecular biology grade water and concentrations
were adjusted to 20 − 50ng/µL as determined by NanoDrop or PicoGreen (see
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Item – Description Company
Equipment
C1000 Thermal Cycler Bio-Rad Laboratories Inc., Her-
cules, CA
GeneMate Minifuge BioExpress, Kaysville, UT
Chemicals – Reagents – Commercial Solutions and -Kits
AmpliTaq Gold R© DNA Poly-
merase with Buffer II and MgCl2
Life Technologies, Grand Island,
NY
dNTP Mix (10mM) Life Technologies, Grand Island,
NY
Primer FGFR3 exon 7F and
primer FGFR3 exon 7R [57]
Integrated DNA Technologies Inc.,
Coralville, IA
TE Buffer Life Technologies, Grand Island,
NY
HyCloneTM Water, Molecular Biol-
ogy Grade
Fisher Scientific, Hanover Park, IL
Disposables
0.2mL PCR 8-tube FLEX-FREE
strip, attached clear flat caps
USA Scientific, Inc., Ocala, FL
Table 2.38: Materials – FGFR3 PCR.
Primer sequences and references are listed in A.1 in the appendix.
2.3.6). A master mix (see table 2.39) was set up for the respective number of
samples as well as the no template control and one additional sample to account
for dead volume. Setup was done in a microcentrifuge tube at room temperature
directly before use. DNA polymerase was taken out of the −20 ◦C freezer, added
to the master mix, and immediately put back into the freezer to avoid degradation
and loss of activity due to repeated temperature increase of the enzyme stock.
Components of the master mix were mixed homogeneously by flicking the tube,
and spun down using the minifuge. PCR tubes were preloaded with 9µL of master
mix, then 1µL of sample genomic DNA or water for the no template control was
added to the respective well. Master mix and DNA were mixed homogeneously by
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flicking the PCR reaction tubes, spun down using the minifuge and processed in
the PCR cycler applying the temperature protocol in table 2.39. After finishing
the PCR, samples were either kept on ice (if further processed on the same day)
or frozen at −20 ◦C.
FGFR3 PCR – Master Mix
Component Volume Final Concentration
10X PCR Buffer II 1.0µL 1x
25mM MgCl2 0.6µL 1.5mM
10mM dNTP mix 0.2µL 200µM
10µM Primer FGFR3 exon 7F 0.5µL 0.5µM
10µM Primer FGFR3 exon 7R 0.5µL 0.5µM
H2O 5.8µL
AmpliTaq Gold R©DNA Polymerase 0.4µL 2 Units
FGFR3 PCR – Temperature Protocol
Temperature Time Description
95 ◦C 10min Activation (hot-start enzyme)
40 cycles:
95 ◦C 30s Denaturation
65 ◦C 30s Annealing
72 ◦C 30s Elongation
72 ◦C 10min Final extension
4 ◦C Final hold
Table 2.39: FGFR3 PCR – master mix and temperature protocol.
Subsequently, samples were subjected to agarose gel electrophoresis (see 2.3.11)
and Exosap treatment (see 2.3.19) to confirm successful PCR and to clean up
samples for sequencing respectively.
2.3.19 ExoSAP-IT Treatment
Materials
See table 2.40 for the required materials. Unless otherwise specified the company
was located in the USA.
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Item – Description Company
Equipment
C1000 Thermal Cycler Bio-Rad Laboratories Inc., Her-
cules, CA
GeneMate Minifuge BioExpress, Kaysville, UT
Chemicals – Reagents – Commercial Solutions and -Kits
ExoSAP-IT R© For PCR Product
Cleanup
Affymetrix Inc., Santa Clara, CA
Table 2.40: Materials – ExoSAP-IT treatment.
Procedure
ExoSAP-IT contains Exonuclease I and Shrimp Alkaline Phosphatase, which hy-
drolyze single stranded DNA and phosphate monoesters respectively. ExoSAP-IT
treatment was given to each sample before sequencing to eliminate excess primers
and unincorporated nucleotides that potentially interfere with downstream appli-
cations.
Gloved hands were cleaned using 70% ethanol. 2µL of ExoSAP-IT were added to
each tube containing 8µL of PCR product, intermixed by flicking the tubes and
spun down using the minifuge. Thermal treatment was applied as described in
table 2.41.
Temperature Time Description
37 ◦C 20-30min Treatment
80 ◦C 5-15min Inactivation
4 ◦C Final hold
Table 2.41: ExoSAP-IT treatment – temperature protocol.
Following ExoSAP-IT treatment, the samples were frozen and handed over
to the sequencing facility (University of Chicago Comprehensive Cancer Center –
DNA Sequencing & Genotyping Facility) along with the primers used for FGFR3
PCR (see 2.3.18) or FGFR3 RT-PCR (see 2.3.21). For sequencing, primers were
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adjusted to a concentration of 4µM by diluting the primer work solution 1:2.5 with
molecular biology grade water.
2.3.20 Sequencing and Visualization
Samples were sequenced on a 3730XL 96-capillary or a 3130 16-capillary auto-
mated DNA sequencer by the DNA Sequencing and Genotyping Facility at the
University of Chicago Comprehensive Cancer Center. Sequences were provided
as chromatograms and text files. Analysis of the obtained sequencing results was
done by visual inspection of chromatograms using the CodonCode Aligner 5.0.2
software.
2.3.21 FGFR3 RT-PCR
RNA that was used for FGFR3 RT-PCR had previously been DNase digested (ei-
ther on-column digest for cell lines or digest following purification as described in
2.3.8) to remove trace amounts of DNA. Concentrations and purity were deter-
mined via spectrophotometric measurements (see 2.3.6 and 2.3.7), RNA integrity
was measured with a Bioanalyzer (see 2.3.7). Only RNA with satisfying quality
(260/280 ≥ 1.8, 260/230 ≥ 1.8 minor exceptions were allowed, RIN≥ 7.5) was
used for reverse transcription (see 2.3.25).
See table 2.42 for FGFR3 RT-PCR specific primers and table 2.43 for the three
primer combinations used for RT-PCR per sample. Primer FGFR3 exon 6F was
used for direct sequencing. All four primers used for FGFR3 RT-PCR were taken
from Tomlinson et al. [130]. All other materials used for FGFR3 RT-PCR corre-
spond with the materials described for FGFR3 PCR in table 2.38.
Materials
See table 2.42 for the required materials. Unless otherwise specified the company
was located in the USA.
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Item – Description Company
Chemicals – Reagents – Commercial Solutions and -Kits
Primer FGFR3 exon 6F [130], Integrated DNA Technologies Inc.,
primer FGFR3 exon 8R [130], Coralville, IA
primer FGFR3 exon 9R [130],
primer FGFR3 exon 11R [130]
Table 2.42: Materials – FGFR3 RT-PCR.
Primer sequences and references are listed in A.1 in the appendix.
Primer F Primer R Target Fragment length
FGFR3 exon 6F FGFR3 exon 8R FGFR3 IIIb 285bp
FGFR3 exon 6F FGFR3 exon 9R FGFR3 IIIc 290bp
FGFR3 exon 6F FGFR3 exon 11R FGFR3 ∆8-10 368bp
FGFR3 IIIb 710bp
FGFR3 IIIc 679bp
Table 2.43: FGFR3 RT-PCR – primer combinations.
Procedure
FGFR3 RT-PCR was set up as described in the methods for FGFR3 PCR (see
2.3.18) including primer preparation, testing, and optimization of the FGFR3 RT-
PCR specific primers (primer combinations are shown in table 2.43). Master mix
and temperature protocol were slightly modified as shown in table 2.44. 2µL of
cDNA transcribed from 1µg of RNA served as a template for RT-PCR. Since the
total volume per PCR reaction was 10µL, PCR tubes were preloaded with 8µL of
master mix, to which 2µL of cDNA were added.
Following FGFR3 RT-PCR, samples were subjected to agarose gel electrophore-
sis (see 2.3.11) and Exosap treatment (see 2.3.19) to confirm successful PCR, to
check isoform expression and to clean up samples for sequencing respectively. The
samples that had been amplified with primer pair FGFR3 exon 6F/11R had to
be subjected to an additional gel electrophoresis/excision/purification step before
sequencing (2.3.22, 2.3.23), since two major amplification products were detected
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FGFR3 RT-PCR – Master Mix
Component Volume Final Concentration
10X PCR Buffer II 1.0µL 1x
25mM MgCl2 0.6µL 1.5mM
10mM dNTP mix 0.2µL 200µM
10µM Primer FGFR3 exon 6F 0.5µL 0.5µM
10µM Primer FGFR3 exon 8R, 9R, or 11R 0.5µL 0.5µM
H2O 4.8µL
AmpliTaq Gold R©DNA Polymerase 0.4µL 2 Units
FGFR3 RT-PCR – Temperature Protocol
Temperature Time Description
95 ◦C 10min Activation (hot-start enzyme)
35 cycles:
95 ◦C 30s Denaturation
60 ◦C 30s Annealing
72 ◦C 45s Elongation
72 ◦C 5min Final extension
4 ◦C Final hold
Table 2.44: FGFR3 RT-PCR – master mix and temperature protocol.
(see figure 3.26). Samples were sequenced using primer FGFR3 exon 6F and ana-
lyzed as described before (see 2.3.20).
2.3.22 Gel Excision
Materials
See table 2.45 for the required materials. Unless otherwise specified the company
was located in the USA.
Procedure
An agarose gel electrophoresis was run according to 2.3.11 using the volumes and
conditions listed for gel excision in table 2.18.
Following electrophoresis, the gel was imaged immediately and the respective
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Item – Description Company
Equipment
Biorad Universal Hood II Imager Bio-Rad Laboratories Inc., Her-
cules, CA
Disposables
XTRACTA Disposable Gel Ex-
traction Tool
Fisher Scientific, Hanover Park, IL
Table 2.45: Materials – gel excision.
bands were cut out using a disposable gel extraction tool. A new gel extrac-
tion tool was used for each band to avoid any cross contamination of samples. The
cut band was placed in a microcentrifuge tube and gel purification was performed
as described in 2.3.23.
2.3.23 Gel Purification
Materials
See table 2.46 for the required materials. Unless otherwise specified the company
was located in the USA.
Procedure
Purification of DNA from an agarose gel was done using the QIAquick Gel Extrac-
tion Kit following the instructions of the manufacturer. Buffer PE was prepared
before use by adding 100% ethanol (volume was depending on the size of the kit
and indicated on the respective bottle). Purification including all centrifugation
steps was carried out at room temperature. Centrifugation speed was 13000rpm
for all centrifugation steps.
The weight of the gel pieces cut with the XTRACTA gel extraction tool was
approximated by spinning the respective piece in a microcentrifuge tube and esti-
mating the volume. 3 volumes of buffer QG were added to 1 volume of gel and the
gel/buffer mix was incubated at 50 ◦C for 10min and repeatedly vortexed during
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Item – Description Company
Equipment
Eppendorf Microcentrifuge 5415D Eppendorf, Hauppauge, NY
Dry Bath Incubator Fisher Scientific, Hanover Park, IL
Savant DNA120 SpeedVac R© Con-
centrator
Thermo Fisher Scientific Inc.,
Waltham, MA
Chemicals – Reagents – Commercial Solutions and -Kits
QIAquick Gel Extraction Kit QIAGEN Inc., Valencia, CA
Ethyl alcohol, Pure, 200 proof, for
molecular biology
Sigma-Aldrich Corp., St. Louis,
MO
2-Propanol, for molecular biology,
99.5%
Sigma-Aldrich Corp., St. Louis,
MO
Table 2.46: Materials – gel purification.
incubation. If necessary, gel/buffer mix was incubated for up to 30 minutes to
make sure agarose had completely dissolved before proceeding to the next step.
The color of the mixture was always yellow after dissolving the agarose, which
indicates a pH≤ 7.5 and thus ideal conditions for adsorption of DNA to the QI-
Aquick membrane. 1 gel volume of isopropanol was added and intermixed with
each sample to facilitate binding of DNA and hence increase the yield of recovered
DNA fragments – addition of isopropanol helps increase the yield of DNA frag-
ments < 500bp. A QIAquick spin column was placed in a 2mL collection tube, the
sample was applied to the column and centrifuged for 1 minute. The flow-through
was discarded and the spin column was placed back into the same collection tube.
500µL of buffer QG were added to the spin column and the sample was spun again
for 1 minute. This additional cleanup step ensures the removal of trace amounts
of agarose and is necessary, if the recovered DNA is supposed to be used for direct
sequencing. 750µL of buffer PE were added to the spin column, incubated for
5min to reduce salt amounts co-eluted together with DNA, and then centrifuged
for 1 minute. The flow-through was discarded and the spin column was centrifuged
for 1 minute to remove any residual ethanol from the column. The spin column
was placed into a fresh, labeled microcentrifuge tube. DNA was eluted using 30µL
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buffer EB (10mM Tris-Cl, pH 8.5), i.e. 30µL of buffer EB were pipetted to the
center of the spin column membrane, incubated for 1 minute and centrifuged for
1 minute to elute DNA.
Subsequently, another agarose gel was run to doublecheck the results of the gel
excision/purification and to estimate the concentrations of DNA for sequencing
(see 2.3.11 and 2.18). If the samples showed weak bands on the gel, their volumes
were reduced from the original 30µL after elution to approximately 20µL by a
SpeedVac centrifugal evaporator to increase DNA concentration. Samples were
subsequently frozen at −20 ◦C and handed over to the sequencing facility where
they were sequenced using primer FGFR3 exon 6F. For sequencing, primers were
adjusted to a concentration of 4µM by diluting the primer work solution 1:2.5 with
molecular biology grade water. Samples were sequenced and analyzed as described
in 2.3.20.
2.3.24 RNA Purification From Cultured HNC Cells
Materials
See table 2.47 for the required materials. Unless otherwise specified the company
was located in the USA.
Procedure
Purification of RNA from cell lines was done using the RNeasy Mini Kit and the
RNase-Free DNase Set following the instructions of the manufacturer. Purifica-
tion including all centrifugation steps was carried out at room temperature. Before
starting the working area was cleaned with 70% ethanol and subsequently sprayed
and wiped down with RNaseZap to remove any potential sources of contamination
with nucleic acids or nucleases. All working materials that had to be used and that
were put into the clean working area were as well cleaned with RNaseZap. Buffer
RPE was prepared before use by adding 100% ethanol (volume was depending on
the size of the kit and indicated on the respective bottle). A 70% ethanol solution
was prepared from pure molecular biology grade ethanol and molecular biology
grade water. DNase stock solution was prepared according to the instructions of
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Item – Description Company
Equipment
Eppendorf Microcentrifuge 5415D Eppendorf, Hauppauge, NY
GeneMate Minifuge BioExpress, Kaysville, UT
Dry Bath Incubator Fisher Scientific, Hanover Park, IL
Chemicals – Reagents – Commercial Solutions and -Kits
RNeasy Mini Kit QIAGEN Inc., Valencia, CA
β-Mercaptoethanol MP Biomedicals, LLC, Solon, Ohio
Ethyl alcohol, Pure, 200 proof, for
molecular biology
Sigma-Aldrich Corp., St. Louis,
MO
HyCloneTM Water, Molecular Biol-
ogy Grade
Fisher Scientific, Hanover Park, IL
RNase-Free DNase Set QIAGEN Inc., Valencia, CA
Disposables
BDTMInsulin Syringes, 1mL Fisher Scientific, Hanover Park, IL
BDTMPrecisionGlideTMSingle-use
Needles, 20 Gauge
Fisher Scientific, Hanover Park, IL
Additional Supplies
RNaseZap R© Life Technologies, Grand Island,
NY
Table 2.47: Materials – RNA purification from cells.
the manufacturer. The lyophilized DNase I was reconstituted in 550µL of RNase-
free water by carefully injecting the RNase-free water through the lid into the vial
using an RNase-free syringe and needle. DNase was dissolved by gently inverting
the vial. Aliquots were prepared and stored at −20 ◦C.
The homogenized cell lysates that had been prepared for RNA purification using
600µL of buffer RLT with β-mercaptoethanol (10µL/mL) as described in 2.4.6
were taken out of the −80 ◦C freezer and thawed on ice before they were briefly
incubated at 37 ◦C to completely defrost samples and dissolve salts. If any debris
was present, cell lysates were centrifuged for 5min at 5000g and supernatant was
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transfered to a new microcentrifuge tube. 1 volume of 70% ethanol (580-600µL
depending on the previous steps) was added to each sample and intermixed by
pipetting. 700µL of each sample were loaded on a spin column from the kit, which
was placed in a 2mL collection tube, and centrifuged for 15s at 8000g. The flow-
through was discarded and the centrifugation step was repeated with the remaining
part of the sample. Following this centrifugation step, an on-column DNase diges-
tion was performed to remove any trace amounts of DNA. For this purpose, 350µL
of buffer RW1 were added to the spin column, which was then centrifuged for 15s
at 8000g. The flow-through was discarded and the spin column was placed back
into the same collection tube. Per sample, 10µL of the DNase I stock solution
were gently mixed (by inverting the tube) with 70µL of buffer RDD in a separate
microcentrifuge tube, which was then briefly spun using the minifuge to collect
any liquid from the sides or the lid of the tube. 80µL of the DNase I mix were
then added directly to each spin column membrane and incubated on the bench-
top for 15 minutes. Following the DNase digestion step, 350µL of buffer RW1
were added to the spin column. The column was centrifuged for 15s at 8000g, the
flow-through was discarded, and 500µL of wash buffer RPE were added. The col-
umn was centrifuged for 15 seconds at 8000g and the flow-through was discarded
before performing another washing step using 500µL of buffer RPE and spinning
the sample for 2 minutes at 8000g. The spin column was placed in a new 2mL
collection tube and centrifuged for 1 minute at 13000rpm (full speed) to ensure
removal of any traces of buffer RPE or ethanol before eluting the RNA. The spin
column was placed into a new 1.5mL collection tube and 30µL of RNase-free water
were added directly onto the membrane. RNA was eluted by centrifuging for 1
minute at 8000g.
RNA concentration and quality (purity and integrity) were subsequently measured
using NanoDrop (see 2.3.6) and Bioanalyzer (see 2.3.7). RNA samples were stored
at −80 ◦C.
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2.3.25 Reverse Transcription
Materials
See table 2.48 for the required materials. Unless otherwise specified the company
was located in the USA.
Item – Description Company
Equipment
C1000 Thermal Cycler Bio-Rad Laboratories Inc., Her-
cules, CA
GeneMate Minifuge BioExpress, Kaysville, UT
Chemicals – Reagents – Commercial Solutions and -Kits
SuperScript R© III First-Strand
Synthesis System
Life Technologies, Grand Island,
NY
HyCloneTM Water, Molecular Biol-
ogy Grade
Fisher Scientific, Hanover Park, IL
Disposables
0.2mL PCR 8-tube FLEX-FREE
strip, attached clear flat caps
USA Scientific, Inc., Ocala, FL
Additional Supplies
RNaseZap R© Life Technologies, Grand Island,
NY
Table 2.48: Materials – reverse transcription.
Procedure
Reverse transcriptase is an enzyme which uses RNA as a template to synthesize
complementary DNA (cDNA), a process named reverse transcription. The so
produced cDNA can then be used in downstream applications like PCR. Using
the SuperScript R© III First-Strand Synthesis System cDNA can be synthesized
from a total RNA preparation allowing for a wide range of RNA target sizes and
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starting material amounts. RNA concentrations and purity were determined via
spectrophotometric measurements, RNA integrity was measured with Bioanalyzer
(see 2.3.6 and 2.3.7). Only RNA that satisfied certain quality criteria (260/280 ≥
1.8, 260/230 ≥ 1.8 minor exceptions were allowed, RIN≥ 7.5) was used for reverse
transcription. Reverse transcription was performed according to the instructions
of the manufacturer.
The benchtop was first cleaned with 70% ethanol and subsequently with RNaseZap
to remove any potential sources of contamination with nucleic acids or nucleases.
All working materials that were put into the clean working area were as well
sprayed and wiped with RNaseZap. The components of the kit – except for any
enzyme – were thawed on ice, mixed by flicking the tubes, and briefly spun down
using the minifuge before being put back on ice. 1µg of total RNA was taken
from each sample and diluted with DEPC-treated water to reach a total volume of
8µL. 1µL of the 50µM oligo(dT)20 primer as well as 1µL of the 10mM dNTP mix
were added to the diluted RNA. The tubes were flicked to intermix the different
components, briefly spun to bring down any liquid from lid and walls, incubated in
a thermal cycler at 65 ◦C for 5 minutes, and then placed on ice for at least 1 minute.
A master mix for the cDNA synthesis mix was prepared in a microcentrifuge tube
by adding the different components in the following order (given are the volumes
per sample that need to be multiplied by the number of samples), 2µL of 10X RT
buffer, 4µL of 25mM MgCl2, 2µL of 0.1M DTT, 1µL of RNaseOUT
TM (40U/µL),
and 1µL of SuperScript R© III RT (200U/µL). The master mix was briefly mixed by
flicking the tube before spinning down the liquid using the minifuge. 10µL of cDNA
synthesis mix were added to each tube containing the RNA/primer mix. Tubes
were mixed gently and liquid was collected by brief centrifugation. Samples were
incubated applying the following temperatures and incubation times, 50 minutes
at 50 ◦C, then 5 minutes at 85 ◦C to terminate the reaction. Following incubation
and termination, the samples were chilled on ice and the liquid was collected by
briefly spinning the samples. 1µL of RNaseH was added to each tube, intermixed
with the samples, and incubated for 20 minutes at 37 ◦C. cDNA samples were
stored at −20 ◦C.
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2.3.26 FGFR3/TACC3 Fusion RT-PCR
FGFR3/TACC3 fusion RT-PCR was run for 136 HNSCC samples. 115 of the
samples that were subjected to FGFR3/TACC3 fusion RT-PCR had been DNase
digested (either on-column digest for cell lines or digest following purification of
tumor samples as described in 2.3.8), 21 had not been DNAse digested as it was
not essential to remove trace amounts of DNA for this application. Concentrations
and purity of all samples were determined via spectrophotometric measurements,
RNA integrity was measured via Bioanalyzer (see 2.3.6 and 2.3.7). Only RNA with
satisfying quality (260/280 ≥ 1.8, 260/230 ≥ 1.8 minor exceptions were allowed,
RIN≥ 7.5) was used for reverse transcription (see 2.3.25) and FGFR3/TACC3
fusion RT-PCR.
A forward primer for FGFR3 binding to exon 11 and 12 as well as a reverse primer
for the TACC3 gene exon 13 were used for the fusion specific RT-PCR as described
by Singh et al. [117]. The other materials used for FGFR3/TACC3 fusion RT-PCR
correspond with the materials described for FGFR3 PCR in table 2.38.
Materials
See table 2.49 for the specific primers. Unless otherwise specified the company was
located in the USA.
Item – Description Company
Chemicals – Reagents – Commercial Solutions and -Kits
Primer FGFR3 exon 11/12F and
primer TACC3 exon 13R [117]
Life Technologies, Grand Island,
NY
Table 2.49: Materials – FGFR3/TACC3 fusion RT-PCR.
Primer sequences and references are listed in A.1 in the appendix.
Procedure
The setup for FGFR3/TACC3 fusion RT-PCR was done according to the proce-
dure described for FGFR3 PCR (see 2.3.18) including primer preparation, testing,
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and optimization. Master mix and temperature protocol had to be modified ac-
cording to table 2.50. 2µL of cDNA transcribed from 250-1000ng of RNA (for 5
tumor samples less material was available) served as a template for the RT-PCR.
224ng of RNA from the urinary bladder transitional cell carcinoma cell line RT-112
were reverse transcribed and used as a positive control for the RT-PCR targeting
the FGFR3/TACC3 fusion. The total volume per PCR reaction was 10µL, PCR
tubes were preloaded with 8µL of master mix, to which 2µL of cDNA were added.
FGFR3/TACC3 Fusion RT-PCR – Master Mix
Component Volume Final Concentration
10X PCR Buffer II 1.0µL 1x
25mM MgCl2 0.6µL 1.5mM
10mM dNTP mix 0.2µL 200µM
10µM Primer FGFR3 exon 11/12F 0.5µL 0.5µM
10µM Primer TACC3 exon 13R 0.5µL 0.5µM
H2O 4.8µL
AmpliTaq Gold R©DNA Polymerase 0.4µL 2 Units
FGFR3/TACC3 Fusion RT-PCR – Temperature Protocol
Temperature Time Description
95 ◦C 10min Activation (hot-start enzyme)
35 cycles:
95 ◦C 30s Denaturation
60 ◦C 30s Annealing
72 ◦C 90s Elongation
72 ◦C 5min Final extension
4 ◦C Final hold
Table 2.50: FGFR3/TACC3 fusion RT-PCR – master mix and temperature
protocol.
Following FGFR3/TACC3 fusion RT-PCR, samples were subjected to agarose
gel electrophoresis (see 2.3.11) to confirm successful PCR and to identify the tumor
samples containing the fusion.
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2.3.27 Site Directed Mutagenesis (SDM)
Materials
See table 2.51 for the required materials. Unless otherwise specified the company
was located in the USA.
Item – Description Company
Equipment
C1000 Thermal Cycler Bio-Rad Laboratories Inc., Her-
cules, CA
GeneMate Minifuge BioExpress, Kaysville, UT
Chemicals – Reagents – Commercial Solutions and -Kits
FGFR3 IIIb cDNA clone (EX-
Z7256-M02)
GeneCopoeiaTM, Rockville, MD
FGFR3 ∆8-10 cDNA clone (EX-
Z0704-M02)
GeneCopoeiaTM, Rockville, MD
negative control vector (EX-NEG-
M02)
GeneCopoeiaTM, Rockville, MD
Thermo ScientificTM PhusionTM Fisher Scientific, Hanover Park, IL
Hot Start II High-Fidelity DNA
Polymerase
dNTP Mix (25mM) Fisher Scientific, Hanover Park, IL
Primer SDM FGFR3 S249C F
(PAGE purified)
Life Technologies, Grand Island,
NY
Primer SDM FGFR3 S249C R
(PAGE purified)
Life Technologies, Grand Island,
NY
HyCloneTM Water, Molecular Biol-
ogy Grade
Fisher Scientific, Hanover Park, IL
Disposables
0.2mL PCR 8-tube FLEX-FREE
strip, attached clear flat caps
USA Scientific, Inc., Ocala, FL
Table 2.51: Materials – site directed mutagenesis.
Primer sequences and references are listed in A.1 in the appendix.
Information about cDNA clones can be found in A.2.
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Procedure
FGFR3 IIIb and FGFR3 ∆8-10 cDNA clones were purchased as these represented
the two main transcripts found in HNSCC tumors and cell lines (SCC47 and
93VU147T). The respective empty vector was as well purchased. Primers for site
directed mutagenesis to introduce the FGFR3 S249C mutation into cDNA clones
were designed to span the base to be mutated. Dilutions of FGFR3 IIIb and
FGFR3 ∆8-10 cDNA clones were prepared from the purchased stock solutions
using molecular biology grade water to reach a concentration of 20ng/µL for the
work solutions. The work solutions were stored at 4 ◦C. Stock and work solutions
of primers were prepared according to the directions given in 2.3.18 and stored at
−20 ◦C.
SDM was set up as described in the procedure for FGFR3 PCR (see 2.3.18). Master
mix and temperature protocol were modified as shown in table 2.52. PCR tubes
were preloaded with 48µL of master mix, to which 2µL of the respective cDNA
clone work solution were added.
Site Directed Mutagenesis – Master Mix
Component Volume Final Concentration
5X Phusion HF Buffer 10.0µL 1x
25mM dNTP mix 0.4µL 200µM
10µM Primer SDM FGFR3 S249C F 2.5µL 0.5µM
10µM Primer SDM FGFR3 S249C R 2.5µL 0.5µM
H2O 32.1µL
Phusion DNA Polymerase (2U/L) 0.5µL 1 Unit
Site Directed Mutagenesis – Temperature Protocol
Temperature Time Description
98 ◦C 3min Activation (hot-start enzyme)
18 cycles:
98 ◦C 20s Denaturation
72 ◦C 8min 30s Annealing & Elongation
72 ◦C 10min Final extension
4 ◦C Final hold
Table 2.52: SDM – master mix and temperature protocol.
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Following SDM, the reactions were either stored at 4 ◦C, if further processed
and subjected to DpnI treatment on the same day, or at −20 ◦C, if processed later.
2.3.28 DpnI Treatment
Materials
See table 2.53 for the required materials. Unless otherwise specified the company
was located in the USA.
Item – Description Company
Equipment
C1000 Thermal Cycler Bio-Rad Laboratories Inc., Her-
cules, CA
GeneMate Minifuge BioExpress, Kaysville, UT
Chemicals – Reagents – Commercial Solutions and -Kits
Thermo ScientificTM DpnI Fisher Scientific, Hanover Park, IL
Table 2.53: Materials – DpnI treatment.
Procedure
DpnI treatment was applied following SDM. DpnI is a restriction enzyme that di-
gests methylated DNA and hence is a method of purification for products of SDM.
The SDM PCR products do not feature any methylation whereas the template
plasmid that was purified from a bacterial culture will be methylated and hence
degraded by DpnI.
Gloved hands were cleaned using 70% ethanol. 2µL of DpnI were added to each
tube containing 50µL of SDM product, intermixed by flicking the tubes and spun
down using the minifuge. Thermal treatment was applied as described in ta-
ble 2.54.
Following DpnI treatment, the samples were either frozen at −20 ◦C or directly
used for transformation of competent bacteria (see 2.3.29).
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Temperature Time Description
37 ◦C 4h Treatment
80 ◦C 20min Inactivation
4 ◦C Final hold
Table 2.54: DpnI treatment – temperature protocol.
2.3.29 Transformation of Competent E.coli
Materials
See table 2.55 for the required materials. Unless otherwise specified the company
was located in the USA.
Procedure
A stock solution of 100mg/mL Ampicillin was prepared by diluting the antibiotic in
sterile molecular biology grade water. Aliquots were frozen at −20 ◦C. The agar-
containing LB broth powder was reconstituted by dissolving 35g powder in 1L
water and bringing the suspension to a boil while repeatedly mixing the contents
to completely dissolve the powder. Subsequently, the solution was autoclaved
applying the standard program for liquids recommended by the manufacturer.
After autoclaving, the mixture was slightly cooled down before the ampicillin was
added to a final concentration of 100µg/mL (1:1000 dilution of the stock solution,
e.g. 200µL ampicillin were added to 200mL agar broth). Agar broth was then
poured into petri dishes and kept on the benchtop with the lids slightly open to
solidify at room temperature. Lids were then closed and agar plates were wrapped
in polyvinyl wrapping film, inverted, and stored at 4 ◦C until used.
The water bath was set to 42 ◦C, the required number of agar plates were warmed
to 37 ◦C in the incubator. Competent cells were thawed on ice, 1 vial was used for
each transformation of SDM product as recommended by the manufacturer. For
transformations of purchased cDNA clones only half a vial of competent cells was
used. Immediately after thawing 5µL of SDM product (or 1µL of the 20ng/µL
work solution of the purchased WT cDNA clones) were added to the competent
cells and intermixed by tapping the vial gently. Vials were incubated on ice for
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Item – Description Company
Equipment
Isotemp 205 Digital Water Bath Fisher Scientific, Hanover Park, IL
New Brunswick Scientific I-2400
Digital Incubator Shaker
Eppendorf, Hauppauge, NY
Dry Bath Incubator Fisher Scientific, Hanover Park, IL
Microwave Sanyo
Chemicals – Reagents – Commercial Solutions and -Kits
One Shot R© TOP10 Chemically
Competent E. coli
Life Technologies, Grand Island,
NY
LB Broth with agar (Lennox),
Powder microbial growth medium
Sigma-Aldrich Corp., St. Louis,
MO
Ampicillin Sodium Salt (Crys-
talline Powder), Fisher BioRe-
agents
Fisher Scientific, Hanover Park, IL
HyCloneTM Water, Molecular Biol-
ogy Grade
Fisher Scientific, Hanover Park, IL
Disposables
CRYSTALGEN INC Petri Dish Fisher Scientific, Hanover Park, IL
FisherbrandTM Polyvinyl Wrap-
ping Film
Fisher Scientific, Hanover Park, IL
FisherbrandTM Disposable Borosil-
icate Glass Pasteur Pipets
Fisher Scientific, Hanover Park, IL
Table 2.55: Materials – transformation.
30 minutes before the cells were heat-shocked at 42 ◦C for 30 seconds. Vials were
then placed on ice for 2 minutes and 250µL of S.O.C. medium were added to each
vial. Vials were sealed and shaken in horizontal position at 37 ◦C for 1 hour at
225rpm in a bacterial shaking incubator.
From each transformation 2 different volumes of transformed bacteria were spread
on agar plates, 50µL and 200µL from the SDM transformed bacteria and 25µL
and 100µL from the purchased clone transformed bacteria. The respective volumes
were pipetted on the agar plates and spread using a Pasteur pipette that was flame-
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shaped into a bacterial spreader using a bunsen burner. Agar plates were left to
dry for 1-2 minutes with the lids slightly open before they were incubated upside
down in the incubator at 37 ◦C over night for 12-18 hours. Following incubation,
the plates were taken out of the incubator and stored at 4 ◦C until colonies were
selected, usually in the evening of the same day.
2.3.30 Selection of Colonies
Materials
See table 2.56 for the required materials. Unless otherwise specified the company
was located in the USA.
Item – Description Company
Equipment
New Brunswick Scientific I-2400
Digital Incubator Shaker
Eppendorf, Hauppauge, NY
Chemicals – Reagents – Commercial Solutions and -Kits
LB Broth (Lennox), Powder micro-
bial growth medium
Sigma-Aldrich Corp., St. Louis,
MO
LB Broth with agar (Lennox),
Powder microbial growth medium
Sigma-Aldrich Corp., St. Louis,
MO
Ampicillin Sodium Salt (Crys-
talline Powder), Fisher BioRe-
agents
Fisher Scientific, Hanover Park, IL
HyCloneTM Water, Molecular Biol-
ogy Grade
Fisher Scientific, Hanover Park, IL
Disposables
NalgeneTM Centrifuge Tubes with
Sealing Cap, 10mL
Thermo Fisher Scientific Inc.,
Waltham, MA
Table 2.56: Materials – selection of colonies.
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Procedure
Following the transformation of competent E.coli, colonies were selected and am-
plified. An ampicillin stock solution as well as the required number of agar plates
were prepared as described in 2.3.29. Growth media for the bacteria was pre-
pared. The LB broth powder was dissolved in water to a concentration of 20g/L
and autoclaved applying the standard program for liquids recommended by the
manufacturer. The broth was cooled down before the ampicillin was added to a
final concentration of 100µg/mL (1:1000 dilution of the stock solution, e.g. 200µL
ampicillin were added to 200mL broth).
New agar plates were prewarmed in a 37 ◦C incubator. The required number of
bacterial growth tubes were preloaded with 3mL of LB broth containing the se-
lective antibiotic ampicillin to grow transformed cells for a subsequent miniprep.
Colonies were selected using a sterile p100 pipette tip that was utilized to pick
a single colony from the agar plate. To create a library a line of approximately
1cm length was drawn on an agar plate before the pipette tip with the remaining
bacteria was dumped into one of the prepared bacterial growth tubes to inoculate
the medium. Tubes were sealed and both the library on the plate and the bacterial
reaction tube were labeled to belong together. Using this method 10 colonies were
selected from each transformation. The plates containing the remaining colonies
were stored at 4 ◦C. The plates containing the library of selected clones were incu-
bated over night in a bacterial incubator at 37 ◦C before they were as well stored
at 4 ◦C. The bacterial growth tubes containing the pipette tips were incubated in
a bacterial shaking incubator at 37 ◦C and 225rpm over night for 12-18 hours.
2.3.31 Miniprep
Materials
See table 2.57 for the required materials. Unless otherwise specified the company
was located in the USA.
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Item – Description Company
Equipment
Eppendorf Microcentrifuge 5415D Eppendorf, Hauppauge, NY
GeneMate Minifuge BioExpress, Kaysville, UT
Chemicals – Reagents – Commercial Solutions and -Kits
QIAprep Spin Miniprep Kit QIAGEN Inc., Valencia, CA
Ethyl alcohol, Pure, 200 proof, for
molecular biology
Sigma-Aldrich Corp., St. Louis,
MO
Table 2.57: Materials – Miniprep.
Procedure
Buffers of the kit were prepared according to the instructions of the manufacturer.
RNase A solution was added to buffer P1, 100% ethanol was added to buffer PE.
All centrifugation steps, except for the harvesting of the cells, were performed at
13000rpm at room temperature.
The bacterial cells were harvested by centrifuging 1mL of the overnight culture
from 2.3.30 in microcentrifuge tubes at 6800g for 3 minutes at room temperature.
The supernatant was carefully decanted and remaining traces of medium were
pipetted off. The cell pellets were resuspended in 250µL buffer P1 by pipetting up
and down and by vortexing the tubes, if necessary. 250µL buffer P2 were added
and intermixed by inverting the tubes 6 times. 350µL buffer N3 were added and
intermixed by inverting the tubes 6 times. The tubes were then centrifuged at
13000rpm for 10 minutes at room temperature. After centrifugation, the super-
natants were carefully removed and transfered to the QIAprep spin columns by
pipetting. Spin columns were centrifuged for 1 minute and the flow-through was
discarded. 500µL buffer PB were added to wash the spin columns, columns were
centrifuged for 1 minute and the flow-through was discarded. 750µL buffer PE
were added and spin columns were centrifuged for 1 minute as another washing
step. The flow-through was discarded and the columns were spun again for 1
minute to remove traces of residual wash buffer. The spin columns were placed in
fresh microcentrifuge tubes for the elution of DNA. 50µL buffer EB were added
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to the center of each spin column membrane. The columns loaded with EB were
first incubated on the benchtop for 1 minute and then cenrifuged for 1 minute to
elute DNA.
Following elution, quality and quantity of the eluted DNA were determined us-
ing a NanoDrop spectrophotometer (see 2.3.6 and 2.3.7). Samples were frozen at
−20 ◦C and submitted to the sequencing facility along with the respective primers
for FGFR3 – seq EX-M02 F and seq EX-M02 R (sequences were provided by the
manufacturer of the cDNA clones and can be found in A.1) and primer FGFR3
exon 6F from FGFR3 RT-PCR (see 2.3.21). Stock and work solutions of the se-
quencing primers seq EX-M02 F and seq EX-M02 R were prepared as described
in 2.3.18. For sequencing, all primers were adjusted to a concentration of 4µM by
diluting the primer work solution 1:2.5 with molecular biology grade water.
Sequencing and visualization were performed as described in 2.3.20. Sequences
were inspected and compared to the respective reference sequence to confirm either
the wild type clone or the mutation introduced by SDM. Clones to be amplified
for transfection of cell cultures were chosen according to the sequencing results
and subsequently amplified and subjected to a Maxiprep.
2.3.32 Maxiprep
Materials
See table 2.58 for the required materials. Unless otherwise specified the company
was located in the USA.
Procedure
Before starting the procedure, buffers of the kit were prepared following the in-
structions of the manufacturer. RNase A solution was added to buffer P1 to
yield a final concentration of 100µg/mL. 40mL of 100% ethanol were added to
the endotoxin-free water supplied with the kit to give a final concentration of 70%
endotoxin-free ethanol. Buffer P3 was pre-chilled at 4 ◦C. LB broth containing
ampicillin as a selective antibiotic was prepared as described in 2.3.30. A 50%
glycerol solution was prepared by mixing 30mL glycerol with 30mL water, the
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Item – Description Company
Equipment
Sorvall RC-5C Plus Superspeed
Centrifuge and rotor SS34
Thermo Fisher Scientific Inc.,
Waltham, MA
NalgeneTM Centrifuge Bottles
with Sealing Cap, 250mL
Thermo Fisher Scientific Inc.,
Waltham, MA
Pyrex Erlenmeyer Flasks with
Stopper
Corning Inc., Corning, NY
New Brunswick Scientific I-2400
Digital Incubator Shaker
Eppendorf, Hauppauge, NY
Chemicals – Reagents – Commercial Solutions and -Kits
EndoFree Plasmid Maxi Kit QIAGEN Inc., Valencia, CA
Ethyl alcohol, Pure, 200 proof, for
molecular biology
Sigma-Aldrich Corp., St. Louis,
MO
2-Propanol, for molecular biology,
99.5%
Sigma-Aldrich Corp., St. Louis,
MO
LB Broth (Lennox), Powder micro-
bial growth medium
Sigma-Aldrich Corp., St. Louis,
MO
Ampicillin Sodium Salt (Crys-
talline Powder), Fisher BioRe-
agents
Fisher Scientific, Hanover Park, IL
HyCloneTM Water, Molecular Biol-
ogy Grade
Fisher Scientific, Hanover Park, IL
Glycerol (Molecular Biology),
Fisher BioReagentsTM
Fisher Scientific, Hanover Park, IL
Disposables
NalgeneTM Centrifuge Tubes with
Sealing Cap, 10mL
Thermo Fisher Scientific Inc.,
Waltham, MA
Thermo ScientificTM NuncTM50mL
Conical Sterile Polypropylene Cen-
trifuge Tube
Fisher Scientific, Hanover Park, IL
Table 2.58: Materials – Maxiprep.
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50% glycerol solution was autoclaved.
A starter culture of 3mL LB broth containing ampicillin was inoculated with the
respective clone chosen for maxiprep and transfection after sequencing. The clone
was picked from the agar plate containing the library made in 2.3.30 using a sterile
p100 pipette tip that was subsequently dumped into the bacterial tube containing
the prepared 3mL of LB broth. Starter cultures were incubated at 37 ◦C for 8
hours in a bacterial shaking incubator set to 300rpm.
An over night culture was started by inoculating 100mL LB broth containing ampi-
cillin with 200µL starter culture. Over night culture was incubated at 37 ◦C for
12-16 hours in a bacterial shaking incubator set to 300rpm. Following the over
night incubation, a glycerol stock was prepared for each culture by mixing 300µL
50% glycerol with 700µL of the bacterial culture in a microcentrifuge tube, which
was subsequently frozen at −80 ◦C.
Cells were harvested by centrifugation at 6000g for 15 minutes at 4 ◦C. The su-
pernatant was decanted and the pellets were resuspended in 10mL buffer P1 by
pipetting and vortexing. 10mL buffer P2 were added and the tube was inverted 6
times to mix and then incubated for 5 minutes at room temperature. The QIAfil-
ter cartridge was prepared by capping the outlet nozzle and placing the cartridge
into a 50mL conical tube. 10mL pre-chilled buffer P3 were added to the lysate
and intermixed by inverting the tube 6 times before pouring the lysate into the
barrel of the QIAfilter cartridge, where it was incubated for 10 minutes at room
temperature. Following incubation time, the cap was removed from the outside
nozzle of the cartridge and the plunger was inserted and pushed down to filter
the cell lysate into the 50mL conical tube. 2.5mL buffer ER were added to the
filtered lysate and intermixed by inverting the tube 10 times. The tube was then
incubated on ice for 30 minutes. During incubation time a QIAGEN-tip 500 was
equilibrated by applying 10mL buffer QBT. The column was emptied by gravity
flow. After incubation on ice, the filtered lysate was applied to the QIAGEN-
tip, which was left until emptied by gravity flow. The QIAGEN-tip was washed
applying 30mL buffer QC two times. Subsequently, DNA was eluted with 15mL
buffer QN and the eluate was first collected in a conical tube and then split to 13
microcentrifuge tubes for the subsequent isopropanol precipitation. For the iso-
propanol precipitation 0.7 volumes of isopropanol were added to the eluted DNA.
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Tubes were mixed and immediately centrifuged at 15000g for 30 minutes at 4 ◦C.
Supernatant was carefully decanted or pipetted off. DNA pellets were washed with
500µL of endotoxin-free 70% ethanol and spun at 15000g for 10 minutes at 4 ◦C.
Supernatant was carefully pipetted off and pellets were air-dried for 10 minutes or
until the residual ethanol had completely evaporated. Each pellet was redissolved
in 10µL endotoxin-free buffer TE. Pellets were stored at 4 ◦C over night to allow
DNA to completely redissolve before pooling the DNA of the 13 microcentrifuge
tubes that belonged together. DNA was frozen at −80 ◦C.
Quality and quantity of the recovered DNA were measured with a NanoDrop spec-
trophotometer (see 2.3.6 and 2.3.7) as well as with an analytical agarose gel (see
2.3.11). An example for a gel showing satisfactory results is given below in 2.2.
Figure 2.2: Example for an agarose gel showing cDNA clones of good quality.
cDNA clones were amplified to be used for transfection and purified performing a max-
iprep. Image shows an example for cDNA clones of good quality that can be used for
transfection. Circular plasmid DNA is present in the supercoiled and open (slightly
visible) form. No contaminating nucleic acids can be detected.
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2.4 Cell Culture Methods
2.4.1 Cultivation of Cell Lines
Materials
See table 2.59 for an overview over the cell lines that were used for functional val-
idation experiments. H357 was used as a positive control to validate the FGFR3
antibody and to compare FGFR3 expression via Western Blot.
Cell Line Medium Supplements Derivation Source
UM-SCC47 DMEM/F12 10% FBS 53 year-old male, University
1% P/S SCC, oral cavity, of Michigan
2mM L-Gln stage T3N1M0
93VU147T DMEM 10% FBS male VU Medical Center
1% P/S SCC, floor of mouth The Netherlands
2mM L-Gln stage T4N2
H357 DMEM/F12 10% FBS 74 year-old male, University of Bristol
1% P/S SCC, tongue UK
2mM L-Gln
Table 2.59: Cell lines – overview.
Procedure
All cell lines were routinely cultured at 37 ◦C in a humidified atmosphere contain-
ing 5% CO2. Standard 100mm cell culture dishes were used, cells were cultured
in 10mL media. Media types used for each cell line are listed in 2.59, 10% FBS,
100I.U. penicillin, 100µg/mL streptomycin, and 2mM L-glutamine were routinely
added to the respective media as supplements.
Visual inspection of the cells was routinely done using a standard light microscope
to keep track of cell growth/confluence and condition of the cells in general.
A media change was performed every 2–3 days. The used media was aspirated
and replaced by prewarmed fresh media. If many dead cells or a lot of cell debris
were present in the culture, cells were washed twice with 3mL prewarmed PBS to
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remove dead cells and cell debris before the fresh prewarmed media was added.
2.4.2 Trypsinizing and Subculturing Cells
Materials
See table 2.60 for the required materials. Unless otherwise specified the company
was located in the USA.
Item – Description Company
Chemicals – Reagents – Commercial Solutions and -Kits
Trypsin EDTA 1X, 0.25% Trypsin/
2.21 mM EDTA in HBSS without
sodium bicarbonate, calcium and
magnesium
Mediatech Inc., A Corning Sub-
sidiary, Manassas, VA
Disposables
Thermo ScientificTM NuncTM50mL
Conical Sterile Polypropylene Cen-
trifuge Tube
Fisher Scientific, Hanover Park, IL
Table 2.60: Materials – trypsinizing and subculturing cells.
Procedure
Cells were subcultured when they reached approximately 80-90% confluence. The
used media was aspirated and cells were washed twice with 3mL prewarmed PBS
to remove any residual FBS which could inhibit the trypsin used for detachment of
the cells. 1mL of prewarmed trypsin/EDTA was added and cells were incubated
at 37 ◦C for 5-10 minutes to detach. Trypsin is a serin protease that releases
adherent cells from cell culture plates by cleaving extracellular proteins needed for
attachment. EDTA is a chelating agent that sequesters divalent cations that would
inhibit this process. After the incubation, fresh media was added to the cells to
stop the reaction, cells were transfered to a 50mL conical tube, and centrifuged
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at 900rpm for 5 minutes at 4 ◦C. The supernatant was carefully aspirated, the
cells were resuspended in fresh prewarmed media and distributed to fresh culture
dishes. Cells were routinely split with a ratio of 1:6. Upon trypsinization, the
passage number was increased by 1.
2.4.3 Counting Cells
Materials
See table 2.61 for the required materials. Unless otherwise specified the company
was located in the USA.
Item – Description Company
Equipment
Hausser Bright-Line, Neubauer
Hemacytometer
Fisher Scientific, Hanover Park, IL
Chemicals – Reagents – Commercial Solutions and -Kits
Trypsin EDTA 1X, 0.25% Trypsin/
2.21 mM EDTA in HBSS without
sodium bicarbonate, calcium and
magnesium
Mediatech Inc., A Corning Sub-
sidiary, Manassas, VA
Disposables
Thermo ScientificTM NuncTM50mL
Conical Sterile Polypropylene Cen-
trifuge Tube
Fisher Scientific, Hanover Park, IL
Table 2.61: Materials – counting cells.
Procedure
Counting of the cells was performed in order to seed them for subsequent experi-
ments or to freeze them. Cells were detached as described in 2.4.2. Depending on
the subsequent purpose, trypsinized cells were either counted before or after cen-
trifugation. 10µL of the well mixed cell suspension were transfered to the Neubauer
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hemocytometer. Cell number was determined in each of the 4 big squares (con-
taining 16 small squares each). The 4 numbers were added and then divided by 4
to receive the average cell number per big square. This number was multiplied by
1 · 104 to yield the cell number per milliliter.
2.4.4 Thawing and Freezing Cells
Materials
See table 2.62 for the required materials. Unless otherwise specified the company
was located in the USA.
Item – Description Company
Equipment
Hausser Bright-Line, Neubauer
Hemacytometer
Fisher Scientific, Hanover Park, IL
Nalgene R© Mr. Frosty freezing con-
tainer, −1 ◦C/min rate of cooling
Sigma-Aldrich Corp., St. Louis,
MO
Chemicals – Reagents – Commercial Solutions and -Kits
Trypsin EDTA 1X, 0.25% Trypsin/
2.21 mM EDTA in HBSS without
sodium bicarbonate, calcium and
magnesium
Mediatech Inc., A Corning Sub-
sidiary, Manassas, VA
Dimethyl Sulfoxide, DMSO AmericanBio Inc., Natick, MA
Disposables
FisherbrandTM Externally
Threaded Cryogenic Storage Vials,
2mL
Fisher Scientific, Hanover Park, IL
Thermo ScientificTM NuncTM50mL
Conical Sterile Polypropylene Cen-
trifuge Tube
Fisher Scientific, Hanover Park, IL
Table 2.62: Materials – thawing and freezing cells.
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Procedure
Freezing media containing 70% FBS, 20% media without supplements, and 10%
DMSO was freshly prepared for the respective number of vials to be frozen. 1–2
·106 cells were routinely frozen in 1mL freezing media per cryoconservation vial.
Cells were trypsinized and counted before centrifugation (see 2.4.2 and see 2.4.3).
The required amount of cells was transfered to a new conical tube, which was then
centrifuged at 900rpm for 5 minutes at 4 ◦C. The supernatant was carefully aspi-
rated and the cells were resuspended in the required amount of freezing media and
distributed to the respective number of cryoconservation vials. Vials were trans-
fered to the room temperature Mr. Frosty freezing container, which cools cells at
a rate of 1 ◦C per minute, and immediately transfered to a −80 ◦C freezer. On the
following day vials were transfered to the liquid nitrogen tank for long term storage.
A working stock with 4–6 vials of the same passage was established per cell line
for the following functional validation experiments. If the actual passage number
was known, preferably young passages were used. Experiments were performed
within a small range of different passages to reduce the influence of this variable
to a minimum.
2.4.5 Mycoplasma Testing
Materials
See table 2.63 for the required materials. Unless otherwise specified the company
was located in the USA.
Procedure
Cells were routinely and regularly tested for the presence of mycoplasma, e.g. after
taking a new cell line out of the liquid nitrogen tank or before freezing a working
stock for functional validation experiments. Following the initial testing, cells were
tested every 2–3 months on a regular basis or earlier, if indicated.
The MycoAlert kit is able to detect viable mycoplasma in the supernatant of a cell
culture. The supernatant is collected before a media change and cleared of cells by
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Item – Description Company
Equipment
GloMax R© 96 Microplate Lumi-
nometer
Promega Corporation, Madison,
WI
Eppendorf Microcentrifuge 5415D Eppendorf, Hauppauge, NY
Chemicals – Reagents – Commercial Solutions and -Kits
MycoAlertTM Mycoplasma Detec-
tion Kit
Lonza Rockland Inc., Rockland,
ME
Disposables
CostarTM 96-Well Solid Plates,
Untreated, White, Round well,
Nonsterile
Fisher Scientific, Hanover Park, IL
Table 2.63: Materials – mycoplasma testing.
centrifugation. Mycoplasma are then lysed so that mycoplasma enzymes can react
with the substrate and reagent contained in the kit. In the case of mycoplasma
contamination of the culture, ATP is generated during the assay and participates
in a light producing reaction. Luminescence is detected as a measure for ATP and
hence presence of mycoplasma.
The lyophilized MycoAlert reagent and substrate were reconstituted according to
the instructions of the manufacturer. Ready-to-use aliquots were frozen at −20 ◦C.
The components of the kit – buffer, reagent, and substrate – were put on the
benchtop to reach room temperature before use. 1.5mL of cell culture supernatant
were taken out of a cell culture dish, transfered to a microcentrifuge tube, and
centrifuged at 200g for 5 minutes at room temperature to pellet any cells. 50µL
of the cell-free supernatant were transfered to a white 96-well microplate. The
settings of the luminometer were adjusted as recommended by the MycoAlert pro-
tocol to take a 1 second integrated reading. 50µL MycoAlert reagent were added
to each sample and readings were taken after 5 minutes of incubation time (reading
A). 50µL of substrate were then added to each sample and readings were taken
after 10 minutes of incubation time (reading B). The ratio of reading B/reading A
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was calculated. A ratio greater than 1 indicates infection of the culture with my-
coplasma whereas a ratio of less than 1 is produced with uninfected cultures. If a
ratio very close to 1 (either above or below) was measured, the test was repeated
on the following day or 2 days later without changing the media of the respective
cell line in the meantime.
2.4.6 Lysates for RNA Extraction
Materials
See table 2.64 for the required materials. Unless otherwise specified the company
was located in the USA.
Item – Description Company
Chemicals – Reagents – Commercial Solutions and -Kits
RNeasy Mini Kit QIAGEN Inc., Valencia, CA
β-Mercaptoethanol MP Biomedicals, LLC, Solon, Ohio
Disposables
Biox BrandTMCell Scrapers
w/Pivoting Blade, sterile, indi-
vidually wrapped, 24cm x 18mm,
polyethylene
Fisher Scientific, Hanover Park, IL
BDTMInsulin Syringes, 1mL Fisher Scientific, Hanover Park, IL
BDTMPrecisionGlideTMSingle-use
Needles, 20 Gauge
Fisher Scientific, Hanover Park, IL
Additional Supplies
RNaseZap R© Life Technologies, Grand Island,
NY
Table 2.64: Materials – lysates for RNA extraction.
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Procedure
Cells were seeded to a density of 1.5-2 · 106 per 100mm dish depending on the
cell line used and grown under the described conditions (see 2.4.1). Lysates for
RNA extraction were prepared 2 days later when cells had reached a confluence
of approximately 50-60%, hence they were in the log phase when harvested.
The benchtop was first cleaned with 70% ethanol and subsequently with RNaseZap
to remove potential contaminants from the workspace. β-mercaptoethanol was
added to buffer RLT of the RNeasy Mini Kit with a concentration of 10µL/mL.
Phosphate-buffered saline (PBS) was prewarmed in the water bath, a bucket with
ice was prepared and put next to the sterile hood.
Cells were taken out of the incubator and put into the sterile hood. Media was
aspirated and cells were washed twice with 3mL PBS. After the last washing step,
PBS was completely aspirated and 600µL of buffer RLT (containing 10µL/mL
β-mercaptoethanol)were added to each dish to harvest the cells by direct lysis.
Cell dishes were immediately put on ice and taken to the work bench where they
were scraped off the dishes and transfered to a microcentrifuge tube. Finally,
cell lysates were homogenized passing the lysate through a syringe with needle 15
times. Following homogenization, lysates were either subjected to RNA purifica-
tion (see 2.3.24) or stored at −80 ◦C until further processed.
2.4.7 Lysates for Western Blot
Materials
See table 2.65 for the required materials. Unless otherwise specified the company
was located in the USA.
Procedure
Cells were seeded to a density of 2-3.5 · 106 per 100mm dish depending on the
cell line used and grown under the described conditions (see 2.4.1). Lysates for
Western Blot were prepared 2 days later when cells had reached a confluence of
approximately 50-80%, so they were harvested while in the log phase. RIPA buffer
was supplemented with phosphatase and protease inhibitor cocktails (1X final con-
120 CHAPTER 2. MATERIALS AND METHODS
Item – Description Company
Equipment
Centrifuge 5424R, refridgerated Eppendorf, Hamburg, Germany
M53 Basic Shaker, SN 03.348156 IKA R©, Wilmington, NC
Chemicals – Reagents – Commercial Solutions and -Kits
RIPA Buffer Boston BioProducts Inc., Ashland,
MA
Thermo ScientificTM HaltTM Phos-
phatase Inhibitor Cocktail, 100X
Fisher Scientific, Hanover Park, IL
Protease Inhibitor Cocktail Set I -
Calbiochem
EMD Millipore, Billerica, MA
Disposables
Biox BrandTMCell Scrapers
w/Pivoting Blade, sterile, indi-
vidually wrapped, 24cm x 18mm,
polyethylene
Fisher Scientific, Hanover Park, IL
Table 2.65: Materials – lysates for Western Blot.
centration).
Cells were taken out of the incubator, media was aspirated, and cells were washed
twice with ice cold PBS. PBS was thoroughly removed and dishes were put on
ice. Depending on the confluence of the cells 80-100µL of RIPA lysis buffer con-
taining protease and phosphatase inhibitors were added to each dish to cover the
cells (30µL of lysis buffer were used for lysates of transfected cells grown in 6-well
plates). Cells were scraped from the dish, transfered to a microcentrifuge tube
and vortexed. Lysates were incubated on ice for 30 minutes and vortexed every
5 minutes to enhance the lysis process. Following incubation, lysates were cen-
trifuged at 15000rpm for 20 minutes at 4 ◦C to clear them from cell debris. The
supernatant was transfered to a new microcentrifuge tube and frozen at −80 ◦C.
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2.4.8 Transfection and Creation of Stable Cell Lines
Materials
See table 2.66 for the required materials. Unless otherwise specified the company
was located in the USA.
Item – Description Company
Equipment
M53 Basic Shaker, SN 03.348156 IKA R©, Wilmington, NC
Chemicals – Reagents – Commercial Solutions and -Kits
Lipofectamine R© LTX Reagent
with PLUSTM Reagent
Life Technologies, Grand Island,
NY
Geneticin R©Selective Antibiotic
(G418 Sulfate) (50 mg/mL)
Life Technologies, Grand Island,
NY
Opti-MEM R© I Reduced Serum
Medium
Life Technologies, Grand Island,
NY
TE Buffer Life Technologies, Grand Island,
NY
Disposables
Falcon R© 6 Well Clear Flat Bottom
TC-Treated Multiwell Cell Cul-
ture Plate, with Lid, Individually
Wrapped, Sterile
Corning Inc., Corning, NY
Table 2.66: Materials – transfection and creation of stable cell lines.
Procedure
The term transfection describes a technique that enables the insertion of nucleic
acids into mammalian cells. Lipid based transfection uses cationic lipids as trans-
fection reagents. These positively charged liposomes can interact with the nega-
tively charged DNA as well as with the cell membrane and thus facilitate the entry
of the respective nucleic acid into the cell.
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DNA (amplified cDNA clones) purified by maxiprep (see 2.3.32) was required to
meet certain quality criteria in order to be used for transfection. DNA quality
and quantity were determined with a NanoDrop spectrophotometer (see 2.3.6 and
2.3.7) and by running an agarose gel (see 2.3.11). NanoDrop measurements with
a 260/280 ratio and a 260/230 ratio ≥ 1.8 and DNA concentrations ≥ 1µg/µL
were considered satisfactory. An example for satisfactory cDNA quality after the
plasmid purification process is given in figure 2.2. Dilutions of the plasmid DNA
with a final concentration of 1µg/µL were prepared using buffer TE, 8µg of each
plasmid DNA were used per transfection.
Cells were seeded for transfection in 6-well cell culture plates at a density of 2 ·105
cells per well. The following day (or 2 days later if confluence was not sufficient)
cells were washed twice with prewarmed PBS and starved using Opti-MEM media
without any supplements. Cells were starved for 16 to 24 hours before transfec-
tions were performed. Confluence at the time of transfection was 75-90%. 2 wells
were transfected per cDNA clone or empty vector, 1 for stable selection and 1 for
Western Blot to confirm transfection efficiency. The ratio of DNA/transfection
reagent used was 2µg DNA/3µL reagent. If cells failed to transfect the first time
(see figure2.3), transfection was repeated using PLUS reagent in addition to the
regular Lipofectamine LTX reagent. If PLUS reagent was additionally used, the
required ratio was 1µL PLUS reagent/1µg plasmid DNA. Opti-MEM media with-
out any supplements was used to prepare reagent and plasmid DNA.
For transfection of one well 2 sterile microcentrifuge tubes were preloaded with
100µL Opti-MEM each. 8µg plasmid DNA (and 8µL PLUS reagent, if applicable)
were added to one of the tubes, 12µL Lipofectamine LTX reagent were added to
the other tube pipetting the Lipofectamine directly into the liquid to avoid in-
teraction of the transfection reagent with the walls of the tube. To prepare the
transfection mix, the reagent mix was added to the DNA mix. The transfection
mix was subsequently vortexed and incubated for 15 minutes at room tempera-
ture. During incubation time the cells were prepared for transfection by replacing
the starving media with 800µL Opti-MEM media. Each transfection mix was
added to the respective well on the 6-well plate containing the cells. The cells
were put in the incubator for at least 4 hours or over night. Subsequently, trans-
fection media was replaced by complete growth media containing 10% FBS, 1%
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penicillin/streptomycin, and 2mM L-Glutamine.
If PLUS reagent was used, the setup differed slightly. The DNA/PLUS reagent
mix was mixed by pipetting and incubated for 10 minutes at room temperature.
The reagent mix was as well mixed by pipetting. To prepare the transfection
mix the DNA/PLUS reagent mix was added to the reagent mix and intermixed
by pipetting. The transfection mix was then incubated for 30 minutes at room
temperature before it was added to the cells.
Approximately 48 hours after transfection cells reach the expression maximum for
the transfected gene. Therefore, at that time point protein lysates were collected
for Western Blot to check transfection efficiency (see 2.4.7 and figure 2.3). If the
Western Blot results indicated a low transfection efficiency as for FGFR3 IIIb
SDM (see figure 2.3), transfection for the respective clone was repeated. 48 hours
after transfection the selection process to create a stable cell line was started. If
cells exhibited a very stressed appearance, only a media change was performed
and selection was started one or two days later.
Figure 2.3: Example for a Western Blot visualizing expression of the trans-
fected genes 48h after transfection.
Protein lysates were prepared and WB was run using antibodies for the transfected
gene (FGFR3) and β-actin as loading control. WB shows excellent transfection effi-
ciency/FGFR3 expression for the WT and SDM clones of FGFR3 ∆8-10. Transfection
efficiency/protein expression for FGFR3 IIIb WT is sufficient. FGFR3 IIIb SDM could
not be detected, which indicates low transfection efficiency/low expression for this clone.
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Geneticin (G418 Sulfate) was used as a selective antibiotic as the stable selec-
tion marker in the cDNA clones – Neomycin – confers resistance to Geneticin. The
mechanism of action of Geneticin is inhibition of protein synthesis by binding the
ribosome in prokaryotic and eukaryotic cells. The ideal Geneticin concentration
to be used for selection was determined in a pilot experiment with 1mg/mL. Thus
the selection media consisted of the respective growth media used for the cell line,
to which 10% FBS, 2mM L-glutamine, and 1mg/mL Geneticin was freshly added.
Cells were washed twice with prewarmed PBS to assert removal of residual antibi-
otics before the selection media containing Geneticin was added. One well with
non-transfected cells was included as a control for selection. Selection media was
exchanged every 2-3 days, cells were washed twice with PBS to remove dead cells
before fresh media was added. Selection was considered completed after all cells
of the control well had been eliminated by Geneticin, which was the case after
approximately 12-16 days. 3.5 weeks after transfection the Geneticin concentra-
tion was then lowered to 0.5mg/mL and cells were further amplified. A stock of
transfected cells (passage 3 after transfection) was frozen at −80 ◦C.
2.4.9 Viability Assay
Materials
See table 2.67 for the required materials. Unless otherwise specified the company
was located in the USA.
Procedure
In the presence of cells the non-fluorescent, blue compound resazurin is reduced to
resorufin, which is fluorescent and pink (see figure 2.4). The increase in fluorescence
can be taken as a direct measure for cell viability/proliferation. [90]
The resazurin assay was used to determine cell viability as a measure for cell
proliferation. Viability measurements using resazurin were taken over a time course
of 96 hours with readout time points every 24 hours (endpoint measurements in
different plates seeded at the same time). The ideal cell number per well and the
ideal incubation time with resazurin were determined in a pilot experiment.
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Item – Description Company
Equipment
Infinite M200 PRO Microplate
Reader
Tecan Group Ltd., Ma¨nnedorf,
Switzerland
Chemicals – Reagents – Commercial Solutions and -Kits
Resazurin sodium salt, powder,
BioReagent, suitable for cell cul-
ture
Sigma-Aldrich Corp., St. Louis,
MO
Disposables
Falcon R© 96 Well Clear Flat Bot-
tom TC-Treated Cell Culture
Plate, with Lid, Individually
Wrapped, Sterile
Corning Inc., Corning, NY
Table 2.67: Materials – viability assay.
Figure 2.4: Resazurin and Resorufin structures [90].
Figure shows resazurin and its reduced form resorufin as published by O’Brien et al. [90].
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A resazurin stock solution containing 0.015% resazurin was prepared by dissolving
7.5mg resazurin in 50mL water. The stock solution was stored at 4 ◦C protected
from light as exposure to UV light increases background fluorescence. Cells were
trypsinized and counted as described previously (2.4.2 and 2.4.3) and seeded for
the assay in a 96-well plate (1 plate for each readout time point) at a density
of 4000 cells in 150µL media per well using media supplemented with 2mM L-
glutamine and 10% FBS (no antibiotics). 5 replicates were seeded per clone. No
cell control wells to measure background fluorescence were included.
The resazurin stock solution was diluted 1:11 with media containing 10% FBS
and 2mM L-glutamine. Media was aspirated from the cells. 165µL of the freshly
prepared resazurin dilution were added to each well (including the no cell control
wells). Cells were incubated at 37 ◦C for 3.5 hours. Readout was done using a
plate reader with the settings described in table 2.68. Readout time points for
the proliferation assay were 0, 24, 48, 72, and 96 hours after seeding the cells.
Incubation of cells with resazurin for the 0 hour time point differed slightly from
the description above, since cells had not attached to the plate yet. Therefore, 15µL
of the undiluted resazurin stock solution were added to the freshly seeded 150µL
cell suspension in the plate and intermixed by pipetting carefully up and down
before incubating the plate at 37 ◦C for 3.5 hours. Data analysis was performed
as described in 2.6.3.1.
Viability Assay – Plate Reader Settings
Excitation Wavelength 530nm
Emission Wavelength 590nm
Mode Fluorescence Top Reading
Gain manual (60-70), the same for one series from 0-96h
Number of Flashes 25
Integration time 20µs
Lag Time 0
Settle Time 150ms
Z-Position Calculated from well E6
Table 2.68: Viability assay – plate reader settings.
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2.4.10 Wound Healing Assay/In Vitro Scratch Assay
Materials
See table 2.69 for the required materials. Unless otherwise specified the company
was located in the USA.
Item – Description Company
Equipment
IX71 R©inverted microscope (with
attached camera and computer)
Olympus America Inc., Lombard,
IL
Disposables
Falcon R© 24 Well Clear Flat Bot-
tom TC-Treated Cell Culture
Plate, with Lid, Individually
Wrapped, Sterile
Corning Inc., Corning, NY
Table 2.69: Materials – wound healing assay.
Procedure
The wound healing assay/in vitro scratch assay can generally be performed to
assess differences in cell migration. A wound is scratched into a cell monolayer.
Cells migrate from the confluent area to the wound area to close the wound and
images are taken to monitor and analyze this process and to quantify the migra-
tion rate. [33,74]
Cells were trypsinized (2.4.2), counted (2.4.3), and seeded for the assay in a 24-
well plate. Depending on the cell line a density of 0.5 · 105 to 4 · 105 cells per well
was seeded using media supplemented with 10% FBS and 2mM L-glutamine (no
antibiotics). 4 replicates were seeded for each stably transfected cell line clone.
Cells were incubated at 37 ◦C until they were 100% confluent (2-7 days).
The wound healing assay was started at full confluence. A cross was scratched
into the cell monolayer of each well using a p200 pipette tip. The lid of the culture
plate was used as a ruler to scratch one line vertically and one line horizontally
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crossing each other in the middle of the well. A new tip was used for each differ-
ently transfected cell line. Media was aspirated and cells were washed once with
prewarmed PBS before fresh media was added. Images of the scratched area with
the cross were taken immediately (0h) and after 4, 8, 14 and 27 hours of incuba-
tion at 37 ◦C. Images were acquired using 5X magnification and analyzed using
the T-Scratch software [33]. Data analysis was performed as described in 2.6.3.2.
2.4.11 Stimulation with FGF1
Materials
See table 2.70 for the required materials. Unless otherwise specified the company
was located in the USA.
Item – Description Company
Chemicals – Reagents – Commercial Solutions and -Kits
FGF 1 Human, Recombinant ProSpec, Ness-Ziona, Israel
Disposables
Thermo ScientificTM NuncTM50mL
Conical Sterile Polypropylene Cen-
trifuge Tube
Fisher Scientific, Hanover Park, IL
Table 2.70: Materials – stimulation with FGF1.
Procedure
FGF1 was reconstituted according to the instructions of the manufacturer to re-
ceive a stock solution of 100µg/mL and a work solution of 10µg/mL, both were
stored at −20 ◦C. Ideal starvation conditions to reduce basic signaling activity
were determined in a pilot experiment. Ideal FGF1 stimulation time to activate
signaling was as well determined in a pilot experiment. Cells were seeded accord-
ing to the instructions for WB lysates (see 2.4.7). Before collecting the lysates,
cells were starved and stimulated with FGF1.
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For this purpose, cells were washed twice with prewarmed PBS. Starvation media
– the respective growth media containing 1% FBS, 2mM L-glutamine, and no an-
tibiotics – was put on each dish and cells were incubated at 37 ◦C for 4 hours. For
stimulation of cells with FGF1 the FGF1 work solution was diluted 1:2000 in star-
vation media to yield a concentration of 5ng/mL, i.e. 25µL FGF1 work solution
were added to 50mL starvation media directly before use. Following starvation,
cells were stimulated with 5ng/mL FGF1 at 37 ◦C for 5 minutes. Subsequently,
stimulation media was aspirated, ice cold PBS was put on each dish to stop the
stimulation process, and dishes were put on ice. Lysates were prepared as de-
scribed in 2.4.7. Appropriate control dishes that were starved but not stimulated
were included.
2.5 Protein Biochemistry Methods
2.5.1 Determination of Protein Concentrations –
Bio-Rad Protein Assay (Bradford)
Materials
See table 2.71 for the required materials. Unless otherwise specified the company
was located in the USA.
Procedure
The Bio-Rad Protein Assay is based on the Bradford Assay. The Bradford Assay is
based on the binding of Coomassie Brilliant Blue G-250 to protein. Upon binding
of dye to protein, there is a shift in the absorption maximum of the dye from 365
to 595nm, which causes an increase in absorption at 595nm. This increase can be
measured and utilized to quantify the amount of protein in a sample. [11]
A pilot experiment was run to exclude interference from any component of the
RIPA lysis buffer or the protease or phosphatase inhibitors with the assay.
The assay concentrate was diluted 1:5 in distilled, deionized water. To measure
samples of unknown protein concentration, microcentrifuge tubes were preloaded
with 999µL of the diluted dye concentrate before 1µL of each sample was added.
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Item – Description Company
Equipment
Infinite M200 PRO Microplate
Reader
Tecan Group Ltd., Ma¨nnedorf,
Switzerland
M53 Basic Shaker, SN 03.348156 IKA R©, Wilmington, NC
Chemicals – Reagents – Commercial Solutions and -Kits
Bio-Rad Protein Assay Dye
Reagent Concentrate
Bio-Rad Laboratories Inc., Her-
cules, CA
Quick Start Bovine Serum Albu-
min Standard, 2mg/mL
Bio-Rad Laboratories Inc., Her-
cules, CA
Disposables
Corning R©96 Well Clear Flat Bot-
tom Polystyrene Not Treated Mi-
croplate, with Lid, Sterile
Corning Inc., Corning, NY
Thermo ScientificTM NuncTM50mL
Conical Sterile Polypropylene Cen-
trifuge Tube
Fisher Scientific, Hanover Park, IL
Table 2.71: Materials – Bio-Rad protein assay.
Different dilutions of the 2mg/mL BSA stock solution were prepared as a protein
standard by preloading microcentrifuge tubes with diluted dye and adding the
respective volume of BSA stock solution according to table 2.72 taking into account
the linear range of the assay for BSA (1.2-10µg/mL).
Diluted Assay Concentrate BSA Standard BSA Concentration
(1:5 in H2O) (2mg/mL) in Assay
1000µL 0µL 0µg/mL
999µL 1µL 2µg/mL
998µL 2µL 4µg/mL
997µL 3µL 6µg/mL
996µL 4µL 8µg/mL
995µL 5µL 10µg/mL
Table 2.72: Bio-Rad protein assay – pipetting scheme for protein standard.
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Samples were prepared and measured in duplicate and protein standards in
triplicate. Tubes were vortexed and incubated on the benchtop at room temper-
ature for 5 minutes. 200µL of each of the so prepared samples and standards
were pipetted into one well of a 96-well plate and absorbance was measured at
595nm. The absorbance values acquired for the standards were graphed to create
a standard curve, which was then used to determine the protein content of each
sample.
2.5.2 Sample Preparation for SDS-PAGE and Western Blot
Materials
See table 2.73 for the required materials. Unless otherwise specified the company
was located in the USA.
Item – Description Company
Equipment
Eppendorf Microcentrifuge 5415D Eppendorf, Hauppauge, NY
Dry Bath Incubator Fisher Scientific, Hanover Park, IL
M53 Basic Shaker, SN 03.348156 IKA R©, Wilmington, NC
Chemicals – Reagents – Commercial Solutions and -Kits
4X Protein Sample Loading Buffer LI-COR Biotech., Lincoln, NE
β-Mercaptoethanol MP Biomedicals, LLC, Solon, Ohio
Table 2.73: Materials – sample preparation for SDS-PAGE and WB.
Procedure
Following protein determination, the samples were prepared for SDS-PAGE. 4X
sample buffer was premixed with β-mercaptoethanol according to the instructions
of the manufacturer. In a microcentrifuge tube protein lysates were mixed with
water and 4X sample buffer to yield a concentration of 1X sample buffer as well
as 40µg protein/30µL volume (or 30µg protein/30µL volume), which corresponds
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to the amount of protein and to the volume that was loaded on each lane of the
SDS-PAGE gel. Samples were vortexed and subsequently boiled at 95 ◦C for 5
minutes to denature the protein. Samples were either centrifuged at 13000rpm
for 2 minutes at room temperature and directly loaded on the SDS-PAGE gel or
frozen at −20 ◦C.
2.5.3 SDS-PAGE
Materials
See table 2.74 for the required materials. Unless otherwise specified the company
was located in the USA.
Procedure
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) is used to
separate proteins according to their molecular weight. Protein lysates are mixed
with sample buffer containing β-mercaptoethanol, which reduces disulfide linkages,
as well as SDS, which is an anionic detergent that denatures and linearizes pro-
teins, a process supported by heat through near boiling of the samples. Net charge
of the proteins is concealed by SDS that applies a negative charge to proteins pro-
portional to their mass. After loading the protein samples on a polyacrylamide gel,
an electric current is applied and proteins start migrating into the polyacrylamide
gel. Velocity depends on protein size and pore size, smaller proteins migrate faster
than larger proteins, which allows separation along the gel matrix.
A solution containing 10% ammonium persulfate (APS) in water (w/v) was pre-
pared and stored at 4 ◦C. 1mm gels (10% polyacrylamide) were cast using the Next
Gel system by Amresco that enables separation ranging between 3.5 and 212kDa.
The respective amount of Next Gel solution was mixed with APS and TEMED
according to table 2.75 to initiate/catalyze polymerization.
After 30 minutes of polymerization time, gels were either wrapped in moist
paper towels and a plastic bag and stored at 4 ◦C over night or used immediately
for electrophoresis. Electrophoresis buffer was supplied together with the Next
Gel as a 20X solution. Before use a 1X solution was prepared by mixing 50mL
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Item – Description Company
Equipment
Mini-PROTEAN Tetra Cell Cast-
ing Stand with Clamp Kit for Sin-
gle Core System
Bio-Rad Laboratories Inc., Her-
cules, CA
Spacer Plates With 1.0mm Inte-
grated Spacers
Bio-Rad Laboratories Inc., Her-
cules, CA
Short Plates Bio-Rad Laboratories Inc., Her-
cules, CA
Mini-PROTEAN Comb Bio-Rad Laboratories Inc., Her-
cules, CA
Mini-PROTEAN R© Tetra Cell Bio-Rad Laboratories Inc., Her-
cules, CA
PowerPacTMHC High-Current
Power Supply
Bio-Rad Laboratories Inc., Her-
cules, CA
Eppendorf Microcentrifuge 5415D Eppendorf, Hauppauge, NY
M53 Basic Shaker, SN 03.348156 IKA R©, Wilmington, NC
Chemicals – Reagents – Commercial Solutions and -Kits
NEXT GEL R© 10% Solution AMRESCO LLC, Solon, OH
Ammonium Persulfate Fisher Scientific, Hanover Park, IL
N,N,N’,N’-Tetramethylethylene-
diamine 99%, ACROS OrganicsTM
Fisher Scientific, Hanover Park, IL
Thermo ScientificTM PageRulerTM Fisher Scientific, Hanover Park, IL
Prestained 10-170kDa Protein
Ladder
Disposables
Thermo ScientificTM NuncTM50mL
Conical Sterile Polypropylene Cen-
trifuge Tube
Fisher Scientific, Hanover Park, IL
Prot/ElecTM Tips, 1-200µL pipette
tip for gel loading
Bio-Rad Laboratories Inc., Her-
cules, CA
Table 2.74: Materials – SDS-PAGE.
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Reagent Volume/1mm Gel
Next Gel R© 10% solution 7.5mL
APS 45µL
TEMED 4.5µL
Table 2.75: SDS-PAGE – gel preparation.
of running buffer with 950mL water. Samples prepared according to 2.5.2 were
thawed, vortexed, and centrifuged at 13000rpm for 2 minutes at room temperature.
Protein ladder was thawed, briefly mixed by flicking the tube, and spun down.
The comb was removed from the gel and the wells were rinsed with electrophoresis
buffer using a syringe with needle before 5µL protein ladder and 30µL sample
corresponding to 30-40µg protein (an equal amount of protein was loaded for
samples that had to be compared later) were loaded on the gel. Gels were run at
120 Volt for approximately 110-115 minutes.
2.5.4 Western Blot
Materials
See table 2.76 for the required materials and table 2.77 for the primary and sec-
ondary antibodies used. Unless otherwise specified the company was located in
the USA.
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Item – Description Company
Equipment
GENIE R© Electrophoretic Trans-
fer, Premium GENIE BLOTTER
Idea Scientific Company, Min-
neapolis, MN
PowerPacTMHC High-Current
Power Supply
Bio-Rad Laboratories Inc., Her-
cules, CA
GeneMate Rocker, Variable Speed BioExpress, Kaysville, UT
Western Blot Incubation Boxes LI-COR Biotech., Lincoln, NE
Pipet Boy No. D157316 Drummond Scientific Co.,
Broomall, PA
Chemicals – Reagents – Commercial Solutions and -Kits
10X Tris/Glycine Buffer Bio-Rad Laboratories Inc., Her-
cules, CA
Methanol, HPLC Grade, Fisher
Chemical
Fisher Scientific, Hanover Park, IL
Odyssey Blocking Buffer LI-COR Biotech., Lincoln, NE
CorningTM cellgroTM PBS 10X,
Without Calcium and Magnesium
Fisher Scientific, Hanover Park, IL
TweenTM20, Fisher BioReagentsTM Fisher Scientific, Hanover Park, IL
Disposables
Brewrite R© 12 Cup Coffee Filters Staples, Inc., Beloit, WI
Nitrocellulose Membrane, 0.45µm,
30cm x 3.5m
Bio-Rad Laboratories Inc., Her-
cules, CA
Thermo ScientificTM NuncTM50mL
Conical Sterile Polypropylene Cen-
trifuge Tube
Fisher Scientific, Hanover Park, IL
EMD Millipore MillexTM Sterile
Syringe Filters, PES, Modified
acrylic housing, Pore size 0.22µm,
Dia. 33mm
Fisher Scientific, Hanover Park, IL
BDTM Luer-LokTM Disposable Sy-
ringe, 10mL
Fisher Scientific, Hanover Park, IL
Table 2.76: Materials – Western Blot.
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Item – Description Company
Primary Antibodies
Phospho-FGF Receptor
(Tyr653/654) (55H2) Mouse mAb
Cell Signaling Technology Inc.
FGF Receptor 3 (C51F2) Rabbit
mAb
Cell Signaling Technology Inc.
Phospho-Akt (Ser473) (D9E)
XP R© Rabbit mAb
Cell Signaling Technology Inc.
Akt (pan) (40D4) Mouse mAb Cell Signaling Technology Inc.
Phospho-PLCγ1 (Tyr783) Cell Signaling Technology Inc.
PLCγ1 (D9H10) XP R© Rabbit
mAb
Cell Signaling Technology Inc.
Phospho-Stat1 (Tyr701) (D4A7)
Rabbit mAb
Cell Signaling Technology Inc.
Stat1 (9H2) Mouse mAb Cell Signaling Technology Inc.
Phospho-p44/42 MAPK (Erk1/2)
(Thr202/Tyr204) (D13.14.4E)
XP R© Rabbit mAb
Cell Signaling Technology Inc.
p44/42 MAPK (Erk1/2) (L34F12)
Mouse mAb
Cell Signaling Technology Inc.
Phospho-FRS2-α (Tyr436) Cell Signaling Technology Inc.
FRS2 Antibody (H-91), sc-8318 Santa Cruz Biotechnology Inc.
Phospho-Stat3 (Tyr705) (D3A7)
XP R© Rabbit mAb
Cell Signaling Technology Inc.
Stat3 (124H6) Mouse mAb Cell Signaling Technology Inc.
β-Actin (8H10D10) Mouse mAb Cell Signaling Technology Inc.
Secondary Antibodies
IRDye R© 680LT Donkey anti-
Mouse IgG (H+L), 0.5 mg
LI-COR Biotech., Lincoln, NE
IRDye R© 800CW Goat anti-Rabbit
IgG (H+L), 0.5 mg
LI-COR Biotech., Lincoln, NE
Table 2.77: Materials – Western Blot – Antibodies.
All primary antibodies, except for FRS2, were purchased from Cell Signaling Technol-
ogy Inc., Danvers, MA. FRS2 was purchased from Santa Cruz Biotechnology Inc.,Dallas,
TX.
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Procedure
Following SDS-PAGE, a Wet Western Blot (WB) was performed to visualize spe-
cific proteins. During the blotting process proteins are transferred from gel to
membrane by applying an electric current directed vertically to gel and mem-
brane. The immobilized proteins can subsequently be detected by immunodetec-
tion. After blocking unspecific binding spots, the membrane is first incubated with
a primary antibody binding to the specific protein to detect. Secondly, a secondary
antibody directed against the species of the primary antibody and labeled with
an infrared fluorescent dye enables visualization of the respective protein through
near-infrared fluorescence imaging. Antibody specificity and the ideal dilutions in
Odyssey blocking buffer were tested in pilot experiments and are listed in table
2.78.
Nitrocellulose membrane and filters were cut to the appropriate size. 1X trans-
fer buffer was prepared by mixing 100mL 10X buffer with 200mL methanol and
700mL water. PBS 10X was diluted to PBS 1X with water and PBST was pre-
pared by dissolving 0.1% Tween 20 in PBS 1X. After finishing SDS-PAGE, the
gel was taken out of the electrophoresis chamber and the area containing the wells
was cut and discarded. The membrane was briefly pre-wetted in transfer buffer
and the Western Blot was assembled according to figure 2.5.
The tray containing the blot assembly was filled with sufficient transfer buffer,
slid into a plastic cover, and brought into upright position. WB was run at 18 Volt
for 3 hours (4 blots) or at 12 Volt for 1 hour (1 blot). Following protein transfer,
membranes were incubated in blocking buffer for 1 hour at ambient temperature
on a rocker. Blocking buffer was removed, filtered, and stored at 4 ◦C for future
usage. Using the protein ladder as guidance membranes were cut into up to 3
pieces to allow simultaneous detection of multiple proteins. Membrane pieces were
incubated with different primary antibody dilutions over night at 4 ◦C on a rocker.
Antibody solutions were removed, filtered, and stored at 4 ◦C. Membrane pieces
were washed with PBST 5 times for 5 minutes each time at room temperature on a
rocker. The respective secondary antibody solution was added to the membranes,
which were incubated for 1 hour at room temperature on a rocker. Another wash-
ing procedure was performed as described above before membranes were imaged
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Specificity MW (kDa) Isotype/Source Dilution
Phospho-FGF Receptor 120, 145 Mouse IgG2b 1:500
(Tyr653/654)
FGF Receptor 3 165, 145, 125 Rabbit IgG 1:1000
Phospho-Akt (Ser473) 60 Rabbit IgG 1:2000
Akt (pan) 60 Mouse IgG1 1:1000
Phospho-PLCγ1 (Tyr783) 155 Rabbit (P) 1:500
PLCγ1 150 Rabbit IgG 1:1000
Phospho-Stat1 (Tyr701) 84, 91 Rabbit IgG 1:1000
Stat1 84, 91 Mouse IgG1 1:1000
Phospho-p44/42 MAPK (Erk1/2) 44, 42 Rabbit IgG 1:2000
(Thr202/Tyr204)
p44/42 MAPK (Erk1/2) 42, 44 Mouse IgG1 1:2000
Phospho-FRS2-α (Tyr436) 80 to 85 Rabbit (P) 1:500
FRS2 60-90 Rabbit (P) 1:200
Phospho-Stat3 (Tyr705) 79, 86 Rabbit IgG 1:2000
Stat3 79, 86 Mouse IgG2a 1:1000
β-Actin 45 Mouse IgG2b 1:1000
anti-Mouse IgG (H+L) — Donkey 1:20000
anti-Rabbit IgG (H+L) — Goat 1:20000
Table 2.78: Western Blot – antibody dilutions.
Primary and secondary antibodies were diluted in Odyssey blocking buffer to be used
for detection of proteins on a nitrocellulose membrane. MW = molecular weight, P =
polyclonal antibody.
on the Odyssey R© Classic Infrared Imaging System and analyzed using the Image
Studio software.
Following detection, membranes were briefly rinsed with PBST and incubated with
a second primary antibody without prior membrane stripping – for instance detec-
tion of phosphorylated proteins preceded detection of total proteins using primary
antibodies derived from different species. Alternatively membranes were stripped
as described in 2.5.5 before being incubated with another primary antibody.
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Figure 2.5: Schematic example for a Western Blot set-up.
2.5.5 Membrane Stripping
Materials
See table 2.79 for the required materials. Unless otherwise specified the company
was located in the USA.
Item – Description Company
Equipment
GeneMate Rocker, Variable Speed BioExpress, Kaysville, UT
Western Blot Incubation Boxes LI-COR Biotech., Lincoln, NE
Chemicals – Reagents – Commercial Solutions and -Kits
Restore Plus Western Blot Strip-
ping Buffer
Thermo Fisher Scientific Inc.,
Waltham, MA
Table 2.79: Materials – membrane stripping.
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Procedure
Different proteins with an equal or similar molecular weight can be detected on the
same membrane either if primary antibodies derived from different species and thus
secondary antibodies labeled with different dyes are used with the Odyssey R© Sys-
tem or if the antigen-antibody interaction is released through stripping of the
membrane.
After detection, membranes were briefly rinsed in PBST. PBST was removed and
membranes were incubated in 5mL stripping buffer for 15 minutes at room tem-
perature on a rocker. Stripping buffer was removed and membranes were washed
4-5 times for 5 minutes each time in PBST at room temperature on a rocker.
The stripped membranes were imaged on the Odyssey R© Classic Infrared Imaging
System to ensure complete removal of antibody from the membrane. PBST was
discarded and membranes were incubated in Odyssey blocking buffer for 30-40
minutes at room temperature on a rocker. Reprobing with primary and secondary
antibodies as well as detection were performed as described in 2.5.4.
2.6 Data Analysis
2.6.1 Taxonomy
Data analysis of the expression microarray results as well as the Nanostring CNV
assay results was performed by Dr. Zhixiang Zuo as described in Keck et al. [61].
Consensus Clustering and integrative bioinformatics analysis were as well per-
formed by Dr. Zuo [61].
2.6.2 Genomic Analysis
Data analysis and integrative bioinformatics analysis as described in Seiwert et
al. [110] was performed by Dr. Zhixiang Zuo (partly in collaboration with Dr.
Peter Hammerman, Broad Institute).
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2.6.3 Functional Validation
2.6.3.1 Viability Assay
Data analysis was performed using Microsoft Excel. Data were corrected for back-
ground fluorescence by subtracting the mean value of the no cell control wells (6
replicates per microplate) from each assay well. Readings from the 24, 48, 72, and
96 hours time points were normalized to the readings of each corresponding well
of the 0h time point to receive the percentage of viable cells per well for each time
point (0h values were set 100%). Subsequently, these data were used to calculate
the mean percentage of viable cells per time point (mean of five replicates assayed
for each clone), which was then (including the corresponding standard deviations)
plotted versus time (hours in culture).
Statistical analysis was performed to detect significant differences regarding the
proliferation rate of the different clones assayed for each of the two cell lines. Anal-
ysis was done with Microsoft Excel using the Real Statistics Resource Pack add-in
(release 3.1.2.). Using the background corrected and normalized data of the 96
hour time point readings of each experiment the Shapiro-Wilk-Test (α = 0.05) and
the Levene’s-Test (using the medians, α = 0.05) were performed to test for nor-
mality of sample distribution and homogeneity of variances respectively to assert
the requirements for analysis of variance (ANOVA) were satisfied. Subsequently,
one-way/single factor ANOVA as well as ANOVA post-hoc tests – Tukey’s HSD
(Honestly Significant Difference) – were performed (α = 0.05).
In both cell lines in one out of 15 cases (5 groups/clones per experiment, n=3) a
normal distribution of samples could not be confirmed by the Shapiro-Wilk-Test.
Therefore, the non-parametric Kruskal-Wallis-Test (α = 0.05) was additionally
performed on the data of every experiment to confirm the results obtained by
ANOVA.
2.6.3.2 Wound Healing Assay/In Vitro Scratch Assay
Images were acquired repeatedly from the same spot (scratched cross) of each as-
sayed well of a microplate at different time points – 0h, 4h, 8h, 14h, and 27h –
using 5X magnification. The T-Scratch analysis software [33] was used to quantify
the open image area (area of the image not covered by cells) for each time point.
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Using the same software the 4, 8, 14, and 27 hour readings of the open image area
were normalized to the 0h readings of the open image area of each well (0h reading
for open image area was set to correspond to 100% open wound area) to receive
the open wound area in % for each time point. The mean open wound area per
time point (mean of four replicates assayed for each clone) and the corresponding
standard deviations were as well calculated. Subsequently, all data were imported
to Microsoft Excel for further analysis and the mean open wound area was plotted
(including the corresponding standard deviations) for each clone and time point.
Statistical analysis was performed to detect significant differences with respect to
the migration rate of the different clones assayed for each of the two cell lines.
Analysis was done with Microsoft Excel using the Real Statistics Resource Pack
add-in (release 3.1.2.). The normalized data of the 14h time point readings were
found to be most adequate for statistical analysis as image acquisition could be
performed more accurately than for the 27h time points. Normalized data of the
14h time points were therefore subjected to the Shapiro-Wilk-Test (α = 0.05)
and the Levene’s-Test (using the medians, α = 0.05) to test if normality of sam-
ple distribution and homogeneity of variances assumption were fulfilled. One-
way/single factor ANOVA, Kruskal-Wallis-Test (α = 0.05), and ANOVA post-hoc
tests – Tukey’s HSD (Honestly Significant Difference) – were performed (α = 0.05).
The non-parametric Kruskal-Wallis-Test was included in addition to ANOVA since
both normal sample distribution and homogeneity of variances assumption were
slightly violated.
Chapter 3
Results
3.1 Taxonomy
The aim of this part of the study was to identify HNSCC subtypes based on
gene expression and to furthermore characterize these subtypes on the molecular
level by their differential expression profile, underlying biology and prognosis. The
results and figures presented in this section were discussed and published in Keck
et al. [61], bioinformatics and data analysis was performed by Dr. Zhixiang Zuo.
3.1.1 Patient Selection
134 HNSCC patients with locoregionally advanced disease that were treated with
concurrent chemoradiotherapy were included in the investigation making this co-
hort highly homogeneous and thus suitable to study differences in gene expression
that are attributable to the underlying biology of the tumor and not to differences
in tumor stage or treatment. The strength of this patient cohort is furthermore the
complete clinical annotation and the inclusion of a sufficient number of oropharyn-
geal tumors to assert a high number of HPV-positive tumors. Tumor samples had
been derived from surgeries or biopsies before patients underwent treatment. Ta-
ble 3.1 summarizes the patient characteristics of the examined cohort as published
in Keck et al. [61].
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Figure 3.1: Patient and sample overview.
Patient characteristics and clinical data of the investigated cohort as published in Keck
et al. [61]. Patients/samples are sorted according to their group allocation.
3.1.2 Sample Selection
171 treatment-na¨ıve samples were dissected. RNA, DNA, and protein were pu-
rified, quantified, and RNA was subjected to quality control. Stringent criteria
assured that only RNA of sufficient quality (RIN≥7.5, 260/280≥1.8, 260/230≥1.8
for most samples) was used to assure validity of the obtained microarray data. As
a consequence, 37 samples were excluded from further analysis. The remaining
134 samples were subjected to HPV PCR, labeling and expression microarrays,
and 99 of them (101 on total) to the Nanostring copy number assay (see 2.1 for
sample selection criteria and sample processing workflow).
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3.1.3 Determination of HPV Status
HPV PCR was performed at least two times per sample to accurately determine
HPV status. HPV status was confirmed by qPCR (Fluidigm microfluidics, per-
formed by Genentech) targeting HPV oncogenes E6 and E7 of high risk HPV16
and E7 and L1 of high risk HPV18. 44% of the samples, i.e. 59 out of 134, were
detected to be HPV positive, whereas most cases (n=55) were positive for high
risk HPV16, two for HPV18, one for HPV45 and one for HPV35.
3.1.4 Discovery of Three HNSCC Supergroups
The HNSCC cohort with 134 patients was assayed using the Agilent Human Gene
Expression 4x44K v2 Microarray Kit targeting 27,958 Entrez Gene RNAs. Con-
sensusClustering (performed by Dr. Zhixiang Zuo) was done using microarray gene
expression data from the here described Agilent cohort (n=134) together with dif-
ferent published (n=106, Affymetrix HG133 arrays, [18] [94]) and unpublished
(n=131, Illumina BeadArrays, Yordy et al. under review) cohorts as discovery
dataset (n=371) to discover HNSCC subtypes based on gene expression. Since
the discovery dataset includes data from three different platforms, it allows for
a robust classification of HNSCC samples using the described methodology [61].
The derived cross-platform gene signature consisting of 821 reliable and informa-
tive genes was used to perform ConsensusClustering separately in each dataset
resulting in five subtypes respectively. The five subtypes are slightly different in
each dataset, but based on hierarchical clustering of their centroids they cluster
together in three supergroups that are stable across platforms (see figure 3.2A).
These 15 centroids (three datasets with five subtypes each) fit their respective clus-
ter well and thus show a positive silhouette width (average=0.47) in the silhouette
plot (see figure 3.2B). The three supergroups were named inflamed/mesenchymal
(IMS), basal (BA), and classical (CL) according to their molecular profile and con-
sidering the therewith associated nomenclature in other cancers such as lung SCC,
breast cancer, or glioblastoma multiforme (GBM) [120, 136, 141]. Comparison of
the three supergroups with previously published subtypes of HNSCC [17] and lung
SCC [141] by principal component analysis (PCA) shows a high correlation and
thereby confirms the three supergroups (see figure 3.2C). Figure 3.2 shows discov-
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ery and validation of the three supergroups and the underlying 821 predictive gene
signature.
Figure 3.2: Discovery and validation of HNSCC expression subtypes.
Identification and validation of HNSCC expression subtypes as published in Keck et
al. [61]. Centroids were derived for each of the five subtypes of the three discovery
datasets. A Hierarchical clustering of the 15 subtype centroids from the last iteration
of ConsensusClustering. Heatmap shows the Pearson correlation of the centroids, which
cluster together in three supergroups – inflamed/mesenchymal (IMS), classical (CL),
basal (BA). B Silhouette Plot for three supergroups. All 15 subtype centroids have
a positive silhouette width. C Principal component analysis (PCA). PCA indicates
correlation of the three supergroups with subtypes discovered in lung SCC [141] and
HNSCC [17]. D/E Heatmaps show the 821 predictive gene signature from the last
iteration of ConsensusClustering in D the discovery datasets. Samples are sorted ac-
cording to their group prediction and genes are clustered using the discovery datasets
E the validation datasets. Gene order from the training dataset is maintained. Nearest
centroid algorithm was used to assign samples from the validation dataset to one of the
three supergroups.
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3.1.5 Validation of the Discovered HNSCC Supergroups
To assess the reproducibility of the three supergroups, the 821 gene signature was
applied to a validation dataset (n=567) consisting of samples derived from four
different cohorts and two different platforms – Affymetrix n=143 [101, 119, 146]
and RNA-Seq from TCGA n=424. Samples from the validation dataset were
assigned to one of the three newly discovered gene expression supergroups using the
nearest centroid approach. Figure 3.2D shows the strong validation and platform
independence of the supergroups indicated by the 821 gene signature shown in the
heatmaps.
3.1.6 Subclassification into Five HNSCC Subtypes
Subclassification into five different HNSCC subtypes was performed by further
subdividing the three supergroups based on HPV status of the samples (see figure
3.3A). HPV-positive samples were only contained in the CL and IMS supergroups,
but not in the BA supergroup, resulting in two distinct HPV-positive HNSCC sub-
types and three HPV-negative HNSCC subtypes in all the investigated datasets.
This finding makes it evident that HPV-positive tumors are not only one separate
subtype of HNSCC, but represent two different subtypes that fall into two different
supergroups based on their differential gene expression (see figure 3.3). The five
different subtypes were named IMS-HPV, CL-HPV, IMS-nonHPV, CL-nonHPV,
and basal.
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Figure 3.3: Supergroups and subtypes.
Classification of HNSCC into five subtypes as published in Keck et al. [61]. A Partition
of the three supergroups into five subtypes using HPV status of the samples. Across all
cohorts the CL and IMS supergroups can be split into CL-HPV/CL-nonHPV and IMS-
HPV/IMS-nonHPV subtypes respectively. The BA supergroup only contains HPV-
negative samples. B Heatmaps display differential gene expression of the five HNSCC
subtypes. HNSCC-relevant genes/pathways were selected through Ingenuity Pathway
Analysis (IPA). Supergroup/subtype, HPV status and smoking history are indicated.
C Heatmaps show the correlation of the five subtypes with different gene expression
signatures derived for each sample through single sample gene set enrichment analy-
sis (ssGSEA). The displayed pathways are significantly associated with subtypes and
heatmaps illustrate pathway activities.
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3.1.7 Characterization of HNSCC Subtypes
Analysis of gene expression data derived from the 134 samples that had been
subjected to Agilent 4X44Kv2 expression arrays was used to examine the molecular
characteristics of the five newly discovered HNSCC subtypes. TCGA data was
used to confirm the analysis. Results are displayed in figure 3.3B and C.
3.1.7.1 Basal Subtype - BA
All samples clustering together in the BA subtype are exclusively HPV-negative
(see figure 3.3A,B). The basal subtype is characterized by strong overexpression of
hypoxia related genes such as for instance HIF1α, CA9, and VEGF, and the hy-
poxia signaling pathway is significantly associated with the basal subtype shown
through the nearly perfect correlation with a hypoxia gene signature [143] (see
figure 3.2D,E and figure 3.3B,C). Furthermore, overexpression of growth factor
signaling genes shown through overexpression of EGFR and its ligands amphireg-
ulin (AREG) and neuregulin 1/heregulin (NRG1) is another prominent feature of
this subtype (see figure 3.2D,E and figure 3.3B). Overexpression of genes charac-
teristic for the epithelial lineage – cytokeratins (KRT1, KRT9, KRT16, KRT17)
and P-cadherin (CDH3) – is detected in the gene expression profile and confirmed
by comparison with a published EMT gene signature [125] (see figure 3.3B and
C). Cell adhesion related genes are characteristic of the basal subtype as well (see
figure 3.3B).
3.1.7.2 Classical Subtypes - CL-HPV and CL-nonHPV
The most prominent feature of the CL supergroup is overexpression of genes in-
volved in the putrescine/polyamine degradation pathway (see figure 3.2D). Fur-
thermore, the CL supergroup exhibits a strong proliferative phenotype, which is
characteristic for both the CL-HPV and the CL-nonHPV subtype as shown by
comparison with a published gene signature [140] (see figure 3.3C). While the two
CL subtypes of the CL supergroup show significant overlap regarding their upreg-
ulated pathways, they can still be differentiated by their gene expression profile.
The CL-HPV subtype shows enrichment for cell cycle related genes – MCM2,
MCM10, CDC7, CDKN2A, E2F2, and RPA2 – whereas the CL-nonHPV subtype,
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which contains a high percentage (74%) of heavy smokers, is characterized by
overexpression of genes related to xenobiotic metabolism pathways – AKR1C1,
AKR1C3, ALDH3A1 – known to be associated with smoking [59, 122] (see figure
3.3B).
3.1.7.3 Inflamed/Mesenchymal Subtypes – IMS-HPV and IMS-nonHPV
The IMS supergroup shows similar pathway activities as the CL supergroup re-
garding the upregulation of cell cycle related genes in the HPV-associated subtype
(IMS-HPV) and the upregulation of genes related to xenobiotic metabolism in
the HPV-negative subtype (IMS-nonHPV) (see figure 3.3B). Another set of genes
(VIM, MMP9, S100A4) that confers to a mesenchymal phenotype is upregulated
in the IMS supergroup and, consistent with this finding, epithelial markers are
downregulated suggesting epithelial-to-mesenchymal transition (EMT) [125] (see
figure 3.3B,C). Comparison of the expression profile with a published EMT gene
expression signature [125] shows that upregulation of mesenchymal genes seems to
be more relevant in the IMS-nonHPV subtype, while the IMS-HPV subtype has a
higher proliferation rate (see figure 3.3C). However, the unique feature of the IMS
supergroup as compared to the other groups is that genes, which are involved in
the regulation of immune response – antigen-presentation pathway and T-helper
cell differentiation (CD8A, ICOS, LAG3, HLA-DRA) – are upregulated in both
subtypes of the IMS supergroup (see figure 3.2D,E and figure 3.3B).
3.1.8 CD8 mRNA Expression Differs Between HNSCC Sub-
types
CD8 mRNA expression was analyzed (by Dr. Zuo) in the Agilent, RNAseq (TCGA)
and Illumnia (Yordy et al. under review) cohorts. CD8 mRNA expression is signif-
icantly higher in the IMS supergroup than in the other supergroups across all three
datasets and that is true for the HPV-associated as well as the HPV-negative IMS
subtype (see figure 3.4A). Differences in CD8 mRNA expression levels are indepen-
dent of the anatomic location and detected between the different subtypes when
analyzing exclusively oropharyngeal tumors in the Agilent and TCGA datasets.
Differences in CD8 mRNA expression levels are independent of HPV status – CD8
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mRNA levels are higher for tumors of the IMS supergroup when comparing expres-
sion within the HPV subtypes (CL-HPV vs. IMS-HPV) and within the nonHPV
subtypes (BA+CL-nonHPV vs. IMS-nonHPV) (see figure 3.4B).
Figure 3.4: CD8 mRNA Expression and HNSCC subtypes.
Shown is CD8 mRNA expression in the five HNSCC subtypes. Figure was modified
after Keck et al. [61]. A Boxplots show CD8 mRNA expression in the five subtypes
across three different cohorts (Agilent, RNA-seq, Illumina). CD8 mRNA expression is
higher in the IMS subtypes independent of HPV status. B Boxplots show CD8 mRNA
expression in HPV-positive and HPV-negative oropharyngeal tumors of the Agilent and
RNA-seq cohorts. CD8 mRNA levels are higher in the IMS subtypes than in the other
subtypes.
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3.1.9 Patient Characteristics and Survival
Survival rates were investigated in three of the cohorts (analysis was done by Dr.
Zuo), namely the Agilent dataset (newly created and described here), RNAseq data
from TCGA and the Illumina dataset (Illumina BeadArrays, Yordy et al. under
review). Figure 3.5A shows five-year survival rates for the three datasets. Five-year
survival rates show the same trend in all three datasets. HPV-positive HNSCC
shows better outcome compared to HPV-negative HNSCC, whereas there is a
difference in survival rate between the two HPV-positive subtypes with the IMS-
HPV subtype showing higher five-year survival than the CL-HPV subtype. The
CL-nonHPV subtype shows the worst survival rates. Five-year survival rates for
the BA and the IMS-nonHPV subtypes lie between the CL-nonHPV and the CL-
HPV subtype. As shown in figure 3.5B, overall survival (OS) for the five subtypes
was further analyzed by applying Kaplan-Meier estimator to these three datasets
as well as a combined dataset consisting of data derived from all three cohorts.
Subsequently, Kaplan-Meier curve difference was assessed using the log-rank test.
Comparing the p-values derived from the log-rank tests a significant difference in
survival between the five subtypes is calculated for two of the three datasets –
Agilent (P = 0.036) and TCGA (P = 0.003) – as well as for the combined dataset
(P = 8 · 10−6). Kaplan-Meier analysis of the combined dataset comprising 588
samples shows the clearest result with the lowest p-value (P = 8 · 10−6) of all four
analysis indicating that there is a significant difference in survival between the five
subtypes. As seen before for the five-year survival rates the IMS-HPV subtype
shows the best survival rate followed by the second HPV-associated subtype, CL-
HPV. The IMS-nonHPV subtype comes third and shows the best survival rate of
all HPV-negative groups. Fourth is the basal subtype, and worst survival rates
are calculated for the CL-nonHPV subtype.
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Figure 3.5: Survival analysis.
Survival analysis as published in Keck et al. [61]. A 5-year survival rate is shown for all
five subtypes in the Agilent (n=129), RNA-seq (TCGA) (n=350), and Illumina (n=99)
cohorts. B Overall survival (OS) is analyzed for all five subtypes in the Agilent, RNA-
seq (TCGA), and Illumina cohorts and in a dataset combining the three cohorts using
KaplanMeier estimator. Significance of differences in survival between the five subtypes
is indicated by p-values derived from log-rank tests.
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3.1.10 Distinct Copy Number Alterations per Subtype
The Nanostring copy number (CN) assay was run on 101 samples (99 samples of
the Agilent cohort und two additional samples) to detect copy number aberrations
using the nCounter Cancer CN Kit (n=46) as well as a custom designed assay
(n=55). Probes of the nCounter Cancer CN Kit covered 86 genes, probes of
the custom designed assay covered 147 genes with an overlap with the nCounter
Cancer CN Kit of 75 genes. Copy number discovery analysis was performed on all
samples (n=101) and the 75 overlapping genes. Copy number validation analysis
was performed on 55 samples and the 72 additional genes (in previously identified
aberrant regions) covered by the custom designed assay. Analysis was done by Dr.
Zuo using methodology described in Keck et al. [61].
Figure 3.6 shows copy number analysis in all five subtypes. Significant CN gains
(in 12 genes) and losses (in 16 genes) were detected. These include gains and
losses in well-known oncogenes and tumor suppressor genes respectively, namely
PIK3CA (3q26.3), VEGFA (6p12), EGFR (7p12), MYC (8q24.21), and CCND1
(11q13), which are amplified, as well as CDKN2A (9p21) and RB1 (13q14.2), which
are deleted. TP63 (3q28), SOX2 (3q26.3-q27), and PIK3CA(3q26.3), which are
located in the same genomic region, are coamplified in many of the tumors. Both
CN gains and losses differ between the five subtypes. Amplifications of EGFR
(7p12), CCND1 (11q13), and FADD (11q13.3) mainly occur in the HPV-negative
subtypes. The same is true for deletions of FHIT (3p14.2) and CDKN2A (9p21).
VEGFA is enriched in all subtypes to a different extent, but most in the basal
subtype. Similarly, PIK3CA amplifications are present in all subtypes, but occur
more frequently in the two CL subtypes compared to the three other subtypes.
Amplification of the 3q26–28 genomic region differs between the two HPV-positive
subtypes (see figure 3.7). MYC is significantly amplified in the IMS-nonHPV
subtype and in the basal subtype, ITGB4 (17q25) is significantly amplified in the
basal subtype. E2F3 (6p22) amplifications accumulate in the classical subtypes
and even though overall frequency is low, they might be of relevance as discussed
later.
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Figure 3.6: Copy number analysis – A and B.
Copy number (CN) analysis in the five subtypes as published in Keck et al. [61]. A Copy
number G-scores across all samples are shown for the five subtypes that are represented
through the different colors. Chromosomal region is indicated on the right. B Copy
number aberrations in the discovery dataset (75 genes in 101 samples). Chromosomal
region is indicated on the left, genes on the right, subtype and smoking history on
the top. Samples are ordered in columns and genes in rows by chromosomal region.
Copy numbers are normalized to -2–2. -2=high-level deletion, -1=low-level deletion,
1=low-level amplification, 2=high-level amplification.
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Figure 3.7: Copy number analysis – C.
Copy number (CN) analysis in the HPV-positive subtypes as published in Keck et
al. [61]. C Boxplots show CN aberrations in different genes of the 3q26–28 region
(PIK3CA, TP63, SOX2). PIK3CA was used as a marker for 3q26–28 amplification
in the discovery dataset (101 samples), TP63 and SOX2 were used as markers in the
validation dataset (55 of the 101 samples). 3q26–28 amplification differs between the
two HPV-positive subtypes.
3.2 Genomic Analysis
The aim of this part of the study was to determine the mutational and copy num-
ber profile of HPV-positive versus HPV-negative HNSCC to identify targetable
genetic aberrations in both disease entities. The results and figures presented in
this chapter were published in Seiwert et al. [110], bioinformatics and data ana-
lysis was performed by Dr. Zhixiang Zuo (partly in collaboration with Dr. Peter
Hammerman, Broad Institute).
3.2.1 Patient selection
The same patient cohort used for the classification of HNSCC was used for the
genomic analysis of HNSCC with the exception that a subset of 120 patients were
selected due to limited availability of tumor DNA and matching normal tissue sam-
ples. 55.8% of oropharyngeal tumors were included to assert a high representation
of HPV-positive cases. Patients with locoregionally advanced disease (95.8% stage
IV tumors) that were treated on six FHX-based chemoradiotherapy protocols were
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selected for this study leading to a highly homogeneous patient cohort. The me-
dian age of patients is 56 years. Full clinical annotation and survival data are
available, median follow-up time is 48 months. 42.5% HPV-positive tumors are
included to provide an insight into the genomic differences of HPV-positive ver-
sus HPV-negative HNSCC. The cohort consists of 45% non-smokers/light smokers
and 55% heavy smokers, which includes 35% of the HPV-positive patients that are
heavy smokers. Tumor samples were derived from surgeries or biopsies and were
treatment-na¨ıve. Matched normal DNA was derived from blood (n=24) or normal
tissue (n=96) such as tumor adjacent normal tissue, uninvolved lymph nodes, and
skin biopsies. Table 3.8 summarizes patient characteristics of the examined cohort
as published in Seiwert et al. [110].
Figure 3.8: Patient and sample overview.
Patient characteristics and clinical data of the investigated cohort as published in Sei-
wert et al. [110]. Patients/samples are sorted according to HPV status.
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3.2.2 Sample Selection
DNA derived from treatment-na¨ıve tumor and matching normal samples was avail-
able in sufficient quantity and quality for 120 of the cohort of 134 patients used for
the classification of HNSCC. Tumor DNA was purified from frozen OCT blocks
(n=120), normal DNA was purified from frozen OCT blocks (n=59), formalin-
fixed, paraffin-embedded (FFPE) slides (n=37) or peripheral blood (n=24). DNA
derived from blood had been purified by the Department of Pathology at the Uni-
versity of Chicago. This DNA was additionally subjected to isopropanol precipita-
tion to concentrate and clean up the samples. Quality control and quantification of
DNA was done using NanoDrop, DNA of sufficient quality (260/280≥1.8) was fur-
ther processed. Additional quantification was done using PicoGreen to determine
the exact amount of double stranded DNA, which is needed as starting material for
the preparation of sequencing libraries. This step is crucial when using DNA de-
rived from FFPE samples as the amount of single stranded DNA after purification
varies substantially. Due to the limited number of available matched normal sam-
ples, only 120 samples (out of the cohort of 134 used for classification) were further
processed and subjected to HPV PCR (120 tumor samples) and DNA sequencing
library preparation (120 tumor and matched normal samples). Normal DNA of
twelve samples was amplified through whole genome amplification (WGA) to yield
a sufficient amount of starting material for library preparation. A sufficient amount
of DNA to perform the Nanostring copy number assay was available for a part of
the samples (81 tumor and four reference normal samples derived from blood). See
3.9 for sample processing and analysis workflow as published in Seiwert et al. [110].
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Figure 3.9: Sample processing and analysis workflow.
Sample processing and analysis workflow of the investigated cohort as published in
Seiwert et al. [110]. 120 tumor/normal pairs were processed, HPV status as well as
copy number and mutational status were determined and validated.
3.2.3 Determination of HPV Status
HPV PCR for five high-risk HPV types was run at least two times per sam-
ple to determine HPV status of the 120 samples. HPV status was confirmed by
HPV16/HPV18 qPCR (Fluidigm microfluidics, performed by Genentech) target-
ing HPV oncogenes E6/E7 (HPV16) and E7/L1 (HPV18). If available, further
data were applied to confirm HPV status of the samples, i.e. p16/CDKN2A ex-
pression, HPV gene expression signature (unpublished, Dr. Zuo), and TP53 mu-
tations [151]. 42.5% of the samples, i.e. 51 out of 120, are HPV-positive with most
cases being positive for high risk HPV16 (n=46) and a few cases for HPV18 (n=3),
HPV45 (n=1), and HPV35 (n=1).
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3.2.4 Detection of Somatic Mutations
617 genes were targeted using Agilent CGH capture (solid phase capture) and
sequenced in 120 tumor and matching normal samples. 5,476 point mutations and
4,562 insertions/deletions (indels) were identified across the entire cohort. 1,536
of the point mutations and 200 of the indels are in coding regions with 1,209 of
the 1,536 being non-synonymous mutations. The mean point mutation rate per
megabase is 2.33 in the targeted regions and 0.22 in the coding regions. The most
frequent events are transitions and transversions at CpG sites (21/Mb) followed by
mutations at Tp*Cp(A/C/T) sites (13/Mb), which occur more frequently in HPV-
positive patients. Overall mutation rates are comparable in HPV-positive and
HPV-negative HNSCC both in all targeted bases (HPV-negative 2.22/Mb, HPV-
positive 2.46/Mb, P=0.64) and in the coding regions (HPV-negative 0.23/Mb,
HPV-positive 0.21/Mb, P=0.79). For validation of sequencing data, a solution
phase capture approach was chosen using NimbleGen EZ Choice capture. 87%
of coding mutations were validated. The MutSig algorithm [68], which takes into
account mutational heterogeneity and context to identify significantly mutated
genes, was applied to the overall cohort and separately to the HPV-positive and
HPV-negative samples (see figure 3.10).
11 genes were found to have significant enrichment for mutations (q-value <
0.1) when analyzing the entire cohort. These are TP53, CDKN2A, PIK3CA,
MLL2, TPRX1, CUL3, FLG, NSD1, DDX3X, RIPK4, and HRAS – q-values for
FGFR3 and FBXW7 are between 0.1 and 1. A different set of genes is dis-
covered as significantly mutated, if analysis is limited to genes of the COSMIC
database, which contains genes that are known to be somatically mutated in can-
cer. TP53, CDKN2A, PIK3CA, HRAS, FGFR3, and FBXW7 are re-discovered
and KRAS, MLL3, FGFR2, ZNF217, and RIMS2 are newly discovered (q-value
< 0.1). TP53, CDKN2A, MLL2/3, NOTCH1, PIK3CA, NSD1, FBXW7, DDR2,
and CUL3 are enriched in HPV-negative HNSCC and PIK3CA, MLL3, DDX3X,
FGFR2/3, NOTCH1, NF1, KRAS, and FBXW7 are enriched in HPV-positive tu-
mors. Figure 3.11A and B displays the mutated genes together with frequency and
nature of the mutation in HPV-negative and HPV-positive HNSCC respectively.
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Figure 3.10: Significantly mutated genes in HPV-positive and HPV-negative
HNSCC.
Selection of mutated genes in HPV-positive and HPV-negative HNSCC as published in
Seiwert et al. [110]. Histogram shows percentage of samples with mutations in the genes
indicated on the bottom. Samples are separated in HPV-positive and HPV-negative
samples. Genes are sorted by HPV association, which is expressed through q-values.
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Figure 3.11: Mutation events sorted by HPV status.
Mutation and copy number (CN) events in each sample as published in Seiwert et
al. [110]. Samples are sorted in columns and genes in rows. A Mutations in HPV-
negative samples. Top histogram: mutations per Mb. Right: affected gene. Left:
percentage of samples with the respective altered gene. Heatmap: type of alteration.
B Mutations in HPV-positive samples. C CN aberrations in HPV-negative samples.
CN gains are displayed in red and CN losses in blue. Samples are ordered according to
their CN aberrations. D CN aberrations in HPV-positive samples.
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3.2.5 Detection of Somatic Copy Number Aberrations
Copy number aberrations were detected by applying the CONTRA (copy number
analysis for targeted resequencing) algorithm to the sequencing data. The CON-
TRA algorithm is a method specifically developed to identify CN aberrations in
data derived from targeted resequencing [72]. Recurrent peaks of amplification
or deletion were identified in 192 genes (false discovery rate < 0.25) by applying
a modification of GISTIC 2.0 analysis [84]. Validation (at a rate of 83%) was
performed using the Nanostring copy number assay on 81 of the samples. Focal
gains were detected in EGFR, REL, BCL6, PIK3CA, TP63, CCDN1, and MDM2.
Losses were detected in ATM, CDKN2A, RB1, NOTCH1, and NF1 (see figure
3.11C and D). HPV-negative tumors show amplifications of EGFR (7p12) as well
as the long arm of chromosome 11 (11q13, contains CCND1) that are not found in
HPV-positive tumors. Both HPV-positive and HPV-negative tumors harbor am-
plifications of 3q2628 (contains SOX2/TP63/PIK3CA). Loss of 3p and CDKN2A
occurs mainly in HPV-negative tumors, while deletion of ATM is primarily found
in HPV-positive tumors. Figure 3.12 displays the genes with copy number aber-
rations in HPV-negative and HPV-positive HNSCC.
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Figure 3.12: Copy number analysis.
GISTIC-like copy number analysis as published in Seiwert et al. [110]. NGS data were
leveraged to derive copy number aberrations, graphs show the aberrant regions. Left
side of each panel indicates chromosomal region, bottom shows negative log2 of the q
value of the alteration. A Copy number gain in HPV-negative HNSCC. B Copy number
gain in HPV-positive HNSCC. C Copy number loss in HPV-negative HNSCC. D Copy
number loss in HPV-positive HNSCC.
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3.2.6 Network Analysis
Using VarWalker, altered networks/pathways were compared in HPV-negative and
HPV-positive tumors to identify further biologic differences between these two sub-
sets of HNSCC (see figure 3.13 and figure 3.14). VarWalker identifies mutation
networks – possible driver genes and their functional interactions – in cancer sam-
ples using NGS data [58]. Here in this cohort, the altered networks contain 84
proteins connected by 76 interactions in the HPV-negative tumors and 88 pro-
teins connected by 83 interactions in the HPV-positive tumors. Network analysis
further shows that some pathways are altered in HPV-negative and HPV-positive
HNSCC, e.g. PI3K signaling, Notch aberrations, SMAD signaling. Regarding other
pathways, there are substantial differences between the two subsets of HNSCC. Al-
teration of oxidative stress pathway genes such as CUL3, NFE2L2, and KEAP1 is
mainly found in HPV-negative tumors and alteration of p53 signaling and cell-cycle
pathway genes is almost exclusively found in HPV-negative tumors. On the other
hand, alterations of various pathways such as DNA damage pathway (BRCA1,
BRCA2, FANCG, FANCA, FANCD2, ATM), FGF signaling (FGFR2, FGFR3,
FGFR4), JAK/STAT signaling (STAT1, JAK1, JAK2) as well as alterations in
immune response genes (HLA-A and HLA-B) are mainly found in HPV-positive
tumors. Figure 3.13 and figure 3.14 show the results of the network analysis for
HPV-negative versus HPV-positive HNSCC.
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Figure 3.13: Network analysis in HPV-negative tumors.
Network/pathway analysis as published in Seiwert et al. [110]. Using VarWalker,
protein-protein interaction networks affected by mutations were identified in HPV-
negative tumors. Size of symbols corresponds to frequency of aberration. Connections
are shown with gray lines, connecting genes without aberrations are shown with gray
font. Colors illustrate similarities and differences between HPV-negative and HPV-
positive tumors. M=nonsynonymous mutation, A=amplification, D=deletion
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Figure 3.14: Network analysis in HPV-positive tumors.
Network/pathway analysis as published in Seiwert et al. [110]. Using VarWalker,
protein-protein interaction networks affected by mutations were identified in HPV-
positive tumors. Size of symbols corresponds to frequency of aberration. Connections
are shown with gray lines, connecting genes without aberrations are shown with gray
font. Colors illustrate similarities and differences between HPV-negative and HPV-
positive tumors. M=nonsynonymous mutation, A=amplification, D=deletion
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3.2.7 Targetable Genomic Alterations
Using CHASM (stands for: Cancer-specific High-throughput Annotation of So-
matic Mutations), a computational method to identify and prioritize oncogenic
driver mutations [15], the sequencing data were analyzed. According to their
CHASM score, missense mutations were predicted to be potential drivers of onco-
genesis. PIK3CA is the most altered oncogene in this HNSCC cohort with a trend
(statistically not significant, P=0.20) towards a higher incidence of PIK3CA mu-
tations in HPV-positive tumors. Mutations in the PI3K signaling pathway include
canonical mutations in PIK3CA (E542K, E545K, H1047R) as well as mutations
in PIK3R1, PTEN, TSC1, and TSC2. Targetable mutations in the FGF signaling
pathway, FGFR2 (N569D, N569K) and FGFR3 (S249C, K413N), were identified
exclusively in HPV-positive tumors. FGFR2 N569K and FGFR3 S249C show low
CHASM scores indicating the high probability of them to be oncogenic drivers.
The FGFR3 S249C mutation was identified recurrently in six HPV-positive tu-
mors and validated by Sanger Sequencing in all six samples (see 3.3.1). Another
signaling pathway harboring mutations is the MAPK pathway. Seven canonical
RAS mutations – HRAS (G13V, Q61L, K117N), KRAS (G12D, G13D, L19F),
and NRAS (Q61R) – were identified. Additionally, multiple mutations of unclear
significance were discovered in the tumor suppressor NF1. Some of the DDR2
and EPHA2 mutations also show a low CHASM score, however these are neither
recurrent nor do they cluster in a domain. Figure 3.15 and figure 3.16 show an
overview of the discovered targetable genomic changes in this HNSCC cohort.
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Figure 3.15: Targetable genomic alterations in HPV-negative and HPV-
positive HNSCC – A.
Genomic alterations with translational or clinical relevance as published in Seiwert et
al. [110]. A Frequency and type of alteration in some of the potentially targetable
genes and the affected downstream key pathways in HPV-negative and HPV-positive
HNSCC.
170 CHAPTER 3. RESULTS
Figure 3.16: Targetable genomic alterations in HPV-negative and HPV-
positive HNSCC – B.
Genomic alterations with translational or clinical relevance as published in Seiwert et
al. [110]. B Selection of mutations in potentially targetable genes is shown. Left side of
gene diagram shows the number of mutated samples per mutation, diagram itself shows
gene domains and location of mutation, CHASM score (red font means CHASM score
< 0.5, which predicts gene to be an oncogenic driver) and incidence in other cancers is
indicated on the right side.
3.2. GENOMIC ANALYSIS 171
3.2.8 Clinical Correlation
The mutational spectrum and the overall mutational burden differ when compar-
ing tumors from smokers (≥10 pack years) versus nonsmokers. In smokers of this
HNSCC cohort there are 11.5 mutations per patient as compared to 5.6 mutations
per patient in nonsmokers (P = 0.0007, t test). Furthermore, smoking is asso-
ciated with mutations in TP53 (P = 0.0009), CSMD3 (P = 0.0062), RB1CC1
(P = 0.0161), and THSD7A (P = 0.0319). Significant enrichment of mutations in
ZFHX4 (P = 0.0167, Fisher exact test) and TRRAP (P = 0.0392, Fisher exact
test) in smokers versus nonsmokers are as well found.
As shown in 3.1.9, prognosis differs between HPV-positive and HPV-negative tu-
mors in this patient cohort with HPV-associated tumors showing better overall
survival (OS; P = 0.015) as well as progression-free survival (PFS; P = 0.013)
both when looking at the entire cohort and at oropharyngeal tumors separately
(OS, P = 4 ∗ 10−5; PFS, P = 0.0001) (see figure 3.17).
Survival in FGFR3 S249C mutated HNSCC tumors was analyzed and com-
pared to survival of patients without the FGFR3 S249C mutation (see figure
3.18). Only HPV-positive tumors were considered. Both OS and PFS show a
trend towards better survival in patients with FGFR3 S249C mutated tumors
(OS, P = 0.219; PFS, P = 0.179). However sample size is small (n=6) and
differences do not reach statistical significance.
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Figure 3.17: Overall survival (OS) and progression free survival (PFS).
Figure shows OS and PFS as published in Seiwert et al. [110]. OS and PFS were
analyzed in HPV-positive versus HPV-negative HNSCC considering all anatomic sites
(see top figure) as well as oropharyngeal tumors only (see bottom figure).
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Figure 3.18: Overall survival (OS) and progression free survival (PFS) in
FGFR3 mutated HPV-positive HNSCC.
Figure shows OS and PFS in HPV-positive tumors containing the FGFR3 S249C mu-
tation versus HPV-positive tumors without FGFR3 S249C.
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3.2.9 Expression of FGFR3 is higher in FGFR3 mutated
HNSCC
To further investigate FGFR3 and FGFR3 mutated HNSCC, expression of FGFR3
in tumors containing FGFR3 S249C was compared to expression of FGFR3 in
tumors without FGFR3 S249C using the microarray data created for the HNSCC
taxonomy analysis. Only HPV-positive tumors were considered. As shown by the
boxplots, expression of FGFR3 is higher in samples that contain FGFR3 S249C
as compared to FGFR3 WT samples (see figure 3.19).
Figure 3.19: FGFR3 expression in FGFR3 mutated HPV-positive HNSCC.
Figure shows expression of FGFR3 in HPV-positive tumors containing the FGFR3
S249C mutation versus HPV-positive tumors without FGFR3 S249C.
3.3 Functional Validation
FGFR3 S249C was discovered in 12% (6 out of 51) of the HPV-positive tumors
(see figure 3.11, 3.15, and 3.16). Technical and functional validation of FGFR3
S249C were performed to investigate the capacity of FGFR3 S249 as an oncogenic
driver in HNSCC.
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3.3.1 Technical Validation of FGFR3 S249C
3.3.1.1 Validation of FGFR3 S249C by Sanger Sequencing
Direct sequencing of tumor DNA was performed as an additional technical val-
idation of the NGS results besides the Fluidigm assay (Fluidigm microfluidics,
performed by Genentech) to confirm the amino acid change S249C (nucleotide
change c.746C>G) in exon 7 of FGFR3, which had been selected for functional
validation in cell lines. DNA of the two HPV positive HNC cell lines SCC47 and
93VU147T selected for functional validation was subjected to direct sequencing as
well to confirm wild type FGFR3. Primers for amplification and sequencing were
taken from Jebar et al. [57] (see appendix A.1 for primer sequences). Both strands
were sequenced.
Mutational status of the six HPV positive tumors that had shown an FGFR3
S249C mutation in NGS could be confirmed in both DNA strands by direct se-
quencing as shown in figure 3.20. Absence of FGFR3 S249C mutations in the two
HPV positive cell lines SCC47 and 93VU147T that had been selected for func-
tional validation experiments could as well be confirmed. Both DNA strands were
sequenced (see figure 3.21).
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Figure 3.20: Technical validation of FGFR3 S249C in tumors.
Sequencing chromatograms of 6 HPV positive tumors that had shown an FGFR3 S249C
mutation in NGS. Primers flanking the S249C mutation in exon 7 of FGFR3 were used
for PCR and direct sequencing. Left: Sequencing was done with primer FGFR3 exon
7F. Right: Sequencing was done with primer FGFR3 exon 7R. The vertical line shows
the position of the S249C mutation, C to G transversion can be seen in both strands
at that position.
Figure 3.21: Technical validation of WT FGFR3 in cell lines.
Sequencing chromatograms of 2 HPV positive cell lines (SCC47 and 93VU147T) that
had been negative for the FGFR3 S249C mutation in NGS. Primers flanking the S249C
mutation in exon 7 of FGFR3 were used for PCR and direct sequencing. Left: Sequenc-
ing was done with primer FGFR3 exon 7F; Right: Sequencing was done with primer
FGFR3 exon 7R. The vertical line shows the position of the S249C mutation, C to G
transversion cannot be detected at that position.
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3.3.1.2 Expression of FGFR3 S249C and Different FGFR3 Isoforms
Reverse transcription polymerase chain reaction (RT-PCR) and subsequent se-
quencing were performed on the six tumor samples with mutated FGFR3 (S249C)
to investigate, if mutated FGFR3 was expressed in these samples and to deter-
mine which isoforms were present. The two cell lines (SCC47 and 93VU147T)
that had been selected for functional validation were as well subjected to FGFR3
RT-PCR. One forward primer and three isoform specific reverse primers were used
for RT-PCR (see primer table, table 2.42, table 2.43) as described by Tomlinson
et al. [130]. The forward primer was used for sequencing.
All six tumor samples as well as the two cell line transcripts align perfectly to the
reference sequence of FGFR3 IIIb, which confirms expression of the FGFR3 IIIb
isoform seen after PCR (285bp band) using primers FGFR3 exon 6F and exon 8R
(see figure 3.22 and figure 3.23).
Figure 3.22: Expression of FGFR3 IIIb in tumors and cell lines.
Six HPV-positive tumors and two HPV-positive cell lines were subjected to FGFR3
RT-PCR using primer pair exon 6F/8R and subsequent agarose gel electrophoresis.
Shown is the agarose gel, which demonstrates expression of the IIIb isoform of FGFR3
in tumors and cell lines.
Furthermore, the tumor samples express mutated and WT FGFR3 IIIb, whereas
the cell lines only show presence of the wild type receptor. In one of the tumor sam-
ples, mainly expression of the mutated receptor can be detected. See figure 3.23
for the sequencing results of primer pair FGFR3 exon 6F/8R PCR products.
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Figure 3.23: Expression of FGFR3 IIIb and FGFR3 S249C in tumors and cell
lines.
Six HPV-positive tumors (left) and two HPV-positive cell lines (right) were subjected
to FGFR3 RT-PCR using primer pair exon 6F/8R and direct sequencing using primer
exon 6F. Shown are the chromatograms obtained through direct sequencing, which
confirm the expression of FGFR3 IIIb in tumors and cell lines as well as the expression
of the S249C mutation of FGFR3 in tumors and its absence in cell lines. The position
of S249C is highlighted by the vertical line.
Primer pair FGFR3 exon 6F/9R is supposed to amplify the FGFR3 IIIc isoform
(290bp). Imaging of the gel after PCR shows expression of FGFR3 IIIc on a very
low level with almost invisible bands after 35 PCR cycles. However, there is an
unexpected PCR product between 400 and 500bp, which possibly is an unspliced
form of FGFR3 that contains both exon 8 and exon 9 as described by Tomlinson
et al. [130] (see figure 3.24) – the length of such a PCR product would be 441bp.
Sequencing analysis after PCR confirms this showing a transcript that aligns
perfectly to a reference sequence containing exon 8 and exon 9. Regarding the
mutational status of the sequenced PCR product, the mutated as well as the wild
type form can be found in all six tumor samples, but only the wild type form can
be found in cell lines (see figure 3.25).
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Figure 3.24: Expression analysis of FGFR3 IIIc in tumors and cell lines.
Six HPV-positive tumors and two HPV-positive cell lines were subjected to FGFR3
RT-PCR using primer pair exon 6F/9R and subsequent agarose gel electrophoresis.
Image shows the agarose gel, which indicates low expression of the FGFR3 IIIc isoform
in tumors and cell lines. Expression of a longer transcript, which could potentially
represent an unspliced transcript of FGFR3 containing exon 8 and exon 9, is detected.
Figure 3.25: Expression analysis of FGFR3 IIIc and FGFR3 S249C in tumors
and cell lines.
Six HPV-positive tumors (left) and two HPV-positive cell lines (right) were subjected to
FGFR3 RT-PCR using primer pair exon 6F/9R and direct sequencing using primer exon
6F. Shown are the chromatograms after sequencing, which confirm both the expression
of a transcript containing exon 8 and exon 9 as suspected after PCR as well as the
expression of the S249C mutation of FGFR3 in tumors and its absence in cell lines.
The position of S249C is highlighted by the vertical line.
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Primer pair FGFR3 exon 6F/11R is designed to amplify 368bp of the FGFR3 ∆8-
10 isoform transcript as well as 710bp of the FGFR3 IIIb and 679bp of the
FGFR3 IIIc isoform. Agarose gel electrophoresis after PCR shows two main am-
plification products, one between 300 and 400bp, supposedly FGFR3 ∆8-10, and
a second one between 700 and 800bp, supposedly FGFR3 IIIb. The gel confirms
the low abundance of FGFR3 IIIc measured before (see figure 3.26).
Figure 3.26: Expression analysis of FGFR3 ∆8-10 in tumors and cell lines.
Six HPV-positive tumors and two HPV-positive cell lines were subjected to FGFR3 RT-
PCR using primer pair exon 6F/11R. Results were visualized by subsequent agarose
gel electrophoresis. Image shows the agarose gel which indicates expression of the
FGFR3 ∆8-10 isoform in tumors and cell lines. It further shows expression of a longer
transcript.
Direct sequencing confirms the smaller product as FGFR3 ∆8-10 (see fig-
ure 3.27).
The bigger product cannot be unambiguously identified as the at 710bp sus-
pected FGFR3 IIIb, since the chromatogram shows more than one amplification
product after exon 10 – probably due to gel cutting, where a weak band directly
above the major amplification product between 700 and 800bp was as well cut (see
figure 3.26 and figure 3.28). Sequence data perfectly align with the sequence of
FGFR3 IIIb until the last base of exon 10, then two different amplification prod-
ucts are present. It is highly likely that one of the two products is FGFR3 IIIb,
the other one might be a transcript retaining the intron after exon 10. Similar to
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Figure 3.27: Expression analysis of FGFR3 ∆8-10 and FGFR3 S249C in tu-
mors and cell lines.
Six HPV-positive tumors (left) and two HPV-positive cell lines (right) were subjected
to FGFR3 RT-PCR using primer pair exon 6F/11R and to direct sequencing using
primer exon 6F. Shown are the chromatograms obtained after sequencing of one of
the two major amplification products (400bp product) which confirm the expression of
FGFR3 ∆8-10 as well as the expression of the S249C mutation of FGFR3 (position
highlighted by the vertical line) in tumors and its absence in cell lines.
the other transcripts, the mutated as well as the wild type forms of FGFR3 are
detected in all six tumor samples, whereas only the wild type receptor is detected
in the two cell lines (see figure 3.27 and figure 3.28).
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Figure 3.28: Expression analysis of the 700bp amplification product detected
after FGFR3 RT-PCR (primer pair exon 6F/11R) in tumors and cell lines.
Six HPV-positive tumors and two HPV-positive cell lines (SCC47 and 93VU147T) were
subjected to FGFR3 RT-PCR using primer pair exon 6F/11R and direct sequencing
using primer exon 6F. Shown are different regions of the chromatograms obtained after
sequencing of one of the two major amplification products (700bp product). Left:
Shown is the expression of the S249C mutation of FGFR3 (position highlighted by the
vertical line) in tumors and its absence in cell lines. Right: The vertical line highlights
the first base after exon 10, from which on more than one amplification product is
detected.
3.3.2 FGFR3/TACC3 fusion is not detected in HNSCC
tumor samples
136 HNSCC tumor samples (59 HPV-positive and 77 HPV-negative samples) were
subjected to FGFR3/TACC3 fusion RT-PCR using primer FGFR3 exon 11/12F
and primer TACC3 exon 13R [117] to amplify a 993bp region spanning the fusion
breakpoint of FGFR3 and TACC3 as previously reported for glioblastoma and
bladder cancer [117,142]. The two HPV-positive cell lines SCC47 and 93VU147T
selected for functional validation were included in the screen as well. The urinary
bladder transitional cell carcinoma cell line RT-112 served as a positive control
for the PCR. None of the screened tumors or cell lines showed any evidence for
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the presence of the FGFR3/TACC3 fusion. Figure 3.29 shows an example for an
agarose gel visualizing the results of the fusion PCR.
Figure 3.29: Screening results for the FGFR3/TACC3 fusion in HNSCC tu-
mors.
136 HNSCC tumors and two HNSCC cell lines were screened for the FGFR3/TACC3
fusion via RT-PCR. Primer FGFR3 exon 11/12F and primer TACC3 exon 13R [117]
were flanking the fusion breakpoint. Bladder cancer cell line RT-112 was included in
the PCR as a positive control. The results were visualized by subsequent agarose gel
electrophoresis. Image shows an example for an agarose gel after PCR. FGFR3/TACC3
fusion could not be detected in any of the HNSCC samples or cell lines.
As a control step, RT-PCR using tumor cDNA samples of each reverse tran-
scription batch and a validated primer pair was successfully performed to confirm
adequate quality of the cDNA and to ensure validity of the obtained negative
results.
3.3.3 Functional Validation of FGFR3 S249C
Cell line candidates for functional validation (SCC47 and 93VU147T) were chosen
from a pool of six available HPV-positive cell lines according to their FGFR3
expression profile derived from RNA sequencing. Selection criteria for functional
validation were the absence of FGFR3 S249C as confirmed in 3.3.1, expression of
the same isoforms as in the six tumor samples (see 3.3.1) as well as low endogenous
expression of FGFR3, which was confirmed by Western blotting (see figure 3.30).
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Figure 3.30: Expression of FGFR3 in cell lines.
Lysates from three different timepoints to confirm low expression levels of FGFR3 in
SCC47 and 93VU147T. H357 was included as a positive control for FGFR3 expression.
Cells were lysed and subjected to SDS-PAGE and WB. 40µg protein were loaded per
lane.
The two selected cell lines SCC47 and 93VU147T were transfected with the
two different main isoforms of FGFR3 expressed in HNSCC tumor samples –
FGFR3 ∆8-10 and FGFR3 IIIb (see 3.3.1.2) – both as the wild type gene and
carrying the FGFR3 S249C mutation respectively. Stable cell lines were created
and subjected to the functional validation experiments described in the following
sections (3.3.3.1, 3.3.3.2, 3.3.3.3).
3.3.3.1 Influence of FGFR3 S249C on Cell Proliferation
The influence of the FGFR3 S249C mutation on cell proliferation was investigated
in SCC47 and 93VU147T HNSCC cells. For this purpose, a resazurin based via-
bility assay was performed as described in 2.4.9. Data were analyzed as described
in 2.6.3.1.
SCC47 Figure 3.31 visualizes data of one viability experiment. Visual inspection
of the histograms of all three experiments indicates increased proliferation for
FGFR3 IIIb wild type transfected SCC47 cells. Results for the three other clones
are not as clear and/or inconsistent. Visual results are confirmed by statistical
analysis (see below).
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Figure 3.31: Influence of FGFR3 S249C on proliferation in SCC47 cells.
Viability assay was performed as described in 2.4.9. Data were corrected for background
fluorescence and normalized to the readings of the 0h time point as described in 2.6.3.1.
Cell viability (%) was plotted versus time (hours in culture) to visualize proliferation
(0h values were set 100%). Data of one experiment are shown, error bars represent
standard deviations. Experiment was performed three times (n=3). D = ∆
Data were corrected for background fluorescence and normalized to the 0h time
point readings. Shapiro-Wilk-Test (α = 0.05) was performed to test for normality
of sample distribution. Results are displayed in table 3.1. Normality of sample
distribution is present in 14 out of the 15 groups tested.
Levene’s-Test (using the medians, α = 0.05) was done to test for homogeneity
of variances, which is confirmed for all three experiments with p-values 0.1776,
0.8348, and 0.5911. Results of the subsequent one-way/single factor ANOVA
(α = 0.05) indicate a significant difference in proliferation between the differently
transfected SCC47 clones (p-values experiments I–III: 0.000003, 0.0192, 0.00001).
The Kruskal-Wallis-Test (α = 0.05) that was additionally performed on data of
experiment II (normality of sample distribution assumption had been slightly vio-
lated) as well confirms the results of ANOVA (p-value: 0.0406). ANOVA post-hoc
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Exp Empty FGFR3 FGFR3 FGFR3 FGFR3
Vector ∆8-10 WT ∆8-10 S249C IIIb WT IIIb S249C
I 0.8789 0.1816 0.1511 0.9973 0.9564
II 0.0366 0.9842 0.4205 0.8038 0.9810
III 0.8367 0.2695 0.3990 0.2574 0.3448
Table 3.1: SCC47 – proliferation – p-values of the Shapiro-Wilk-Test.
Shapiro-Wilk-Test (α = 0.05) was performed on data of the viability assay. Data were
corrected for background fluorescence and normalized to the 0h time point. Table shows
the calculated p-values for each sample group (five replicates per clone) for all three
experiments. Exp=experiment, WT=wild type
test Tukey’s HSD (α = 0.05) was done to compare proliferation of SCC47 cells
transfected with the different FGFR3 wild type and mutated clones to prolifer-
ation of SCC47 cells transfected with the empty vector (q- and q-crit-values see
table 3.2). Results of Tukey’s HSD indicate that the FGFR3 IIIb wild type trans-
fected SCC47 cells, but not any of the mutants, proliferate faster than SCC47 cells
transfected with the empty vector (|q| > q-crit). Results are consistent across the
three experiments with two significant and one marginally significant result.
Exp I-III FGFR3 FGFR3 FGFR3 FGFR3
q-crit = 4.232 ∆8-10 WT ∆8-10 S249C IIIb WT IIIb S249C
EV 4.466 1.264 10.281 1.029
EV -1.909 0.246 3.496 0.377
EV -2.673 0.186 6.923 -2.061
Table 3.2: SCC47 – q-values of Tukey’s HSD Test – empty vector.
Tukey’s HSD-Test (α = 0.05) was performed on data of the viability assay. Data were
corrected for background fluorescence and normalized to the 0h time point. Table shows
the q-crit value as well as the q-values obtained by comparing proliferation of SCC47
cells transfected with different FGFR3 wild type and mutated clones to proliferation of
SCC47 cells transfected with the empty vector. Shown are data of three experiments.
Exp=experiment, WT=wild type, EV=empty vector
Tukey’s HSD Test was subsequently applied to test every possible combination
involving SCC47 cells transfected with FGFR3 IIIb WT (see figure 3.3). Q-values
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of these pairwise comparisons show that SCC47 cells transfected with FGFR3 IIIb
WT have an increased proliferation rate compared to SCC47 cells transfected with
any of the other three FGFR3 wild type and mutant clones (|q| > q-crit). Results
are consistent across the three experiments with two significant and one marginally
significant result for the comparison with FGFR3 ∆8-10 S249C and FGFR3 IIIb
S249C and three significant results for the comparison with FGFR3 ∆8-10 WT.
Tukey’s HSD Test was as well applied to test for a significant difference in pro-
liferation between the remaining possible pairwise combinations. Results did not
reach statistical significance for any of these comparisons with q-values ranging
between 0.131 and 3.437.
Exp I-III FGFR3 FGFR3 FGFR3
q-crit = 4.232 ∆8-10 WT ∆8-10 S249C IIIb S249C
FGFR3 IIIb WT 5.815 9.017 9.252
FGFR3 IIIb WT 5.405 3.249 3.119
FGFR3 IIIb WT 9.596 6.736 8.984
Table 3.3: SCC47 – q-values of Tukey’s HSD-Test – FGFR3 IIIb WT.
Tukey’s HSD-Test (α = 0.05) was performed on data of the viability assay that had been
corrected for background fluorescence and normalized to the 0h time point. Table shows
the q-crit value as well as the q-values obtained by comparing proliferation of SCC47
cells transfected with FGFR3 IIIb WT to proliferation of SCC47 cells transfected with
the remaining different FGFR3 wild type and mutated clones. Shown are data of three
experiments. Exp=experiment, WT=wild type
93VU147T Figure 3.32 shows data of one viability experiment. Visual inspec-
tion of the histograms of all three experiments does not indicate consistent results
across experiments. Statistical analysis is described below.
As described for SCC47, data were corrected for background fluorescence and
normalized to the readings obtained for the 0h time point. Shapiro-Wilk-Test
(α = 0.05) was performed to investigate normality of sample distribution. Results
are displayed in table 3.4. Normality of sample distribution is confirmed in 14 out
of the 15 groups tested.
Levene’s-Test (using the medians, α = 0.05) confirms homogeneity of variances
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Figure 3.32: Influence of FGFR3 S249C on proliferation in 93VU147T cells.
Viability assay was performed as described in 2.4.9. Data were corrected for background
fluorescence and normalized to the readings of the 0h time point as described in 2.6.3.1.
Cell viability (%) was plotted versus time (hours in culture) to visualize proliferation
(0h values were set 100%). Data of one experiment are shown, error bars represent
standard deviations. Experiment was performed three times (n=3). D = ∆
Exp Empty FGFR3 FGFR3 FGFR3 FGFR3
Vector ∆8-10 WT ∆8-10 S249C IIIb WT IIIb S249C
I 0.3054 0.7939 0.0910 0.9705 0.9272
II 0.7991 0.2284 0.2360 0.5410 0.7820
III 0.1061 0.0024 0.3264 0.6676 0.4617
Table 3.4: 93VU147T – proliferation – p-values of the Shapiro-Wilk-Test.
Shapiro-Wilk-Test (α = 0.05) was performed on data of the viability assay. Data were
corrected for background fluorescence and normalized to the 0h time point. Table shows
the calculated p-values for each sample group (five replicates per clone) for all three
experiments. Exp=experiment, WT=wild type
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for all three experiments with p-values 0.5874, 0.5512, and 0.9292. One-way/single
factor ANOVA (α = 0.05) shows a significant difference in proliferation between
the different 93VU147T clones (p-values for experiments I–III: 0.0374, 0.00001,
0.0028). The Kruskal-Wallis-Test (α = 0.05) that was additionally performed
on the data of experiment III (normality of sample distribution assumption had
been slightly violated) confirms the results of ANOVA (p-value: 0.0068). Tukey’s
HSD (α = 0.05) was done as ANOVA post-hoc test to compare proliferation
of 93VU147T cells transfected with the different FGFR3 clones to proliferation
of 93VU147T cells transfected with the empty vector (q- and q-crit-values see
table 3.5). Tukey’s HSD Test confirms the results obtained by visual inspection
of the histograms (figure 3.32 and figure 3.5). Results are not consistent across
experiments and no conclusions can be made regarding the influence of the different
FGFR3 wild type and mutant clones on proliferation, when compared to the empty
vector (see figure 3.5).
Exp I-III FGFR3 FGFR3 FGFR3 FGFR3
q-crit = 4.232 ∆8-10 WT ∆8-10 S249C IIIb WT IIIb S249C
EV 0.125 -1.278 -4.092 -2.438
EV 7.572 1.649 8.335 6.614
EV -2.481 -6.222 -1.900 -4.573
Table 3.5: 93VU147T – results of Tukey’s HSD-Test – q-values.
Tukey’s HSD-Test (α = 0.05) was performed on data of the viability assay. Data
were corrected for background fluorescence and normalized to the 0h time point. Table
shows the q-crit value as well as the q-values obtained by comparing proliferation of
93VU147T cells transfected with different FGFR3 wild type and mutated clones to
proliferation of 93VU147T cells transfected with the empty vector. Shown are data of
three experiments. Exp=experiment, WT=wild type, EV=empty vector
3.3.3.2 Influence of FGFR3 S249C on Cell Migration
The effect of the FGFR3 S249C mutation on the migration rate of HNSCC cells
was investigated in SCC47 and 93VU147T using the in vitro scratch assay (see
2.4.10) and the T-Scratch analysis software [33]. Data analysis was performed as
described in 2.6.3.2.
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SCC47 Figure 3.33 shows the results obtained by one migration experiment
(Wound Healing Assay). Results are similar for all three runs of the Wound Healing
Assay. SCC47 cells transfected with the empty vector seem to close the wound
slightly faster than SCC47 cells transfected with either the wild type or mutant
form (S249C) of the different FGFR3 isoforms – FGFR3 ∆8-10 and FGFR3 IIIb –
though the differences in migration rate seem to be rather subtle. Hence expression
of different FGFR3 mutant and wild type isoforms does not increase migration rate
in SCC47 cells, but rather seems to slow down the migration process. Results of
the statistical analysis (see below) confirm the results of visual inspection of the
histograms in two out of three experiments.
Figure 3.33: Influence of FGFR3 S249C on wound healing in SCC47 cells.
SCC47 HNSCC cells transfected with FGFR3 ∆8-10 and FGFR3 IIIb, both wild type
and S249C, were subjected to the in vitro scratch assay and analyzed using the T-
Scratch software [33]. SCC47 cells transfected with the empty vector served as a control.
Open image area was quantified at each time point and normalized to the 0h value of the
respective well using the T-Scratch analysis tool to calculate the open wound area for
each time point. Shown is the data of one experiment (mean open wound area of four
replicate wells), error bars indicate the standard deviation. Experiment was performed
three times (n=3). D = ∆
Normalized data of the 14h time point readings were used for statistical anal-
ysis. Normality of sample distribution was tested applying the Shapiro-Wilk-Test
(α = 0.05). Results are presented in table 3.6. Normality of sample distribution
is present in 13 out of the 15 groups tested.
The homogeneity of variances assumption was tested applying Levene’s-Test
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Exp Empty FGFR3 FGFR3 FGFR3 FGFR3
Vector ∆8-10 WT ∆8-10 S249C IIIb WT IIIb S249C
I 0.2125 0.6721 0.4810 0.4030 0.8985
II 0.0027 0.5192 0.7332 0.3125 0.0326
III 0.6155 0.4590 0.4668 0.4234 0.1116
Table 3.6: SCC47 – migration – p-values of the Shapiro-Wilk-Test.
Shapiro-Wilk-Test (α = 0.05) was performed on data of the Wound Healing Assay to
test for normality of sample distribution. Normalized data of the 14h time points were
used for statistical analysis. Table shows p-values of three independent experiments as
calculated with the Shapiro-Wilk-Test for each sample group (4 replicates per clone).
Exp=experiment, WT=wild type
(using the medians, α = 0.05). Homogeneity of variances could be confirmed for
two out of three experiments with p-values 0.3204 (exp. I), 0.0367 (exp. II), and
0.3229 (exp. III).
Results of the one-way/single factor ANOVA (α = 0.05) are not consistent across
experiments with p-values 0.198422 (exp. I), 0.000089 (exp. II), and 0.000056 (exp.
III). Therefore, no clear conclusion can be made regarding the difference in migra-
tion rate, but the trend indicates that migration rate might differ in the differently
transfected SCC47 clones. The Kruskal-Wallis-Test (α = 0.05) and the Welch’s
Test (α = 0.05), which were performed in addition on data of experiment II,
since the normality of sample distribution and homogeneity of variances assump-
tion were not entirely met, confirm the results of ANOVA with p-values 0.0031
(Kruskal-Wallis-Test) and 0.0017 (Welch’s Test). ANOVA post-hoc test Tukey’s
HSD (α = 0.05) was performed on the data of experiments II and III (experiment I
did not show any difference in migration rate by ANOVA) to compare the migration
rate of SCC47 cells transfected with the different FGFR3 wild type and mutated
clones to the migration rate of SCC47 cells transfected with the empty vector (q-
and q-crit-values see table 3.7). Results of Tukey’s HSD for experiments II and III
confirm the results obtained by visual inspection of the histograms and show that
the migration rate of SCC47 cells transfected with the different FGFR3 wild type
and mutated clones is slower than the migration rate of SCC47 cells transfected
with the empty vector (|q| > q-crit). With one exception (FGFR3 IIIb S249C in
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exp. II) results are consistent across the two experiments that could be subjected
to ANOVA post-hoc tests.
Exp I-III FGFR3 FGFR3 FGFR3 FGFR3
q-crit = 4.367 ∆8-10 WT ∆8-10 S249C IIIb WT IIIb S249C
EV — — — —
EV 4.8541 8.9830 5.8379 1.2723
EV 9.9633 5.8489 5.1408 8.0965
Table 3.7: SCC47 – migration – q-values of Tukey’s HSD Test.
Tukey’s HSD-Test (α = 0.05) was performed on data of the Wound Healing Assay.
Data of the 14h time point readings were normalized to the 0h time point. Table
shows the q-crit value and the q-values obtained by comparing migration of SCC47
cells transfected with different FGFR3 wild type and mutated clones to migration of
SCC47 cells transfected with the empty vector. Shown are data of the two experiments
that had yielded relevant results by ANOVA or comparable tests. Exp=experiment,
WT=wild type, EV=empty vector
93VU147T Figure 3.34 shows the results of one migration experiment (Wound
Healing Assay). The mean values computed for the open wound area at different
time points are similar in 93VU147T cells transfected with the different mutant
and wild type isoforms of FGFR3 as compared to 93VU147T cells transfected with
the empty vector in all three independent runs of the Wound Healing Assay. Hence
the FGFR3 S249C mutation does not seem to affect migration rate in 93VU147T
HNSCC cells. Results of the visual inspection of the histograms were confirmed
by statistical analysis (see below) in two out of three experiments. In one of the
three experiments migration rate between the different clones was differing and
partly statistically significant. However, effect size was small.
Statistical analysis was performed on the normalized data of the 14h time point
readings. Normality of sample distribution was tested using the Shapiro-Wilk-Test
(α = 0.05). Results are shown in table 3.8. Normality of sample distribution is
confirmed in 14 out of the 15 groups tested.
The homogeneity of variances assumption was tested applying Levene’s-Test
(using the medians, α = 0.05). Homogeneity of variances is confirmed in one out
of three experiments with p-values 0.6890 (exp. I), 0.0404 (exp. II), and 0.0049
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Figure 3.34: Influence of FGFR3 S249C on wound healing in 93VU147T cells.
93VU147T HNSCC cells transfected with FGFR3 ∆8-10 and FGFR3 IIIb, both wild
type and S249C, were subjected to the in vitro scratch assay and analyzed using the
T-Scratch software [33]. 93VU147T cells transfected with the empty vector served as
a control. Open image area was quantified at each time point and normalized to the
0h value of the respective well using the T-Scratch analysis tool to calculate the open
wound area for each time point. Shown is the data of one experiment (mean open wound
area of four replicate wells), error bars indicate the standard deviation. Experiment was
performed three times (n=3). D = ∆
Exp Empty FGFR3 FGFR3 FGFR3 FGFR3
Vector ∆8-10 WT ∆8-10 S249C IIIb WT IIIb S249C
I 0.9396 0.1487 0.5682 0.7026 0.3509
II 0.5909 0.0372 0.1671 0.7667 0.4737
III 0.5783 0.4226 0.6098 0.4202 0.4306
Table 3.8: 93VU147T – migration – p-values of the Shapiro-Wilk-Test.
Shapiro-Wilk-Test (α = 0.05) was performed on data of the Wound Healing Assay to
test for normality of sample distribution. Normalized data of the 14h time points were
used for statistical analysis. Table shows p-values of three independent experiments as
calculated with the Shapiro-Wilk-Test for each sample group (four replicates per clone).
Exp=experiment, WT=wild type
194 CHAPTER 3. RESULTS
(exp. III).
One-way/single factor ANOVA (α = 0.05) was performed on data of all three
experiments. The trend indicates that there is no difference in migration rate be-
tween the different clones, however results are not consistent across experiments as
for one out of three experiments analysis showed a significant difference regarding
migration rate – p-values for ANOVA are 0.1505 (exp. I), 0.3080 (exp. II), and
2.33 ∗ 10−8 (exp. III). Both the normality of sample distribution and homogeneity
of variances assumption were not fulfilled for experiment II and the homogeneity
of variances assumption was not met for experiment III. Therefore, the Kruskal-
Wallis-Test (α = 0.05) and the Welch’s Test (α = 0.05) were applied additionally
to confirm the results obtained by ANOVA. P-values for experiment II are 0.1817
(Kruskal-Wallis-Test) and 0.1619 (Welch’s Test), which confirms the results ob-
tained by ANOVA – no difference in migration between the different clones. P-
values for experiment III are 0.0031 (Kruskal-Wallis-Test) and 3.46∗10−6 (Welch’s
Test), which as well confirms ANOVA results and shows a difference in migration.
Subsequently, ANOVA post-hoc test Tukey’s HSD (α = 0.05) was performed on
the data of experiment III to compare the migration rate of 93VU147T cells trans-
fected with the different FGFR3 wild type and mutated clones to the migration
rate of 93VU147T cells transfected with the empty vector (for q- and q-crit-values
see table 3.9). Results of Tukey’s HSD for experiment III show that the migration
rate of 93VU147T cells transfected with FGFR3 ∆8-10 S249C is slower than the
migration rate of 93VU147T cells transfected with the empty vector (|q| > q-crit),
whereas the migration rate of 93VU147T cells transfected with FGFR3 IIIb S249C
is faster.
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Exp I-III FGFR3 FGFR3 FGFR3 FGFR3
q-crit = 4.367 ∆8-10 WT ∆8-10 S249C IIIb WT IIIb S249C
EV — — — —
EV — — — —
EV 3.2988 10.9882 3.4462 -8.1209
Table 3.9: 93VU147T – migration – q-values of Tukey’s HSD Test.
Tukey’s HSD-Test (α = 0.05) was performed on data of the Wound Healing Assay.
Data of the 14h time point readings were normalized to the 0h time point. Table
shows the q-crit value and the q-values obtained by comparing migration of 93VU147T
cells transfected with different FGFR3 wild type and mutated clones to migration of
93VU147T cells transfected with the empty vector. Shown are data of one experiment
that had yielded relevant results by ANOVA and comparable tests. Exp=experiment,
WT=wild type, EV=empty vector
3.3.3.3 Influence of FGFR3 S249C on FGFR3 Signaling
Basic signaling without prior stimulation and signaling upon stimulation with
FGF1 were studied in SCC47 stably transfected cells. Appropriate controls were
included. Pilots were run for stimulation experiments to determine the ideal star-
vation time and conditions to shut down basic signaling to be able to see poten-
tial effects upon stimulation later. The ideal stimulation time with FGF1 was
as well determined. Three phosphorylated proteins, phospho-FGFR, phospho-
FRS2α, and phospho-PLCγ1 could not be adequately detected using the available
antibodies.
Basic Signaling SCC47 HNSCC parental and stably transfected cells were sub-
jected to SDS-PAGE and Western blotting to study differences in basic FGFR3
signaling without prior stimulation (see figure 3.35).
No consistent or obvious differences in basic FGFR3 signaling could be detected
in SCC47 cells transfected with FGFR3 ∆8-10 and FGFR3 IIIb when compared
to SCC47 cells transfected with the empty vector only. Subtle differences could be
noted in Akt-, STAT1-, and Erk-phosphorylation compared to the empty vector,
but results were not consistent across experiments or even contradictory.
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Figure 3.35: Basic FGFR3 signaling in stably transfected SCC47 cells.
Figure shows signaling without prior stimulation in SCC47 HNSCC cells transfected
with FGFR3 ∆8-10 and FGFR3 IIIb, wild type and S249C respectively. Cells were
harvested at 50-80% confluence, lysed and subjected to SDS-PAGE and WB. 40µg
protein were loaded per lane. (n=3)
Signaling upon Stimulation with FGF1 Following basic signaling studies,
SCC47 stably transfected cells were first starved with media containing 1% FBS
for 4 hours and then stimulated with 5ng/mL FGF1 for 5 minutes to investigate
differences in signaling upon stimulation (see figure 3.36).
No activation of STAT1 or STAT3 signaling could be detected upon stimulation
with FGF1. FGF1 stimulated signaling involves the Akt (protein kinase B – PKB)
and MAP kinase (mitogen-activated protein kinase – MAPK) pathways in HNSCC
cells. Subtle differences between the different stable clones regarding the extent of
phosphorylation upon stimulation were detected with respect to Akt and MAPK
activation. However results were not consistent across experiments.
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Figure 3.36: Stimulated FGFR3 signaling in stably transfected SCC47 cells.
Figure shows signaling upon stimulation with FGF1 in SCC47 HNSCC cells transfected
with FGFR3 ∆8-10 and FGFR3 IIIb, wild type and S249C respectively. Cells were
starved with 1% FBS for 4 hours and subsequently stimulated with 5ng/mL FGF1
for 5 minutes, then lysed and subjected to SDS-PAGE and WB. Cells were stimu-
lated/harvested at 50-80% confluence. 30µg protein were loaded per lane. (n=3)
Chapter 4
Discussion
4.1 Taxonomy
A total of 171 patient samples with full clinical annotation, including 40-50%
oropharyngeal tumors, were dissected and processed to RNA/DNA extraction and
quality control as described. 134 samples passed quality control resulting in a
cohort of 134 locoregionally advanced, treatment-na¨ıve tumor samples that were
subjected to HPV testing, Agilent 4X44Kv2 gene expression arrays, and Nanos-
tring copy number assays. All patients received concurrent chemoradiotherapy
for treatment making this cohort very homogeneous regarding tumor stage and
treatment. The objective was the identification of HNSCC subtypes using gene
expression data derived from patient samples. The resulting subtypes were further
characterized by analyzing their respective gene expression profiles, copy number
status, and prognosis.
HNC patients are treated depending on stage and location of the tumor using
a combination of surgery, radiation, and chemotherapy, yet treatment does not
reflect the underlying tumor biology [3, 96]. To date, there is no molecular clas-
sification that is clinically relevant, since published studies report small cohorts
without full clinical annotation and either include a small number of HPV-positive
samples or do not investigate HPV status [17, 119, 138]. In the Agilent cohort re-
ported here, application of the described patient selection criteria resulted in a
homogeneous, clinically annotated HNSCC patient cohort and a sufficient number
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of HPV-positive cases to perform meaningful bioinformatics analysis. To realize a
comprehensive analysis of HNSCC, the newly generated Agilent cohort was stud-
ied and analyzed together with all other available HNSCC cohorts (including data
from TCGA), which resulted in a total of 938 samples.
HPV status of the samples was determined through different methods. In the Agi-
lent cohort, HPV testing was performed through HPV PCR after Sotlar et al. [121]
and subsequent verification of HPV status through qPCR (Fluidigm microfluidics,
performed by Genentech). In the Agilent cohort of 134 samples, 59 were found
to be HPV-positive (=44%). This constitutes a large enough representation of
HPV-positive cases to allow meaningful analysis and discovery of subtypes, which
is essential given the fact that the frequency of HPV-associated HNCs is on the
rise [16,115]. In the literature derived cohorts, HPV status was determined through
analysis of RNAseq and exome sequencing data (TCGA) as well as the application
of an HPV gene signature (unpublished, Dr. Zuo) to microarray data (Illumina
and Affymetrix).
Three different HNSCC supergroups were discovered through ConsensusCluster-
ing on four different gene expression datasets derived from three different plat-
forms – Agilent, Affymetrix [18, 94], Illumina (Yordy et al. under review) – in an
unsupervised manner leading to cross-cohort and cross-platform validity of the
supergroups. A predictive gene signature of 821 genes was derived and super-
groups were validated by assigning samples from the validation dataset to the
identified supergroups using nearest centroid algorithm. Samples of the valida-
tion dataset were derived from four different datasets and two different platforms
– Affymetrix [101, 119, 146], RNAseq (TCGA) – confirming cohort and platform
independence of the supergroups. The three newly discovered supergroups were
named basal (BA), classical (CL), and inflamed/mesenchymal (IMS) – according
to their expression profiles and the similarity with existing subtypes in lung SCC,
breast cancer, and glioblastoma multiforme (GBM) [120, 136, 141]. The validity
of this classification is confirmed by the results of principal component analysis
(PCA), which underlines the substantial similarity between the three supergroups
and subtypes discovered in lung SCC [141] and previous studies of HNSCC [17].
HPV status of the samples was used to further subdivide two of the three super-
groups that exhibited mixed sample distribution – CL and IMS. This resulted in
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five HNSCC subtypes that were named BA, CL-HPV, CL-nonHPV, IMS-HPV,
and IMS-nonHPV. Four samples of the Agilent cohort (4 out of 134) were unde-
fined/not classifiable.
HNSCC consists of HPV-negative and HPV-associated tumors, which are consid-
ered to be two distinct disease entities [5, 16, 36, 70]. Besides three HPV-negative
subtypes, two different HPV-associated subtypes are identified here in this study
– CL-HPV and IMS-HPV – that differ regarding their molecular profile and sur-
vival. The finding of two different HPV-positive subtypes is novel and reflects the
clinical heterogeneity which can be seen among HPV-positive HNSCC – a subset
of HPV-positive tumors shows a lower rate of survival than other HPV-positive
tumors [5].
The five newly discovered HNSCC subtypes (two HPV-positive and three HPV-
negative subtypes) can be further characterized by their expression profiles and
copy number status. The basal supergroup/subtype exhibits multiple features as-
sociated with a poor prognosis such as hypoxia or overexpression of EGFR [51] and
consequently is among the worse prognosis subtypes with a five-year survival of
approximately 50%. It only contains HPV-negative samples and a high percentage
of smokers. The basal subtype shows overexpression of epithelial genes – cytoker-
atins and P-cadherin – which is confirmed by comparison with a published EMT
gene signature [125]. Cell adhesion related genes such as LAMC2, COL17A1, and
ITGB1 are overexpressed in the basal subtype, ITGB4 is significantly amplified
and overexpressed. LAMC2 is an invasion marker that is overexpressed in can-
cer cells of epithelial origin and correlates with a poor prognosis, recurrence, and
metastasis [48, 98, 132]. Integrins play an important role in migration, invasion,
and proliferation [24]. ITGB1 is involved in cell survival and the development of
resistance to cytotoxic therapy [21,63].
Overexpression of hypoxia related genes – HIF1α, CA9, and VEGF/VEGFA –
and correlation with a hypoxia gene expression signature [143] are one charac-
terizing feature of the basal subtype. Tumor hypoxia is associated with a more
malignant phenotype by contributing to angiogenesis, tumor cell survival, pro-
gression, invasion, and metastasis [1,51,113]. The effects of hypoxia are mediated
by the transcription factors HIF1α and HIF2α [1, 10]. The direct HIF target
gene VEGFA (6p12) [28, 113] is not only overexpressed, but also amplified in the
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basal subtype. Besides its role in angiogenesis, VEGF possibly exerts immunosup-
pressive properties and interferes with T-cell development and suppresses T-cell
proliferation and activation [31]. Immune suppression in cancer can potentially
be driven by hypoxia and/or HIF activity, which also causes resistance to conven-
tional chemotherapy and radiation [28,113]. Interestingly, the transcription factor
MYC (8q24.21) is significantly amplified in the hypoxic subgroup. Recent find-
ings suggest that MYC might be responsible for increasing HIF1α protein levels
via posttranscriptional stabilization of HIF1α under hypoxia and normoxia [26].
However, HIF1α is not only activated by hypoxia, but also through growth factor
signaling under normoxic conditions [28]. Of note, besides HIF1α some of the
other hypoxia markers, CA9 and VEGF, are also partly controlled by EGFR [51],
and EGFR mediated upregulation of VEGF may cause resistance to anti-EGFR
therapy, which provides a rationale for dual targeting of EGFR and VEGF [38].
Further evidence suggests that colocalization of EGFR and hypoxia might lead to
worse locoregional control [51]. Fittingly, the basal subtype is enriched for HER
signaling apparent through amplification and overexpression of the growth fac-
tor receptor EGFR (7p12) as well as overexpression of its ligands amphiregulin
(AREG) and neuregulin 1/heregulin (NRG1). Considering these results the basal
subtype might be driven by EGFR signaling, hypoxia, or both and hence might
serve as a candiate predictive biomarker for EGFR-targeting, VEGF-targeting and
hypoxia-targeting therapy [61].
The classical supergroup consists of two subtypes, namely CL-HPV and CL-
nonHPV, that share some characteristic features such as increased cell prolifer-
ation, but differ regarding other characteristics. The canonical amplification of
the 3q26-28 region, which contains PIK3CA [119], occurs more frequently in the
two CL subtypes compared to the three other subtypes and is validated by differ-
ent markers (TP63 and SOX2) of that region. PIK3CA (3q26.3) is a well-known
oncogene in HNSCC. The role of TP63 (3q28) is not fully investigated. TP63
supposedly defines a squamous epithelial phenotype and suppresses properties of
mesenchymal cells – it might act as an oncogene, but also as a metastasis sup-
pressor [6]. SOX2 (3q26.3-q27) amplifications are oncogenic in lung squamous
cell carcinomas [52]. E2F3 (6p22) amplification shows a low frequency (5%), but
mostly occurs in the CL supergroup, where it is also overexpressed. Overexpression
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and amplification of the E2F3 cell cycle regulatory transcription factor supposedly
activates tumor cell proliferation in invasive bladder cancer [91]. Consistently, be-
sides amplification and overexpression of E2F3 in the CL-HPV subtype, there is
as well increased proliferation in CL-HPV compared to IMS-HPV. Furthermore,
E2F3 is not amplified in the IMS-HPV subtype, which highlights the difference
in biology between the two HPV-associated subtypes. E2F3 is controlled by the
retinoblastoma (pRb) tumor suppressor [91], which, in the context of an infection
with HPV, is deactivated by the oncogenic HPV E7 protein [99].
A similar situation as in the classical supergroup is found in the inflamed/mesen-
chymal subtypes, IMS-HPV and IMS-nonHPV, that show differences in gene ex-
pression, but share important features such as upregulation of immune response
genes and mesenchymal genes.
Both HPV-associated subtypes, CL-HPV and IMS-HPV, exhibit overexpression
of cell cycle related genes. However, the CL-HPV subtype shows higher prolif-
eration – demonstrated through comparison with a published proliferation gene
signature [140] – while the IMS-HPV subtype shows increased expression of mes-
enchymal and immune response genes. A similar situation becomes evident for
the HPV-negative subtypes, CL-nonHPV and IMS-nonHPV, that are mainly rep-
resented by medium to heavy smokers. 74% of the CL-nonHPV and 85% of IMS-
nonHPV are heavy smokers and both subtypes show overexpression of genes re-
lated to xenobiotic metabolism – AKR1C1, AKR1C3, ALDH3A1. AKR1C1 and
AKR1C3 are part of a cigarette smoke signature of genes that were found to be
related to tobacco associated impact [59] and ALDH3A1 expression was reported
to be increased in the airway epithelium of smokers versus non-smokers [122]. The
difference between the CL-nonHPV and the IMS-nonHPV subtypes is again the in-
creased expression of mesenchymal and immune response genes, which is a unique
characteristic of the IMS supergroup. Simultaneous downregulation of epithelial
genes suggests epithelial-to-mesenchymal transition (EMT) [125].
Consistent with the finding of two distinct HPV-associated subtypes that show
different gene expression profiles and a different immune phenotype, differences
in survival between these two subtypes were as well identified – the IMS-HPV
subtype shows a trend towards improved survival in all the investigated datasets.
This further supports the validity of the classification into two biologically differ-
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ent HPV-associated subtypes.
A validation of the immune associated subtypes is provided through the investiga-
tion of CD8 mRNA expression. CD8 expression is elevated in both IMS subtypes
independent of anatomic location – evident when investigating oropharyngeal tu-
mors only – and independent of HPV status of the tumor. The identification
of two immune subtypes in HNSCC is an important finding given that immune
surveillance, i.e. host specific immune answer against cancer cells, is an important
mechanism to eliminate transformed cells [64] and immune escape/”avoiding im-
mune destruction” is an emerging hallmark of cancer [46]. Infiltration of the tumor
with T cells has been shown before in HNC and presence of CD8+ cytotoxic T cells
in tumor core and margin has been positively associated with survival – disease-free
survival and overall survival – in various tumors including HNC [30]. Consistently,
the IMS-HPV subtype shows improved survival compared to the CL-HPV subtype
and the IMS-nonHPV subtype shows the best survival of all HPV-negative sub-
types. Association with an immune phenotype/subtype has implications in the
clinical setting in a way that testing for tumor specific immune response might
be used to predict likelihood of disease recurrence or response to immunothera-
pies [30]. Accordingly, infiltration of the tumor with CD8+ cytotoxic T cells might
be used to predict HNC patients that may benefit from targeted immunothera-
pies, such as anti-programmed cell death protein 1 (PD1), and hence guide treat-
ment choices. PD1 is a receptor on activated T cells and binding of PD1-ligands
(PD-L1), expressed by tumor cells, leads to immunosuppression – thus anti-PD1
treatment restores T cell activity and exhibits anti-tumor activity in various tu-
mor types including lung SCC [131]. Preliminary results suggest that at least a
subset of HNC patients might benefit from anti-PD1 therapy [111]. Furthermore,
the presence of tumor infiltrating lymphocytes and PD-L1 was shown in HNSCC
and correlated with the IMS supergroup [107]. The subset of HPV-positive and
HPV-negative head and neck tumors with functional immune response (= T cell
inflamed phenotype (TCIP)) – shown by intratumoral CD8+ and PD-L1+ stain-
ing – constitutes a potential target for immune therapy with PD1 inhibitors [106],
whereas the basal subtype may represent a biomarker of non-TCIP tumors [152].
To summarize, a new classification for HNSCC was discovered by analyzing a
newly created HNSCC patient cohort (Agilent, n=134) together with several lit-
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erature derived cohorts (total number n=938). This resulted in the finding of five
HNSCC subtypes – BA, CL-HPV, CL-nonHPV, IMS-HPV, IMS-nonHPV – that
differ regarding survival outcome as well as expression profiles and copy number
aberrations. Importantly, two distinct HPV-associated subtypes were discovered
(CL-HPV, IMS-HPV). One immune supergroup consisting of two subtypes (IMS-
HPV, IMS-nonHPV) shows expression of immune response genes, which may make
it a suitable target for immune therapy with PD1 inhibitors. The BA supergroup
has a strong hypoxia and EGFR signaling profile and patients with BA head and
neck tumors might benefit from EGFR-targeting and hypoxia-targeting therapies.
4.2 Genomic Analysis
A cohort of 120 matched tumor/normal samples was analyzed integrating results
from next generation sequencing (NGS), Nanostring copy number assays, and
HPV testing to unravel the genomic differences between HPV-positive and HPV-
negative HNSCC. The 120 patients are part of the cohort created and analyzed for
the classification of HNSCC – a homogeneous cohort of locoregionally advanced
pre-treatment tumors with full clinical annotation and similar treatment regimens
of patients consisting of surgery, radiation, and chemotherapy.
HPV status of the samples was determined through HPV consensus testing. As de-
scribed before (see 2.3.10), HPV status was detected by HPV PCR for five high-risk
HPV types following methodology published by Sotlar et al. [121] and verified by
HPV16/HPV18 qPCR (Fluidigm microfluidics, performed by Genentech). These
results were further confirmed using p16 IHC (performed by the Department of
Pathology, University of Chicago) or CDKN2A mRNA expression (data from 3.1),
an HPV gene expression signature (unpublished, Dr. Zuo, based on data from
3.1) and TP53 mutational status [151]. HPV consensus testing allows to identify
HPV-associated tumor samples with a higher accuracy than either method by it-
self as HPV PCR may overcall and HPV qPCR may underreport HPV association
of the tumor and p16 IHC/CDKN2A mRNA expression is not reliable outside
the oropharynx [151]. 55.8% of oropharyngeal tumors were included in the co-
hort resulting in a total of 42.5% (n=51) HPV-positive tumors. The total sample
number and high proportion of HPV-positive tumors in this cohort is relevant in
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order to detect genomic differences between HPV-positive and HPV-negative tu-
mors and represents a major difference compared to other sequencing studies that
include fewer samples and/or HPV-associated cases [2, 124, 128]. The incidence
of HPV-positive HNC is rising [16, 115], however, little is known about the muta-
tional landscape of HPV-positive HNSCC or the difference between HPV-negative
and HPV-positive tumors, since meaningful studies including enough HPV-positive
samples are missing. Treatments that target specific mutations in HNSCC patients
comparable to EGFR mutations or ALK fusions in lung adenocarcinoma [53] do
not exist due to a lack of knowledge of the genomic profile of both HNSCC disease
entities. Instead all patients receive standard treatment – consisting of surgery, ra-
diation, and chemotherapy – based on stage and location of the tumor [3,96]. The
only clinically available targeted treatment is the anti-EGFR antibody Cetuximab,
which has a low single agent response rate (13% with 95% CI = 7%–21%) [109,137]
and is used without availability of predictive biomarkers.
Solid phase hybrid capture and subsequent sequencing of 617 cancer associated
genes was performed. In contrast to prior approaches that investigate the whole
exome or genome by sequencing [2,124,128], a selection of cancer associated genes
was chosen for target capture before sequencing allowing deep coverage of the in-
vestigated genomic regions. Sequencing data were analyzed to derive information
about somatic mutations and copy number aberrations. Mutations were validated
using a solution phase target capture approach. Copy number aberrations were
validated using the Nanostring copy number assay. The overall mutational burden
is similar in HPV-positive and HPV-negative HNSCC, which is contradictory to
prior smaller publications that report fewer mutations in HPV-associated than in
HPV-negative tumors [2, 124], but consistent with the results of the large TCGA
cohort of HNSCC [128]. The mutational spectrum differs in HPV-positive and
HPV-negative HNSCC and different genes and pathways are mutated. Interest-
ingly, genetic aberrations correlate more with HPV status than anatomic site of
the tumor, which indicates that HPV status is the determinant for genetic aber-
rations and thus tumor biology. The most frequently observed substitution events
are transitions and transversions at CpG sites, which are known to be associated
with exposure to tobacco smoke [68]. The second most frequently observed event
are mutations at Tp*Cp(A/C/T) sites that are enriched in HPV-positive samples
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and caused by innate immunity enzymes that are active in the context of viral in-
fections [68]. CpG transversions and TpC mutations were as well reported for the
TCGA HNSCC cohort, where they were found in HPV-negative and HPV-positive
samples respectively [128]. Genes that were found to have significant enrichment
for mutations (q-value < 0.1) in HPV-negative HNSCC are TP53, CDKN2A,
MLL2/3, NOTCH1, PIK3CA, NSD1, FBXW7, DDR2, and CUL3, most of which
are as well mutated in lung SCC [126] and HNSCC (TCGA cohort) [128]. Signifi-
cant enrichment for mutations in HPV-positive tumors was detected in PIK3CA,
MLL3, DDX3X, FGFR2/3, NOTCH1, NF1, KRAS, and FBXW7 with DDX3X,
CYLD, and FGFR being uniquely mutated in HPV-positive HNSCC.
Inactivating mutations in TP53 and CDKN2A as well as deletion of CDKN2A
occur mainly in HPV-negative tumors and were reported before in smoking asso-
ciated HNSCC and lung SCC [126,128]. In HPV-positive cancers the p53 and pRb
proteins are inactivated by HPV oncogenes E6 and E7 respectively [99]. Both inac-
tivation of CDKN2A (p16) and pRb causes the release of pRb bound transcription
factor E2F, which leads to cell cycle progression [99]. Interestingly, two HPV-
positive tumors were also found to have mutated TP53 (H179R and G361fs). Of
note, these belong to the 35% of HPV-positive patients that are heavy smokers
and have a significantly higher mutational burden. Although patients with HPV-
positive tumors have a better prognosis than patients with HPV-negative tumors,
tobacco use seems to alter the genetic profile of an HPV-positive tumor and lead
to a poorer prognosis in patients with > 10 pack-years of smoking [5]. The TP53
mutated HPV-positive tumors also harbor mutations in KRAS (G12D and L19F)
and PIK3CA (F872L), which suggests that multiple oncogenic drivers are relevant
in these tumors.
CN amplifications that are only present in HPV-negative HNSCC are well-known
cancer-associated amplifications of CCND1 (11q13), EGFR (7p12), and FGFR1
(8p11.23-p11.22), a result that is corroborated by the findings of the TCGA HN-
SCC cohort [128]. FGFR1 is a potential therapeutic target in FGFR1-amplified
lung SCC [75]. EGFR is frequently amplified in HPV-negative but not in HPV-
positive HNSCC [128, 147], it is targetable and clinically relevant drugs (Cetux-
imab) are already approved in HNSCC care, however, biomarkers to identify pa-
tients that will benefit from anti-EGFR therapy remain to be identified [137]. In
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HPV-positive HNSCC the viral oncoprotein E5 interacts with the EGF receptor
by interfering with its degradation, which leads to increased levels of EGFR in
the cell membrane [99]. CCND1 amplification is a common event and a potential
therapeutic target in HNSCC [128,145]. Cell cycle inhibitors (cyclin-dependent ki-
nase 4/6 (CDK4/6) inhibitors) to be used in the context of CDKN2A inactivation
and CCND1 amplification are available [145]. The 3q26-28 region, which contains
SOX2, TP63, and PIK3CA, is amplified in both HPV-positive and HPV-negative
tumors. SOX2 and TP63 are involved in squamous cell differentiation and both
harbor somatic alterations in lung SCC [126]. Amplification of SOX2 was shown to
be oncogenic in lung SCC [52]. Besides being amplified, the oncogene PIK3CA is
the most commonly mutated gene, which harbors numerous mutations (including
the canonical mutations E542K, E545K, and H1047R) and might represent an im-
portant therapeutic target or co-target in both HPV-negative and HPV-positive
HNSCC [123]. Enrichment for PI3K pathway alterations that are predicted as
oncogenic drivers such as somatic mutations in PIK3CA, PIK3R1, PTEN, TSC1,
TSC2, and NF2 is present in HPV-positive tumors. Further somatic events that
are of interest are aberrations in the FGFR pathway, which, besides the described
amplification of FGFR1 in HPV-negative HNSCC, harbors activating mutations
in FGFR2/3 (FGFR2 N569K, FGFR3 S249C) in HPV-positive HNSCC. These ex-
hibit low CHASM scores predicting them to be oncogenic drivers. FGFR3 S249C
is recurrent in six tumors (12% of the HPV-positive tumors, 6 out of 51) in this
cohort. Furthermore, FGFR3 S249C was identified as a potential therapeutic tar-
get in bladder carcinoma and other cancers [14,44,75,80,129] and is targetable by
multiple clinically relevant FGFR inhibitors [25,44]. While a trend towards better
survival of patients with FGFR3 S249C mutated tumors is seen when analyzing
HPV-positive HNSCC only, analysis is limited because of the small sample size (6
tumors contain FGFR3 S249C) and results do not reach statistical significance.
When comparing FGFR3 expression within HPV-positive HNSCCs, FGFR3 ex-
pression is higher in samples harboring the S249C mutation as compared to FGFR3
WT samples, which underlines the importance of functional validation to investi-
gate FGFR3 as a potential target in HNSCC.
More mutated genes and pathways are identified in this HNSCC cohort. Muta-
tions in the histone-modifying genes MLL2 and MLL3 are present in HPV-positive
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and HPV-negative tumors and were as well identified in the TCGA HNSCC co-
hort [128] and in other cancers [41, 86, 97], including lung SCC [126], in which
MLL2 mutations are associated with poor survival outcome [65]. Mutations in
CUL3 and NFE2L2 (NRF2) are identified primarily in HPV-negative HNSCC.
CUL3 is involved in the degradation of NRF2, which is mediated via the adapter
molecule KEAP1 [55]. Mutations in all three genes were detected recently in lung
SCC and HNSCC [126, 128] and mutations of NRF2 were associated with poor
outcome in lung SCC [65]. The NRF2/KEAP1 pathway is a defense pathway that
is activated in response to oxidative stress and evidence suggests that NRF2 can
act as both a tumor suppressor and an oncogene [55]. DDX3X is only mutated in
HPV-positive tumors. The RNA helicase DDX3X is involved in β-catenin signal-
ing and was shown to be mutated in medulloblastoma [97]. A further gene that is
mutated in HPV-positive tumors is CYLD. Degradation of CYLD deubiquitinase
plays a role in HPV oncoprotein E6-mediated activation of NF-κB in response to
hypoxia in squamous cell carcinomas [4]. Infrequent HRAS, KRAS, and NRAS
mutations are present in both HPV-positive and HPV-negative tumors. This is
of interest, since RAS mutations are implicated in resistance to EGFR-targeting
tyrosine kinase inhibitors in non small cell lung cancer (NSCLC) [83]. Albeit at a
low frequency, canonical RAS mutations were described before in HNSCC (HRAS,
KRAS) [69,128] and lung SCC (KRAS, HRAS) [126]. Alterations in genes involved
in DNA repair/the DNA damage pathway such as BRCA1, BRCA2, FANCG,
FANCA, FANCD2, and ATM were predominantly identified in HPV-positive tu-
mors in non-smokers/light smokers and may represent a mechanism to accumulate
genomic aberrations in this non-smoking subset of patients.
In summary, HPV status is a determinant for tumor biology as genetic aber-
rations correlate more with HPV status than anatomic site of the tumor. The
mutational burden is similar, but the mutational spectrum differs in HPV-positive
and HPV-negative HNSCC, which may be one explanation for the distinct biolog-
ical and clinical behavior, for instance regarding response to therapy or prognosis.
Potentially targetable mutations and copy number aberrations are identified and
predicted as oncogenic drivers in PIK3CA, PI3K pathway genes, FGFRs, and fur-
ther genes. The oncogene PIK3CA is amplified and frequently mutated in both
HPV-negative and HPV-positive HNSCC. EGFR, CCND1, and FGFR1 amplifi-
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cations are found in HPV-negative tumors and DDX3X, CYLD, and FGFR2/3
mutations are identified in HPV-positive tumors including FGFR3 S249C, which
is recurrently mutated in 12% of the HPV-positive tumors. Some of the detected
aberrations are of high translational relevance and represent potential therapeutic
targets that will have to be explored and validated further in the future, such as
rare aberrations (DDR2 and EPHA2) or candidate biomarkers (HRAS and KRAS).
This is especially important as there is a lack of targeted therapies for HNSCC and
to date, patients are treated uniformly with a combination of surgery, radiation
and chemotherapy.
4.3 Functional Validation
To date, no targeted therapies are available for the treatment of HNSCC – be-
sides the monoclonal EGFR (epidermal growth factor receptor) antibody Cetux-
imab that shows a low single-agent response rate (13% with 95% CI = 7%–21%)
and is used in palliative and curative care [109, 137] – and patients are treated
uniformly with a combination of surgery, radiation, and chemotherapy [96]. Be-
sides PIK3CA, a well-known oncogene, FGFR3 S249C was detected as the most
frequent mutation in HPV-positive HNSCC with an occurrence of 12% of the
HPV-positive tumors (6 out of 51) in this cohort [110]. Furthermore, FGFR3
expression levels were increased in HPV-positive samples carrying the mutation
FGFR3 S249C as compared to HPV-positive samples with wild type FGFR3 (see
chapter 3.2.9). HPV-positive tumors generally have a more favorable prognosis
than HPV-negative tumors and the incidence of HPV-positive HNSCC is increas-
ing [16,115]. It is estimated that by 2030 approximately 47% of all head and neck
cancers will be oropharyngeal squamous cell carcinomas (OPSCC) and that by
2020 at least 70% of all OPSCCs will be HPV-positive [16]. A therapy, which be-
sides conventional treatment approaches is targeting specific genomic alterations
in HPV-positive HNSCC, would therefore be beneficial for an increasing number of
patients and would eventually allow to reduce treatment intensity and thus nega-
tive side effects of chemoradiotherapy for this better prognosis subgroup [67]. The
identification of FGFR3 S249C as an oncogenic mutation and a potential thera-
peutic target in bladder cancer [14, 129], cervical cancer [14], and lung squamous
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cell carcinoma [75] as well as the availability of clinically important FGFR in-
hibitors such as the monoclonal antibody R3Mab [44], or BIBF1120 (nintedanib),
BGJ398 (a selective inhibitor of FGFR1-3), and other small-molecule tyrosine ki-
nase inhibitors [25], additionally provide a strong rationale for investigating the
oncogenic potential of FGFR3 S249C in HNSCC.
The relevant isoforms of FGFR3 containing the S249C mutation as well as ap-
propriate controls were transfected into two HPV-positive HNSCC cell lines to
investigate the oncogenic properties of FGFR3 S249C – the two cell lines were
confirmed to show low expression of wild type FGFR3. Proliferation, wound heal-
ing abilities, and FGFR3 signaling were investigated. In this context, to further
study FGFR3 in HNSCC, the entire cohort of available HNSCC samples (n = 136
– 59 HPV-positive, 77 HPV-negative – comprises the 120 samples used for genomic
analysis of HNSCC plus 16 additional samples) was screened for presence of the
oncogenic FGFR3/TACC3 fusion gene, which was recently discovered in multiple
tumor types (see 1.2.4).
The presence of the S249C mutation in exon 7 of FGFR3 discovered in six HPV-
positive Head and Neck tumors by NGS (see 3.2) and its expression were confirmed
by direct sequencing of DNA (both strands) and cDNA (one strand) respectively.
Analysis of the sequencing data shows a heterozygous mutation and expression of
the wild type (WT) as well as the mutated allele in the tumor samples (tumor con-
tent ranging between 60% and 90%). Expression of mainly the mutated allele in
the one sample with the highest tumor content (90%) indicates that the sequencing
data showing the wild type allele might stem from admixture with normal tissue
and that tumor cells might only express the mutated allele as shown for example
for FGFR3 mutations in multiple myeloma cell lines [102]. Absence of the FGFR3
S249C mutation was shown in the two HPV-positive HNC cell lines chosen for
functional validation (SCC47 and 93VU147T).
Little is known about the functional role of FGFR3 mutations in HNSCC and the
expression pattern of the different FGFR3 isoforms. One study found a poten-
tially oncogenic mutation in the IIIb isoform of FGFR3 at position 697 (G697C)
in oral squamous cell carcinomas [150]. Here in this study, sequencing of cDNA
of the six tumor samples with mutated FGFR3 and the two WT cell lines SCC47
and 93VU147T showed that the main FGFR3 isoforms expressed in HNC pri-
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mary tumors as well as cultured cells are FGFR3 IIIb and FGFR3 ∆8-10 and that
FGFR3 IIIc is virtually not expressed. This result was not unexpected since HNC
develops in epithelial cells of the upper aerodigestive tract [103] and expression
of the different isoforms of FGFR1–3 has been shown to be tissue specific with
FGFR1–3 IIIb being expressed in epithelial cells and FGFR1–3 IIIc being the pre-
dominant isoform in mesenchymal cells [7] [37,139]. An oncogenic switch from the
IIIb isoform to the IIIc isoform of the FGF receptor 3 as reported for some bladder
cancer cell lines [130] does not seem to occur in HNC. This oncogenic switch is
associated with more aggressive tumors, probably as it changes the ligand binding
spectrum of a cell and hereby enables binding of a broader range of ligands as well
as autocrine stimulation [50, 130]. FGFR3 ∆8-10 is a soluble isoform of FGFR3
that has previously been identified in normal and in cancer cells [54, 130]. Evi-
dence suggests that the FGFR3 ∆8-10 splice variant might function as a negative
regulator of FGFR3 signaling which is expressed in normal proliferating urothelial
cells and downregulated in bladder cancer [130]. Here, FGFR3 ∆8-10 was shown
to be a major transcript in HNSCC tumors and cell lines besides FGFR3 IIIb, but
it has to be noted that expression levels were not compared with normal tissue
and thus it is unknown, if FGFR3 ∆8-10 is expressed more abundantly in normal
tissue than in HNC cells.
Oncogenic and inhibitor sensitive gene fusion events involving FGFR3 and trans-
forming acidic coiled-coil 3 (TACC3) were recently discovered in multiple cancers
including bladder cancer [127, 142], glioblastoma [117], lung adenocarcinoma [13],
lung squamous cell carcinoma [65, 80], nasopharyngeal carcinoma and esophageal
squamous cell carcinoma [148], and HNSCC [128,144]. Since the FGFR3/TACC3
fusion occurs in various solid tumors and potentially plays a role in HNSCC as
well, the entire cohort of 136 HNSCC patient specimens was examined via RT-
PCR for the FGFR3/TACC3 fusion to add to the investigation of FGFR3 as a
therapeutic target. However, the FGFR3/TACC3 fusion was not detected in any
of the 136 HNSCC samples screened. The recently published results of the TCGA
HNSCC study support the hypothesis that this could be due to a rare occurrence
of the fusion in HNSCC as they found the FGFR3/TACC3 fusion in two out of
279 samples (2 out of 36 HPV-positive tumors) [128]. A similar finding was as well
described for lung adenocarcinoma where the incidence is 0.5% [13].
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Since the FGFR3/TACC3 fusion was not detected in this HNSCC sample cohort,
only the FGFR3 S249C mutation, which had been identified in six HPV-positive
HNC tumors, was chosen for functional validation in the HPV-positive HNC cell
lines SCC47 and 93VU147T. SCC47 and 93VU147T were shown to express the
wild type receptor and the same FGFR3 isoforms as the tumor samples. Low
expression of endogenous FGFR3 on the protein level was confirmed by Western
Blot in both cell lines. Cells were stably transfected with the different FGFR3
isoforms, namely FGFR3 IIIb and FGFR3 ∆8-10, containing the S249C mutation
and adequate WT and empty vector controls to evaluate the effects on prolifera-
tion, migration, and FGFR3 signaling.
A resazurin based viability assay was performed to investigate the phenotypic con-
sequences of mutated FGFR3 on cell proliferation. An increased proliferation rate
was calculated for SCC47 cells transfected with FGFR3 IIIb WT compared to the
empty vector control and also compared to the three other clones (FGFR3 IIIb
S249C, FGFR3 ∆8-10 WT, FGFR3 ∆8-10 S249C). This effect was not seen in
93VU147T cells, where a difference in proliferation rate reached statistical sig-
nificance for each clone in one out of three experiments (two out of three for
FGFR3 IIIb S249C, but one time cells grew slower and one time cells grew faster).
Although more data would be needed to confirm these results, this data indicates
that the different clones most likely have no substantial effect on the proliferation
rate of 93VU147T cells, but FGFR3 IIIb WT increases proliferation rate in SCC47
cells.
The in vitro scratch assay was used to examine the effects of mutated FGFR3
on cell migration. Results for both cell lines are inconsistent and do not reach
statistical significance for all three runs of the experiment. SCC47 cells show a
trend towards a faster migration rate when transfected with the empty vector as
compared to any of the FGFR3 clones. However, differences are rather subtle and
only significant in two out of three experiments. ANOVA results indicate no effect
of the different FGFR3 clones on migration rate of 93VU147T cells in two out
of three experiments. Only in one experiment, 93VU147T cells transfected with
FGFR3 ∆8-10 S249C closed the wound slower and 93VU147T cells transfected
with FGFR3 IIIb S249C closed the wound faster as when transfected with the
empty vector.
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Mutations in FGFR3 have been reported in oral squamous cell carcinoma [150],
bladder cancer, cervical cancer, multiple myeloma, prostate cancer, and sperma-
tocytic seminoma, but also in benign tumors like seborrhoeic keratosis or urothe-
lial papilloma [8, 133]. Therefore, the importance of FGFR3 mutations and the
different FGFR3 isoforms in carcinogenesis is not yet fully understood. While dif-
ferent FGFR3 IIIc mutations were reported to be oncogenic in multiple myeloma
as well as transforming in NIH-3T3 cells [102], the situation is less clear for the
mutated IIIb isoform and different possibilities have been discussed for the role
of FGFR3 IIIb S249C. The fact that FGFR3 IIIb S249C is frequently found in
benign tumors such as seborrhoeic keratosis or urothelial papilloma suggests low
oncogenic potential [8]. In one study FGFR3 IIIb S249C was found in seborrhoeic
keratosis, but absent in epidermal carcinomas, and induced benign skin tumors
when expressed in the epidermis of transgenic mice [78]. However, FGFR3 IIIb
was also found mutated in bladder cancer and cervical cancer with S249C being
the most common mutation [14]. It was shown that FGFR3 IIIb S249C expression
led to a higher proliferation rate and anchorage independent growth in NIH-3T3
cells and induced tumor growth in nude mice, but was not oncogenic in the T24
bladder cancer cell line in vitro or in vivo [8]. On the contrary, knockdown of
FGFR3 IIIb S249C in the bladder cancer cell line 97-7 led to decreased prolifer-
ation, decreased colony formation, and decreased anchorage independent growth,
which suggests an oncogenic role for FGFR3 IIIb S249C in at least a subset of
bladder carcinomas [129]. Here in this study, the different clones (FGFR3 IIIb
WT and S249C, FGFR3 ∆8-10 WT and S249C) did not show any clear effect on
proliferation rate or migration rate when transfected into SCC47 and 93VU147T
cells with the one exception that FGFR3 IIIb WT may increase proliferation rate
in SCC47 cells.
Expression of the S249C mutation does not confer any growth advantage to the
investigated HNSCC cell lines SCC47 and 93VU147T, which is consistent with
the findings for bladder cancer cell line T24 [8], but not with the results for 97-
7 [129]. This means that even in a similar context – both T24 and 97-7 are bladder
cancer cell lines – mutated FGFR3 can exhibit different phenotypic consequences,
probably depending on the genetic makeup of the respective cell lines or tumors.
Here in this study, increased proliferation was found for SCC47 transfected with
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FGFR3 IIIb WT but not with FGFR3 IIIb S249C. It was shown in NHU-TERT
(telomerase-immortalized normal human urothelial) cells that expression of wild
type FGFR3 IIIb can lead to increased cell proliferation [130]. As reported in an-
other study, overexpression of FGFR3 in thyroid carcinoma cells did not increase
proliferation rate, but seemed to be involved in contact inhibition, since it caused
overgrowth of confluent cultures [92]. The reason why expression of the wild type
but not the mutated IIIb isoform of the receptor leads to increased cell prolifer-
ation in HNSCC cells remains to be investigated. An inhibitory role of activated
FGFR3 as reported for congenital skeletal disorders [71] could be possible. In gen-
eral, the effects of FGFR activation are diverse – proliferation, migration, but also
differentiation or cell cycle arrest – and the situation is complex and dependent
on tissue specific context [133]. Therefore, the FGFR3 S249C mutation should
be further characterized in HNSCC cells. Effects of S249C on proliferation and
contact inhibition, migration, and anchorage-independent growth should be inves-
tigated by transfecting further HNSCC cell lines as well as normal oral epithelial
cells (keratinozytes). The effects of FGFR3 inhibition and the effectiveness of dif-
ferent FGFR inhibitors should be investigated in HNSCC cell lines derived from
tumors already containing the mutation. Continued studies will need to address
the possible involvement of FGFR3 in the resistance to multiple targeted drugs –
specifically EGFR inhibitors in HNSCC [25].
Two different possibilities for the involvement of FGFRs in cancer progression
have been described in the literature – altered (autocrine or paracrine) ligand-
dependent signaling and constitutive receptor activation [25]. Here, the latter was
investigated first, the effects of constitutive receptor activation by mutation on
downstream signaling pathways. Secondly, it was examined if the introduced mu-
tation leads to enhanced ligand-dependent phosphorylation of downstream targets
and activation of pathways.
Basic signaling without prior stimulation as well as the effects of stimulation with
FGF1 on different downstream pathways (MAPK, PI3K/Akt, PLCγ1, STAT) in
WT and S249C mutant clones of the different isoforms of FGFR3 were investi-
gated in SCC47 cells. No consistent difference in basic signaling compared to the
empty vector was detected, i.e. none of the clones seem to have one of the inves-
tigated FGFR3 downstream pathways constitutively activated in all three repeats
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of the experiment. However, Erk1/2 and Akt phosphorylation were detected in
one of three experiments suggesting that further investigation with adjusted cell
culture conditions might be worthwhile. Evidence that culture conditions, i.e. pas-
sage number and confluence, are of importance and influence FGFR3 mRNA and
protein levels was shown by Tomlinson et al. [130]. The cells used here were of
different passages (however passage number was kept within a small scope) and
harvested at subconfluence.
Little information is available about the oncogenicity – or even the existence – of
the mutated ∆8-10 isoform of FGFR3. WT FGFR3 ∆8-10 is expressed in normal
human urothelial cells. It is secreted and supposedly acts as a ligand trap that
dimerizes and sequesters FGF1 thereby inhibiting binding of FGF1 to its recep-
tor [130]. Transfection of SCC47 with FGFR3 ∆8-10 WT should therefore result
in reduced signaling activity compared to the other FGFR3 clones. The effects
of the S249C mutation on the signaling activity of FGFR3 ∆8-10 are difficult
to predict and should be investigated more extensively. Here in this study, both
FGFR3 ∆8-10 WT and FGFR3 ∆8-10 S249C did neither show constitutive acti-
vation of downstream pathways nor enhanced or reduced signaling activity upon
stimulation compared to the other clones and the empty vector control in a con-
sistent manner. FGFR3 IIIb S249C was shown to induce constitutive receptor
phosphorylation in urothelial cells [129]. However in this study here, expression
of mutant or WT FGFR3 did not lead to constitutive activation of downstream
pathways in SCC47 cells and signaling activity was not detected without addition
of exogenous ligand. Similar to other studies in bladder cancer [44], the MAPK
and PI3K/Akt pathways were activated upon stimulation with FGF1 in all the
differentially transfected SCC47 clones, but no activation of STAT1, STAT3 or
PLCγ1 was detected. Differences in phosphorylation between the different clones
are not consistent in all three experiments.
There are few studies that investigated FGF/FGFR signaling in HNSCC and these
mainly focused on the MAPK pathway [82,118], but no extensive investigation of
FGF/FGFR signaling and pathway activation in HNSCC cell lines exists. The
results obtained here suggest that the MAPK and the PI3K/Akt pathway are the
two important signaling pathways downstream of FGFR3 in HNSCC.
Even though mutated FGFR3 does not seem to constitutively activate downstream
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signaling pathways in the investigated HNSCC cell line, further cell lines should
be added to the investigation. As described above for two different bladder can-
cer cell lines (T24 and 97-7), the S249C mutation can confer oncogenicity and
display transforming properties in one setting, but not in another very similar
context [8, 129]. Its potential to act as an oncogenic mutation in other cancers
and its relatively high prevalence (12%) in HPV-positive HNSCC indicate that
FGFR3 S249C might be oncogenic in a subset of HNSCC tumors and suggest that
further investigation is advisable – especially regarding the circumstance that no
targetable, oncogenic mutations are validated in HNSCC and no approved thera-
pies are linked to genetic alterations as predictive biomarkers [110].
Recent results show that the activation of multiple RTKs may be required to drive
tumor growth and survival in HNSCC [82, 118]. Activation of the FGFR/FGF
signaling axis may be responsible for resistance to chemotherapy via pro-survival
pathways such as PI3K/Akt [133]. Evidence further suggests that upregulation
of FGFR3 is involved in resistance mechanisms leading to relapse during antian-
giogenic anti-VEGF (vascular endothelial growth factor) therapy in HNSCC and
that dual targeting of FGFR and VEGF may help overcome resistance [45]. Clin-
ical response to the EGFR antibody cetuximab cannot be predicted by EGFR
protein expression or EGFR copy number status [82]. Marshall et al. hypothesize
that the low response rate of HNSCC to inhibition of EGFR may be due to ac-
tivation of alternative RTKs and propose concurrent EGFR and FGFR mediated
growth in a subset of HNSCC cell lines [82]. The two HNSCC cell lines SCC47
and 93VU147T exhibit differential sensitivity to the EGFR inhibitor Gefitinib (see
A.3, cell line sensitivity data were obtained through the Cellular Screening Center
at the University of Chicago and analyzed by Johannes Bra¨gelmann) with SCC47
showing modest sensitivity (IC50 ≈ 5.1µM) and 93VU147T being comparatively
sensitive (IC50 ≈ 0.1µM). Sensitivity to Gefitinib remains to be tested in SCC47
and 93VU147T cells transfected with the different mutant and WT isoforms of
FGFR3 to examine the potential of mutant FGFR3 to confer resistance to EGFR
inhibition.
To summarize, FGFR3 S249C does not show an effect on proliferation and migra-
tion rate in the investigated cell lines and does not lead to constitutively activated
FGFR3 signaling or altered activation of FGFR3 downstream pathways upon stim-
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ulation with FGF1. With respect to the role of FGFR3 S249C in other cancers,
further investigation of its possible role as an oncogenic driver or co-driver as well
as its involvement in resistance mechanisms is indicated.
Chapter 5
Conclusion
A novel classification of HNSCC is proposed based on expression profiling of a
homogeneous, clinically annotated cohort of 134 HNSCC tumor samples and com-
prehensive analysis together with several literature derived cohorts (total number
n=938). A comparatively high proportion of oropharyngeal specimens in the co-
hort of 134 samples asserts a balanced representation of HPV-positive (n=59)
and HPV-negative cases (n=75). Two distinct HPV-positive subtypes are iden-
tified – CL-HPV and IMS-HPV – that differ regarding expression of immune re-
sponse genes. Furthermore, three HPV-negative subtypes are discovered – BA,
CL-nonHPV, and IMS-nonHPV – that show differential biology – BA with hy-
poxia and EGFR signaling profile, CL-nonHPV with increased proliferation, IMS-
nonHPV with an immune phenotype. All five subtypes exhibit different prognosis
underlining the clinical implications of the proposed taxonomy. Genomic analysis
of 120 out of the 134 samples shows a distinct mutational profile for HPV-positive
and HPV-negative HNSCC that correlates with HPV status and highlights the
importance to differentiate between HPV-negative and HPV-associated HNSCC.
Potentially targetable aberrations are identified in multiple genes among which is
FGFR3, that is recurrently mutated in six out of 51 HPV-positive tumors (FGFR3
S249C) representing the most frequently mutated gene in HPV-positive tumors be-
sides PIK3CA. Functional validation of FGFR3 S249C does not show an effect on
proliferation and migration rate or FGFR3 signaling in HNSCC cell lines.
Important clinical implications of the identified subtypes and aberrations exist.
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The proposed taxonomy identifies two immune subtypes that may represent a
biomarker for immune therapy with PD1 checkpoint inhibitors that show benefi-
cial effects in patients that exhibit a strong host immune response [79]. Patients in
the BA supergroup may respond to EGFR-targeting and hypoxia-targeting ther-
apies and BA subtype may represent the missing biomarker to identify patients
that benefit most from the set of already existing anti-EGFR therapies that so
far show moderate success in patients [109]. BA subtype may as well be used to
identify patients that are at risk to show radioresistance due to the hypoxic profile
of the tumor. This information may be used to adjust existing therapy options
or to apply hypoxia targeting agents, e.g. HIF1α inhibitors, in combination with
conventional therapy to increase radiosensitivity and improve outcome [1]. The
identified targetable mutations and copy number aberrations may represent onco-
genic drivers of HPV-negative or HPV-positive HNSCC or both. Targeted agents
that are already used or being explored for the treatment of other solid tumors
should as well be tested for their efficacy in HNSCC, e.g. drugs targeting FGFR
in FGFR1-amplified HPV-negative HNSCC. Treating FGFR3 S249C mutated tu-
mors with FGFR inhibitors may prove useful in combination with other targeted
agents.
With the upcoming of genome wide screening technologies and the development of
numerous targeted agents in addition to conventional treatment regimens, a new
era of cancer treatment has started that, despite promising results in some pa-
tients, is still facing enormous challenges. The identification of biomarkers linking
genomic aberrations to specific targeted therapies will be the main challenge for
the near future and will be key to successful cancer care.
Chapter 6
Summary
Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous disease re-
garding both anatomic location and molecular characteristics. It is comprised of
two distinct disease entities – human papillomavirus (HPV)-positive and HPV-
negative HNSCC – that differ regarding primary site of disease as well as aeti-
ology/pathogenesis. Persistent infection with high-risk HPV is causally related
to oropharyngeal HNSCC, whereas tobacco and alcohol consumption are linked to
the development of HPV-negative head and neck cancers. HPV-positive and HPV-
negative HNSCC differ regarding their clinical behavior/response to therapies as
well as prognosis with HPV-positive tumors being associated with a more favorable
prognosis than HPV-negative tumors. However, besides Cetuximab, a monoclonal
antibody against the epidermal growth factor receptor (EGFR), which is used
in palliative and curative care with modest success as no predictive biomarkers
have been identified, no targeted treatments are available that consider the bio-
logic heterogeneity and no classification is used in clinical practice that reflects
the underlying biology of the disease. As a consequence, all patients are treated
uniformly with a combination of surgery, radiation, and chemotherapy depending
on stage and location of the tumor.
In this study, a homogeneous (regarding tumor stage and treatment) and clini-
cally annotated cohort of 134 treatment-na¨ıve HNSCC specimens, including 59
HPV-positive samples (44%), were processed, subjected to Agilent 4X44Kv2 gene
expression arrays and Nanostring copy number assays, and analyzed together with
all available HNSCC cohorts (n=938). As a result, a clinically meaningful classifi-
cation was identified for HNSCC – which was hampered in previous studies due to
a limited inclusion of HPV-positive samples or unknown HPV status, small sample
size, and missing clinical annotation. Three HNSCC supergroups were identified –
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basal (BA), classical (CL), inflamed/mesenchymal (IMS) – and further subdivided
by HPV status into five HNSCC subtypes – BA, CL-HPV, CL-nonHPV, IMS-
HPV, IMS-nonHPV – that differ regarding survival and show different expression
profiles and copy number (CN) aberrations. Importantly, two HPV-associated
subtypes with different molecular profile and prognosis were identified – CL-HPV
and IMS-HPV. The IMS subtypes show a strong immune phenotype with expres-
sion of immune response genes and may benefit from immune therapies such as
programmed cell death protein 1 (PD-1) inhibitors. The BA supergroup/subtype
shows markedly increased expression of EGFR and hypoxia related genes, which
might render these tumors susceptible to EGFR-targeting and hypoxia-targeting
therapies.
Besides differences regarding their biological and clinical behavior, HPV-positive
and HPV-negative HNSCC show a distinct mutational landscape. The incidence
of HPV-positive tumors is rising, however, studies are missing that investigate a
sufficient number of HPV-positive tumors to derive meaningful information and
assign targetable genomic changes to either disease entity. 120 (51 HPV-positive,
69 HPV-negative) out of the cohort of 134 samples were further used to build
DNA sequencing libraries and processed to next generation sequencing (NGS)
on the Illumina platform (Illumina HiSeq 2000/2500 sequencers) to detect novel
and/or targetable genomic changes. The overall mutational burden is similar in
both disease entities, however, the mutational landscape differs. In addition to
known aberrations, novel targetable aberrations with predicted driver potential
are identified in various genes, among which are EGFR, CCND1, and FGFR1 in
HPV-negative tumors, and FGFR2/FGFR3, KRAS, BRCA1/2 in HPV-positive
tumors, as well as PIK3CA and PI3K pathway genes in both and rare aberrations
in DDR2 and EPHA2. The fibroblast growth factor receptor 3 (FGFR3) S249C
mutation is recurrently found in six HPV-positive tumors, which makes FGFR3
the second most mutated gene in HPV-positive tumors – after the well-known
oncogene PIK3CA.
Therefore, functional validation of FGFR3 S249C was performed in vitro in the
two HNSCC cell lines SCC47 and 93VU147T. Two different FGFR3 isoforms were
identified in all six FGFR3 mutated HNSCC tumor samples – FGFR3 IIIb and
the soluble FGFR3 ∆8-10. Both isoforms were used to stably transfect the S249C
222 CHAPTER 6. SUMMARY
mutation into SCC47 and 93VU147T and to study its effects on proliferation and
migration (both cell lines) as well as FGFR3 signaling (only SCC47). No effect on
proliferation or migration rate is seen beyond an increase in proliferation rate in
SCC47 cells transfected with wild type (WT) FGFR3 IIIb. No constitutive activa-
tion of downstream pathways is seen in unstimulated SCC47 cells. Investigation of
different downstream signaling pathways identifies the MAPK and the PI3K/Akt
pathway as the two important signaling pathways downstream of FGFR3 in HN-
SCC cell lines. FGFR3 S249C cannot be confirmed as an oncogenic driver in
SCC47 and 93VU147T. However, its possible role as an oncogenic co-driver be-
sides other receptor tyrosine kinases and its function in drug resistance mechanisms
– especially resistance to EGFR inhibitors – remain to be investigated.
Chapter 7
Zusammenfassung
Plattenepithelkarzinome im Kopf- und Halsbereich (head and neck squamous cell
carcinoma – HNSCC) umfassen eine Gruppe heterogener Tumoren, sowohl hin-
sichtlich ihrer anatomischen Lokalisation als auch ihrer molekularen Eigenschaften.
Sie werden differenziert in human papillomavirus (HPV)-positive und HPV-negative
Karzinome, welche an verschiedenen Stellen im Kopf-Hals-Bereich auftreten und
unterschiedliche Risikofaktoren aufweisen. Persistierende Infektionen verursacht
durch high-risk HPV begu¨nstigen die Entstehung von Plattenepithelkarzinomen
im Oropharynx, Tabak- und Alkoholkonsum sind Risikofaktoren fu¨r HPV-negative
Kopf- und Halstumoren. Die Unterscheidung in HPV-positive und HPV-negative
Tumoren spiegelt sich klinisch sowohl im unterschiedlichen Ansprechen auf eine
entsprechende Therapie als auch in der gu¨nstigeren Prognose fu¨r HPV-positive
Kopf- und Halstumoren wider. Der monoklonale, gegen den epidermal growth
factor receptor (EGFR) gerichtete Antiko¨rper (anti-EGFR) Cetuximab ist derzeit
die einzige zugelassene zielgerichtete Therapie zur palliativen als auch kurativen
Behandlung von Kopf- und Halstumoren. Cetuximab wird mit ma¨ßigem Erfolg
eingesetzt, da bislang keine Indikatoren bekannt sind, die fu¨r eine Therapie mit
Cetuximab geeignete Patienten identifizieren ko¨nnen. Daru¨ber hinaus gibt es
weder zielgerichtete Therapien noch eine Klassifikation, die die molekulare Het-
erogenita¨t der Erkrankung beru¨cksichtigen. In der Folge werden alle Patienten in
Abha¨ngigkeit der Ergebnisse des Staging sowie der Lokalisation des Tumors meist
mit einer Kombination aus Chemotherapie und Bestrahlung behandelt und einem
chirurgischen Eingriff unterzogen.
Eine homogene und klinisch dokumentierte Kohorte bestehend aus Tumorproben
von 134 unbehandelten HNSCCs, davon 59 HPV-positive Tumoren (44%), wurde
mittels Agilent 4X44Kv2 gene expression arrays und Nanostring Copy Number
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Assays untersucht und zusammen mit bereits vorhandenen HNSCC Daten aus-
gewertet (n=938). Im Gegensatz zu bereits publizierten kleineren Studien mit
unzureichender klinischer Dokumentation sowie einem geringem Anteil von HPV-
positiven Tumoren, ergibt sich hierdurch eine klinisch relevante Klassifikation
von Kopf- und Halstumoren in drei Hauptgruppen – basal, classical, inflamed/
mesenchymal (BA, CL, IMS) – welche anhand ihres HPV Status in fu¨nf Unter-
gruppen unterteilt werden ko¨nnen (BA, CL-HPV, CL-nonHPV, IMS-HPV, IMS-
nonHPV). Diese unterscheiden sich hinsichtlich ihrer jeweiligen Prognose, ihrer
Genexpression und Gen-Kopienzahl. Ein wichtiges Ergebnis ist die Identifizierung
von zwei verschiedenen HPV-positiven Untergruppen (CL-HPV und IMS-HPV),
die deutliche Unterschiede bezu¨glich ihres molekularen Profils und ihrer Prognose
aufweisen. Expression von immune-response-Genen in Tumoren der IMS Unter-
gruppen ist mo¨glicherweise ein Biomarker fu¨r das Ansprechen auf Immunthera-
pien mit programmed cell death protein 1 (PD-1) Inhibitoren. U¨berexpression
von EGFR und hypoxie-induzierten Genen ist charakteristisch fu¨r die BA Haupt-
bzw. Untergruppe und ko¨nnte ein Indikator fu¨r die Wirksamkeit von Therapien
sein, die gegen EGFR und Hypoxie gerichtet sind.
HPV-positive und HPV-negative Tumoren weisen Unterschiede bezu¨glich ihrer Bi-
ologie, ihres klinischen Erscheinungsbildes und der fu¨r sie charakteristischen Mu-
tationen auf. Trotz eines Anstiegs der Inzidenz der auf HPV zuru¨ckzufu¨hrenden
Tumoren gibt es bislang keine Studien, die eine hinreichende Anzahl von HPV-
positiven Tumoren untersuchen, um aussagekra¨ftige Informationen abzuleiten sowie
behandelbare Vera¨nderungen im Genom von HPV-positiven bzw. -negativen Tu-
moren zu identifizieren. DNA sequencing libraries von 120 Tumoren (51 HPV-
positive, 69 HPV-negative) aus der im ersten Teil untersuchten Kohorte von 134
Tumorproben wurden sequenziert (Illumina HiSeq 2000/2500 Sequenzierer), um
neue und behandelbare genomische Vera¨nderungen zu identifizieren. Wa¨hrend die
Anzahl der Mutationen in beiden HNC-Arten a¨hnlich ist, unterscheiden sich diese
hinsichtlich der Art der genomischen Vera¨nderungen. Es wurden sowohl bere-
its bekannte als auch neue, behandelbare potenzielle Driver identifiziert: EGFR,
CCND1 und FGFR1 in HPV-negativen Tumoren, FGFR2/FGFR3, KRAS und
BRCA1/2 in HPV-positiven Tumoren, PIK3CA und Gene des PI3K Signalweges in
beiden Unterarten sowie selten vorkommende Aberrationen in DDR2 und EPHA2.
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Die fibroblast growth factor receptor 3 (FGFR3) Mutation S249C wurde in sechs
HPV-positiven Tumoren identifiziert und ist somit nach PIK3CA die ha¨ufigste
Mutation in HPV-positiven Tumoren.
Die funktionelle Validierung von FGFR3 S249C wurde in vitro in zwei HNSCC
Zelllinien durchgefu¨hrt, SCC47 und 93VU147T. Zwei verschiedene Isoformen von
FGFR3, FGFR3 IIIb und der nicht membrangebundene, lo¨sliche FGFR3 ∆8-10
wurden in allen sechs FGFR3 mutierten Tumorproben identifiziert. Zwei sta-
bile Zelllinien, SCC47 und 93VU147T, wurden hergestellt und die Effekte von
FGFR3 IIIb S249C und FGFR3 ∆8-10 S249C auf Proliferation und Migration
(beide Zelllinien) sowie FGFR3 Signaling (SCC47) wurden untersucht. FGFR3
S249C beeinflusst nicht die Proliferations- und Migrationsrate der untersuchten
Zelllinien, mit Ausnahme von FGFR3 IIIb wild type (WT), welcher zu einem
Anstieg der Proliferation in SCC47 fu¨hrt. Eine konstitutive Aktivierung von
Signalwegen downstream von FGFR3 wurde nicht verzeichnet. MAPK sowie
PI3K/Akt wurden nach Stimulation von FGFR3 als relevante Signalwege in HN-
SCC identifiziert. Eine Besta¨tigung von FGFR3 S249C als Driver in HNSCC
beziehungsweise den Zelllinien SCC47 und 93VU147T ist anhand der erlangten
Daten nicht mo¨glich. Die Rolle von FGFR3 S249C als Co-Driver zusammen mit
weiteren Rezeptortyrosinkinasen sowie deren Funktion in Resistenzmechanismen,
insbesondere der Resistenz gegen EGFR-Inhibitoren, sollte jedoch Gegenstand
zuku¨nftiger Untersuchungen sein.
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Appendix A
Additional Data
A.1 Oligo Sequences
Primer Primer Sequence (5’–3’) Prod. Ref.
(bp)
HPV E6-3F for GGGWGKKACTGAAATCGGT 630 [121]
HPV E6-5R rev CTGAGCTGTCARNTAATTGCTCA
HPV E6-6R rev TCCTCTGAGTYGYCTAATTGCTC
HPV16 for CACAGTTATGCACAGAGCTGC 457 [121]
HPV16 rev CATATATTCATGCAATGTAGGTGTA
HPV18 for CACTTCACTGCAAGACATAGA 322
HPV18 rev GTTGTGAAATCGTCGTTTTTCA
HPV31 for GAAATTGCATGAACTAAGCTCG 263
HPV31 rev CACATATACCTTTGTTTGTCAA
HPV59 for CAAAGGGGAACTGCAAGAAAG 215
HPV59 rev TATAACAGCGTATCAGCAGC
HPV45 for GTGGAAAAGTGCATTACAGG 151
HPV45 rev ACCTCTGTGCGTTCCAATGT
HPV33 for ACTATACACAACATTGAACTA 398
HPV33 rev GTTTTTACACGTCACAGTGCA
HPV6/11 for TGCAAGAATGCACTGACCAC 334
HPV6/11 rev TGCATGTTGTCCAGCAGTGT
HPV58 for GTAAAGTGTGCTTACGATTGC 274
HPV58 rev GTTGTTACAGGTTACACTTGT
HPV52 for TAAGGCTGCAGTGTGTGCAG 229
HPV52 rev CTAATAGTTATTTCACTTAATGGT
HPV56 for GTGTGCAGAGTATGTTTATTG 181
HPV56 rev TTTCTGTCACAATGCAATTGC
HPV35 for CAACGAGGTAGAAGAAAGCATC 358
HPV35 rev CCGACCTGTCCACCGTCCACCG
Continued on Next Page. . .
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Primer Primer Sequence (5’–3’) Prod. Ref.
(bp)
HPV42 for CCCAAAGTAGTGGTCCCAGTTA 277
HPV42 rev GATCTTTCGTAGTGTCGCAGTG
HPV43 for GCATAATGTCTGCACGTAGCTG 219
HPV43 rev CATGAAACTGTAGACAGGCCAAG
HPV44 for TAAACAGTTATATGTAGTGTACCG 163
HPV44 rev TATCAGCACGTCCAGAATTGAC
HPV68 for GCAGAAGGCAACTACAACGG 333
HPV68 rev GTTTACTGGTCCAGCAGTGG
HPV39 for GACGACCACTACAGCAAACC 280
HPV39 rev TTA TGA AAT CTT CGT TTG CT
HPV51 for GAGTATAGACGTTATAGCAGG 223
HPV51 rev TTTCGTTACGTTGTCGTGTACG
HPV66 for TTCAGTGTATGGGGCAACAT 172
HPV66 rev AAACATGACCCGGTCCATGC
FGFR3 exon 7F CGGCAGTGGCGGTGGTGGTG 120 [57]
FGFR3 exon 7R AGCACCGCCGTCTGGTTGGC
FGFR3 exon 6F aactacacctgcgtcgtggag [130]
FGFR3 exon 8R ggcctccacactctcactgatc 285
FGFR3 exon 9R tagctccttgtcggtggtgttag 290
FGFR3 exon 11R agctcgagctcggagacattg 368,
710,
679
FGFR3 exon 11/12F CGTGAAGATGCTGAAAGACGATG 993 [117]
TACC3 exon 13R AAACGCTTGAAGAGGTCGGAG
SDM FGFR3 S249C F CTGGAGCGCTgCCCGCACCGG
SDM FGFR3 S249C R ccggtgcgggCagcgctccag
seq EX-M02 F CAGCCTCCGGACTCTAGC
seq EX-M02 R TAATACGACTCACTATAGGG
Table A.1: Primer sequences
for or F = forward primer, rev or R = reverse primer
sequences for the sequencing primers seq EX-M02 were provided by the manufacturer
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Oligo Oligo Sequence (5’–3’)
IS1 A*C*A*C*TCTTTCCCTACACGACGCTCTTCCG*A*T*C*T
IS2 G*T*G*A*CTGGAGTTCAGACGTGTGCTCTTCCG*A*T*C*T
IS3 A*G*A*T*CGGAA*G*A*G*C
IS4 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTT
Index 1 CAAGCAGAAGACGGCATACGAGATcctgcgaGTGACTGGAGTTCAGACGTGT
Index 2 CAAGCAGAAGACGGCATACGAGATtgcagagGTGACTGGAGTTCAGACGTGT
Index 3 CAAGCAGAAGACGGCATACGAGATacctaggGTGACTGGAGTTCAGACGTGT
Index 4 CAAGCAGAAGACGGCATACGAGATttgatccGTGACTGGAGTTCAGACGTGT
Index 5 CAAGCAGAAGACGGCATACGAGATatcttgcGTGACTGGAGTTCAGACGTGT
Index 6 CAAGCAGAAGACGGCATACGAGATtctccatGTGACTGGAGTTCAGACGTGT
Index 7 CAAGCAGAAGACGGCATACGAGATcatcgagGTGACTGGAGTTCAGACGTGT
Index 8 CAAGCAGAAGACGGCATACGAGATttcgagcGTGACTGGAGTTCAGACGTGT
Index 9 CAAGCAGAAGACGGCATACGAGATagttggtGTGACTGGAGTTCAGACGTGT
Index 10 CAAGCAGAAGACGGCATACGAGATgtaccggGTGACTGGAGTTCAGACGTGT
Index 11 CAAGCAGAAGACGGCATACGAGATcggagttGTGACTGGAGTTCAGACGTGT
Index 12 CAAGCAGAAGACGGCATACGAGATacttcaaGTGACTGGAGTTCAGACGTGT
Index 13 CAAGCAGAAGACGGCATACGAGATtgatagtGTGACTGGAGTTCAGACGTGT
Index 14 CAAGCAGAAGACGGCATACGAGATgatccaaGTGACTGGAGTTCAGACGTGT
Index 15 CAAGCAGAAGACGGCATACGAGATcaggtcgGTGACTGGAGTTCAGACGTGT
Index 16 CAAGCAGAAGACGGCATACGAGATcgcattaGTGACTGGAGTTCAGACGTGT
Index 17 CAAGCAGAAGACGGCATACGAGATggtacctGTGACTGGAGTTCAGACGTGT
Index 18 CAAGCAGAAGACGGCATACGAGATggacgcaGTGACTGGAGTTCAGACGTGT
Index 19 CAAGCAGAAGACGGCATACGAGATgagattcGTGACTGGAGTTCAGACGTGT
Index 20 CAAGCAGAAGACGGCATACGAGATgagcatgGTGACTGGAGTTCAGACGTGT
Index 21 CAAGCAGAAGACGGCATACGAGATgttgcgtGTGACTGGAGTTCAGACGTGT
Index 22 CAAGCAGAAGACGGCATACGAGATccaatgcGTGACTGGAGTTCAGACGTGT
Index 23 CAAGCAGAAGACGGCATACGAGATcgagatcGTGACTGGAGTTCAGACGTGT
Index 24 CAAGCAGAAGACGGCATACGAGATcatattgGTGACTGGAGTTCAGACGTGT
BO1 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCT-
CTTCCGATCT-Pho
BO2 AGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTAGATCTCGGTGGTCG-
CCGTATCATT-Pho
BO3 AGATCGGAAGAGCACACGTCTGAACTCCAGTCAC-Pho
BO4 GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT-Pho
BO5 ATCTCGTATGCCGTCTTCTGCTTG-Pho
BO6 CAAGCAGAAGACGGCATACGAGAT-Pho
IS5 AATGATACGGCGACCACCGA
IS6 CAAGCAGAAGACGGCATACGA
Index 25 CAAGCAGAAGACGGCATACGAGATgacgtcaGTGACTGGAGTTCAGACGTGT
Index 26 CAAGCAGAAGACGGCATACGAGATtggcatcGTGACTGGAGTTCAGACGTGT
Index 27 CAAGCAGAAGACGGCATACGAGATgtaattgGTGACTGGAGTTCAGACGTGT
Index 28 CAAGCAGAAGACGGCATACGAGATcctatctGTGACTGGAGTTCAGACGTGT
Index 29 CAAGCAGAAGACGGCATACGAGATcaatcggGTGACTGGAGTTCAGACGTGT
Index 30 CAAGCAGAAGACGGCATACGAGATgcggcatGTGACTGGAGTTCAGACGTGT
Index 31 CAAGCAGAAGACGGCATACGAGATagtactgGTGACTGGAGTTCAGACGTGT
Index 32 CAAGCAGAAGACGGCATACGAGATtactattGTGACTGGAGTTCAGACGTGT
Index 33 CAAGCAGAAGACGGCATACGAGATccggatgGTGACTGGAGTTCAGACGTGT
Index 34 CAAGCAGAAGACGGCATACGAGATaccatgaGTGACTGGAGTTCAGACGTGT
Continued on Next Page. . .
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Index 35 CAAGCAGAAGACGGCATACGAGATcggttctGTGACTGGAGTTCAGACGTGT
Index 36 CAAGCAGAAGACGGCATACGAGATtattccaGTGACTGGAGTTCAGACGTGT
Index 37 CAAGCAGAAGACGGCATACGAGATcctcctgGTGACTGGAGTTCAGACGTGT
Index 38 CAAGCAGAAGACGGCATACGAGATaggtattGTGACTGGAGTTCAGACGTGT
Index 39 CAAGCAGAAGACGGCATACGAGATgcattcgGTGACTGGAGTTCAGACGTGT
Index 40 CAAGCAGAAGACGGCATACGAGATttgcgaaGTGACTGGAGTTCAGACGTGT
Index 41 CAAGCAGAAGACGGCATACGAGATttgaattGTGACTGGAGTTCAGACGTGT
Index 42 CAAGCAGAAGACGGCATACGAGATctgcgcgGTGACTGGAGTTCAGACGTGT
Index 43 CAAGCAGAAGACGGCATACGAGATagaccttGTGACTGGAGTTCAGACGTGT
Index 44 CAAGCAGAAGACGGCATACGAGATgtccagtGTGACTGGAGTTCAGACGTGT
Index 45 CAAGCAGAAGACGGCATACGAGATacctgctGTGACTGGAGTTCAGACGTGT
Index 46 CAAGCAGAAGACGGCATACGAGATccggtacGTGACTGGAGTTCAGACGTGT
Index 47 CAAGCAGAAGACGGCATACGAGATcttgaccGTGACTGGAGTTCAGACGTGT
Index 48 CAAGCAGAAGACGGCATACGAGATcatcattGTGACTGGAGTTCAGACGTGT
Index 49 CAAGCAGAAGACGGCATACGAGATtctgactGTGACTGGAGTTCAGACGTGT
Index 50 CAAGCAGAAGACGGCATACGAGATtctagttGTGACTGGAGTTCAGACGTGT
Index 51 CAAGCAGAAGACGGCATACGAGATgccatagGTGACTGGAGTTCAGACGTGT
Index 52 CAAGCAGAAGACGGCATACGAGATaccgtcgGTGACTGGAGTTCAGACGTGT
Index 53 CAAGCAGAAGACGGCATACGAGATcttggttGTGACTGGAGTTCAGACGTGT
Index 54 CAAGCAGAAGACGGCATACGAGATtacgccgGTGACTGGAGTTCAGACGTGT
Index 55 CAAGCAGAAGACGGCATACGAGATggactgcGTGACTGGAGTTCAGACGTGT
Index 56 CAAGCAGAAGACGGCATACGAGATgcgcgagGTGACTGGAGTTCAGACGTGT
Index 57 CAAGCAGAAGACGGCATACGAGATgtcgcagGTGACTGGAGTTCAGACGTGT
Index 58 CAAGCAGAAGACGGCATACGAGATcatacgtGTGACTGGAGTTCAGACGTGT
Index 59 CAAGCAGAAGACGGCATACGAGATtcagtatGTGACTGGAGTTCAGACGTGT
Index 60 CAAGCAGAAGACGGCATACGAGATctaagtaGTGACTGGAGTTCAGACGTGT
Index 61 CAAGCAGAAGACGGCATACGAGATttagcttGTGACTGGAGTTCAGACGTGT
Index 62 CAAGCAGAAGACGGCATACGAGATcgccgtcGTGACTGGAGTTCAGACGTGT
Index 63 CAAGCAGAAGACGGCATACGAGATgtcttctGTGACTGGAGTTCAGACGTGT
Index 64 CAAGCAGAAGACGGCATACGAGATgccggacGTGACTGGAGTTCAGACGTGT
Index 65 CAAGCAGAAGACGGCATACGAGATaagctgaGTGACTGGAGTTCAGACGTGT
Index 66 CAAGCAGAAGACGGCATACGAGATgcgctctGTGACTGGAGTTCAGACGTGT
Index 67 CAAGCAGAAGACGGCATACGAGATcgtaggcGTGACTGGAGTTCAGACGTGT
Index 68 CAAGCAGAAGACGGCATACGAGATatgattaGTGACTGGAGTTCAGACGTGT
Index 69 CAAGCAGAAGACGGCATACGAGATgcaggttGTGACTGGAGTTCAGACGTGT
Index 70 CAAGCAGAAGACGGCATACGAGATaatcgtcGTGACTGGAGTTCAGACGTGT
Index 71 CAAGCAGAAGACGGCATACGAGATcggcctaGTGACTGGAGTTCAGACGTGT
Index 72 CAAGCAGAAGACGGCATACGAGATctatgccGTGACTGGAGTTCAGACGTGT
Index 73 CAAGCAGAAGACGGCATACGAGATggttgaaGTGACTGGAGTTCAGACGTGT
Index 74 CAAGCAGAAGACGGCATACGAGATgagttaaGTGACTGGAGTTCAGACGTGT
Index 75 CAAGCAGAAGACGGCATACGAGATtagactaGTGACTGGAGTTCAGACGTGT
Table A.2: Oligo sequences for the preparation of sequencing libraries and
target capture as published by Meyer and Kircher [85].
* denotes PTO bond, Pho denotes 3’-phosphate
index 1–24 and 25–75: small letters mark the index consisting of seven bases
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A.2 cDNA Clones
All cDNA clones were purchased from GeneCopoeiaTM(Rockville, MD). Relevant
information is listed below.
• Plasmid/cDNA clone: FGFR3 IIIb
Catalog number: EX-Z7256-M02
Vector: pEZ-M02
Antibiotic: Ampicillin
Stable selection marker: Neomycin
Whole plasmid size: 8250 bp
ORF length: 2427 bp
• Plasmid/cDNA clone FGFR3 ∆8-10
Catalog number: EX-Z0704-M02
Vector: pEZ-M02
Antibiotic: Ampicillin
Stable selection marker: Neomycin
Whole plasmid size: 7908 bp
ORF length: 2085 bp
• Plasmid negative control vector
Catalog number: EX-NEG-M02
Vector: pReceiver-M02CT
Antibiotic: Ampicillin
Stable selection marker: Neomycin
Whole plasmid size: 5823 bp
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A.3 Sensitivity of SCC47 and 93VU147T to Gefi-
tinib
Figure A.1: Gefitinib sensitivity for SCC47 and 93VU147T.
Different HNSCC cell lines were subjected to drug testing using the EGFR small
molecule inhibitor Gefitinib. Shown are the calculated IC50 values of all tested cell
lines. Cell lines are ordered according to their IC50 values which represent their sensi-
tivity to Gefitinib. Data are unpublished, therefore the names of the remaining tested
cell lines are blinded. Drug testing data were provided by the Cellular Screening Center
at the University of Chicago and analyzed by Johannes Bra¨gelmann.
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Glossary and Acronyms
aCGH array comparative genomic hybridization
AFA Adaptive Focused Acoustics
AKR1C1 Aldo-Keto Reductase Family 1, Member C1
AKR1C3 Aldo-Keto Reductase Family 1, Member C3
Akt/PKB protein kinase B
ALDH3A1 Aldehyde Dehydrogenase 3 Family, Member A1
ANOVA analysis of variance
APS ammonium persulfate
AREG amphiregulin
ARID1A AT Rich Interactive Domain 1A
ATM Ataxia Telangiectasia Mutated
β-ME β-mercaptoethanol
BCL6 B-Cell CLL/Lymphoma 6
BIRC2 Baculoviral IAP Repeat Containing 2
bp base pair(s)
BRCA Breast Cancer, Early Onset
◦C degree Celsius
CA9 Carbonic Anhydrase IX
CASP8 Caspase 8
CCND1 Cyclin D1
CCNE1 Cyclin E1
CD8A CD8a Molecule
CDC7 Cell Division Cycle 7
CDH3 P-cadherin
CDK Cyclin-Dependent Kinase
CDKN2A Cyclin-Dependent Kinase Inhibitor 2A
cDNA complementary DNA
CEBPA CCAAT/Enhancer Binding Protein (C/EBP), Alpha
CHASM Cancer-specific High-throughput Annotation of Somatic Mutations
CN copy number
CNV copy number variation
CO2 carbon dioxide
CoC chip on chip
COL17A1 Collagen, Type XVII, Alpha 1
CONTRA copy number analysis for targeted resequencing
COSMIC catalogue of somatic mutations in cancer
cRNA complementary RNA
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CSMD3 CUB And Sushi Multiple Domains 3
CTLA-4 Cytotoxic T-Lymphocyte-Associated Protein 4
CTP cytidintriphosphat
CTTN Cortactin
CUL3 Cullin 3
CYLD Cylindromatosis
DAG diacylglycerol
DDR2 Discoidin Domain Receptor Tyrosine Kinase 2
DDX3X DEAD (Asp-Glu-Ala-Asp) Box Helicase 3, X-Linked
DNA deoxyribonucleic acid
dsDNA double stranded DNA
e.g. exempli gratia (for example)
E early gene
E2F E2F Transcription Factor
EDTA ethylenediaminetetraacetic acid
EGFR epidermal growth factor receptor
EMT epithelial-mesenchymal transition
EPHA2 EPH Receptor A2
ER endoplasmic reticulum
ERBB2 Erb-B2 Receptor Tyrosine Kinase 2
ERK extracellular signal-regulated kinase
FADD Fas (TNFRSF6)-Associated Via Death Domain
FANC Fanconi Anemia, Complementation Group
FAT1 FAT Atypical Cadherin 1
FBS fetal bovine serum
FBXW7 F-Box And WD Repeat Domain Containing 7, E3 Ubiquitin Protein Ligase
FES FES Proto-Oncogene, Tyrosine Kinase
FFPE formalin-fixed, paraffin-embedded
FGF fibroblast growth factor
FGFR fibroblast growth factor receptor
FHF FGF homologous factor
FHIT Fragile Histidine Triad
FHX 5-fluorouracil, hydroxyurea, and radiation
FLG Filaggrin
FOV Field of View
FRS2α FGFR substrate 2α
g standard acceleration due to gravity
GAB1 GRB2-associated binding protein 1
GBM glioblastoma multiforme
gDNA genomic DNA
GISTIC Genomic Identification of Significant Targets in Cancer
Gln glutamine
GRB2 growth factor receptor-bound 2
H2O water
H&E hematoxylin and eosin
HGAC High-throughput Genome Analysis Core
HIF1α Hypoxia Inducible Factor 1, Alpha Subunit
HLA Major Histocompatibility Complex
HLA-DRA Major Histocompatibility Complex, Class II, DR Alpha
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HNC head and neck cancer
HNSCC head and neck squamous cell carcinoma
HPLC high performance liquid chromatography
HPV human papillomavirus
HRAS Harvey Rat Sarcoma Viral Oncogene Homolog
HSD honestly significant difference
HSP heat shock protein
i.e. id est (that is)
ICOS Inducible T-Cell Co-Stimulator
IGSB Institute for Genomics and Systems Biology
IHC immunohistochemistry
IP3 inositol-1,4,5-trisphosphate
IPA Ingenuity Pathway Analysis
IRF Interferon Regulatory Factor
ITGB Integrin, Beta
JAK Janus kinase
JNK c-Jun amino-terminal kinase
KEAP1 Kelch-Like ECH-Associated Protein 1
KRAS Kirsten Rat Sarcoma Viral Oncogene Homolog
KRT Keratin
L late gene
LAG3 Lymphocyte-Activation Gene 3
LAMC2 Laminin, Gamma 2
M molar
MAPK mitogen activated protein kinase
MAPKK MAPK kinase
MAPKKK MAPK kinase kinase
MARCKS myristoylated alanine-rich C-kinase substrate
mb megabase
MCM Minichromosome Maintenance Complex Component
MDM2 MDM2 Proto-Oncogene, E3 Ubiquitin Protein Ligase
MET hepatocyte growth factor receptor
µL microliter
µM micromolar
mg milligram
min minutes
mL milliliter
MLL2 Lysine (K)-Specific Methyltransferase 2D
MLL3 Lysine (K)-Specific Methyltransferase 2C
mm millimeter
mM millimolar
MMLV–RT Moloney Murine Leukemia Virus Reverse Transcriptase
mRNA messenger RNA
MYC V-Myc Avian Myelocytomatosis Viral Oncogene Homolog
NF-κB nuclear factor-κB
NF1 Neurofibromin 1
NFAT nuclear factor of activated T cells
NFE2L2 Nuclear Factor, Erythroid 2-Like 2
ng nanogram
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NGS next generation sequencing
nm nanometer
NRAS Neuroblastoma RAS Viral (V-Ras) Oncogene Homolog
NRG1 neuregulin 1/heregulin
NSCLC non small cell lung cancer
NSD1 Nuclear Receptor Binding SET Domain Protein 1
OCT Optimal Cutting Temperature compound
OPSCC oropharyngeal squamous cell carcinoma
PAGE polyacrylamide gel electrophoresis
PBS phosphate buffered saline
PBST phosphate buffered saline with Tween R©20
PCA principal component analysis
PCR polymerase chain reaction
PD-1 programmed cell death protein 1
PDK1 Pyruvate Dehydrogenase Kinase, Isozyme 1
PD-L1 PD-1 ligand
PEG polyethylene glycol
PI3K phosphoinositide 3-kinase
PIK3CA Phosphatidylinositol-4,5-Bisphosphate 3-Kinase, Catalytic Subunit Alpha
PIP2 phosphatidylinositol-4,5-bisphosphate
PIP3 phosphatidylinositol-3,4,5-trisphosphate
PKC protein kinase C
PLC phospholipase C
PMD potentially malignant disorders
PTEN Phosphatase And Tensin Homolog
PTO phosphorothioate
QC quality control
qPCR quantitative PCR
Rb/RB Retinoblastoma
RB1CC1 RB1-Inducible Coiled-Coil 1
REL V-Rel Avian Reticuloendotheliosis Viral Oncogene Homolog
RIMS2 Regulating Synaptic Membrane Exocytosis 2
RIN RNA integrity number
RIPA radioimmunoprecipitation assay
RNA ribonucleic acid
RPA2 Replication Protein A2, 32kDa
RIPK4 Receptor-Interacting Serine-Threonine Kinase 4
rpm rounds per minute
RTK receptor tyrosine kinase
RT-PCR reverse transcription PCR
s seconds
S Svedberg
SADDAN severe achondroplasia with developmental delay and acanthosis nigricans
SCC squamous cell carcinoma
SDM site directed mutagenesis
SDS sodium dodecyl sulfate
SMAD SMAD Family Member
SOS son of sevenless
SOX2 SRY (Sex Determining Region Y)-Box 2
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SPRI solid phase reversible immobilization
ssDNA single stranded DNA
ssGSEA single sample gene set enrichment analysis
STAT signal transducer and activator of transcription
STD standard
TACC3 Transforming acidic coiled-coil 3
TCGA The Cancer Genome Atlas
TCIP T cell inflamed phenotype
TEMED N,N,N’,N’-Tetramethylethylene-diamine
TERT Telomerase Reverse Transcriptase
TGF Transforming Growth Factor
THSD7A Thrombospondin, Type I, Domain Containing 7A
TNM tumor, node, metastasis
TP Tumor Protein
TPRX1 Tetra-Peptide Repeat Homeobox 1
TRAF3 TNF Receptor-Associated Factor 3
TS type specific
TSC Tuberous Sclerosis
US United States
USA United States of America
VEGF vascular endothelial growth factor
V voltage
vol. volume(s)
WB Western Blot
WGA whole genome amplification
WT wild type
w/v weight per volume
YAP1 Yes-Associated Protein 1
ZNF217 Zinc Finger Protein 217
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